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ABSTRACT OF DISSERTATION 
 
 
 
 
EFFECT OF AZITHROMYCIN ON MACROPHAGE PHENOTYPE DURING 
PULMONARY INFECTIONS AND CYSTIC FIBROSIS 
 
  
Azithromycin improves clinical outcomes in patients with cystic fibrosis 
(CF), specifically in patients infected with Pseudomonas aeruginosa.  
Azithromycin shifts macrophage programming away from a pro-inflammatory 
classical (M1) phenotype, and towards an anti-inflammatory alternative (M2) 
phenotype; however, little is known about this mechanism, nor of its impact upon 
immune response to pulmonary infection.  We set out to determine the 
mechanism by which azithromycin is able to alter macrophage phenotype, and 
assess the effect of azithromycin induced macrophage polarization on 
inflammation during pulmonary infections.   
 Utilizing macrophage cell culture, we found that azithromycin increased 
IKKβ, a signaling molecule in the NFκB pathway, which likely is altering 
macrophage programming.  Using a Pseudomonas infection model in mice that 
lack physiologic alternative macrophage activation, we showed that 
azithromycin’s ability to alter macrophage function and decrease lung damage 
was independent of interleukin control of macrophage programming.  
Azithromycin increased fibrotic protein production both in vivo and in vitro, but 
blunted immune-driven fibrotic damage.  We extended our study to patients with 
CF, describing gene expression in macrophages isolated from sputum samples.  
We found markers consistent with a shift toward M2 polarization in these 
patients.  These data suggest potential mechanisms by which azithromycin 
benefits patients with CF. 
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Chapter 1:  Introduction 
A.  Overview 
 Cystic Fibrosis (CF) is a genetic disorder characterized by a deficiency in 
the cystic fibrosis transmembrane regulator (CFTR) gene [11].  This deficiency 
results in impaired chloride transfer in epithelial cells.  This impairment results in 
thickened secretions in the digestive and reproductive tracts, as well as in the 
lungs.  While impairments in the digestive and reproductive tracts can commonly 
lead malnutrition and sterility, it is the pulmonary complications in patients that 
lead to long term complications and mortality, with the average life expectancy of 
patients with CF currently at 37 years [11].  Defects in the CFTR cause the lungs 
of these patients to be characterized by increased mucus formation, providing a 
breeding ground for a wide variety of bacteria to colonize, most notably the gram 
negative bacterium Pseudomonas aeruginosa.  The progression of the disease is 
characterized by repeated acute bacterial flares, followed by a latent phase 
where the bacteria are held in check by the immune system.  The inflammatory 
response in the lungs to these recurring infections contributes greatly to a decline 
in lung function in these patients over time [11]. 
 During acute bacterial flares, the lungs of these patients are characterized 
by an influx of phagocytic and inflammatory cells, most notably neutrophils and 
macrophages [12].  These inflammatory cells produce a wide variety of pro-
inflammatory cytokines in the lungs.  Additionally, the production of molecules 
involved in the oxidative burst (e.g. nitric oxide) are up-regulated, resulting in 
destruction of bacteria [13].  Unfortunately, these oxidative molecules also cause 
considerable damage to the lungs of these patients.  This inflammatory response 
is necessary, as without it bacteria would over-proliferate.  If the response is 
overly zealous, however, a large amount of damage can occur in the lungs of 
these patients.  This results in airway remodeling, scarring, and a decline in lung 
function over time in these patients.  In the course of an individual infection of 
bacterial flare, macrophages initially play an important role in phagocytosis and 
inflammation; over time, however, they shift to an anti-inflammatory and pro-
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fibrotic role.  These cells play an important role in killing invading bacteria in the 
lungs, and are responsible for the initiation  of the inflammatory response to a 
bacterial flare, [12].  These infections are treated with a wide variety of 
medications, including oral, IV, and inhaled antibiotics [14].  In an attempt to 
control the number of bacterial exacerbations, these patients also are commonly 
treated with anti-inflammatory medications, including traditional agents (e.g. 
corticosteroids and non-steroidal anti-inflammatory drugs).  Ibuprofen has 
traditionally been shown in patients with CF to prevent decline in FEV1 % 
predicted, as well as improving survival.  The medication is not routinely used in 
patients with CF, however, due to the side effect profile associated with the 
medication [15].   Additionally, azithromycin (AZM), an antibiotic that is utilized for 
its anti-inflammatory properties. 
 AZM is a macrolide antibiotic that is commonly used in this patient 
population.  It has been shown in several clinical studies that chronic AZM 
therapy improves clinical parameters in patients with CF, including forced 
expiratory volume in one second (FEV1), incidence of acute bacterial flares, and 
patient quality of life [16-20].  Unfortunately, long term usage of AZM as an anti-
inflammatory can contribute to increased bacterial resistance as well as to other 
forms of collateral damage resistance [17].  An increased understanding of how 
AZM alters immune responses and thereby improves clinical parameters in these 
patients may lead to potential new therapeutics that provide the beneficial effects 
of AZM without the need to for long-term antimicrobial use.  Including much of 
the work in this dissertation, our group has shown that AZM alters the function 
and phenotype of macrophages in these patients, and hypothesize that this may 
be one of the methods by which patients benefit from taking the drug. 
B.  Cystic fibrosis 
Cystic fibrosis is an autosomal recessive disorder that results in a non-
functional CFTR channel.  The CFTR is a chloride channel found in multiple 
organ systems, most notably the lung.  The lung manifestations of CF are the 
most impactful to patients over the course of their lifetime, contributing the most 
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to morbidity and mortality.  While literally hundreds of mutations in the CFTR 
have been observed, they can be grouped into 5 major groups.  Class 1 
mutations result in a shortened mRNA, and no CFTR protein production.  Class 2 
mutations result in misfolded mRNA, which is then degraded in the endoplasmic, 
resulting in no CFTR protein production.  The ΔF508 mutation, which represents 
70% of all mutations in patients with CF, is a class 2 mutation [11].  In class 3 
mutations, an inactive CFTR is produced.  Class 4 mutations result in a CFTR 
with decreased function.  Finally, Class 5 mutations result in normal function, but 
decreased expression of the CFTR [11, 21].  Interestingly, while different classes 
of mutations can be correlated to disease severity for most organs affected with 
CF (e.g. the gut, pancreas, and reproductive tracts), with classes 4 and 5 
mutations being associated with less serious disease, this correlation does not 
appear to exist in the lungs of patients with CF [22, 23].   
In the lungs, a deficient CFTR leads to salt imbalances at the epithelial 
surfaces, which then results in thickened and dehydrated secretions [11].  Not 
only do these thickened secretions provide a breeding ground for a wide variety 
of pathogens, but this also alters immune cell function in the lungs, making it 
considerably more difficult for phagocytic cells to internalize and destroy bacteria 
[11].  Acute flares of CF also involve an extensive neutrophilic response.  During 
an acute exacerbation of the disease, cytokines produced by macrophages, 
including IL8, IL1 and TNF-α result in the recruitment of neutrophils to the lung.  
Once they reach the lungs, they release elastases, and lyse, they release large 
amounts of DNA into the lung as well [24].  These secreted factors and released 
DNA provide the basis of the thickened secretions and impaired clearance of 
organisms that plague the lungs of patients with CF [11].  The prolonged 
inflammatory response that this causes also plays an important role in the 
decline of lung function in patients with CF.  Disease progression is characterized 
by blockage of the small and medium bronchioles, although the alveoli are by 
and large spared [11].  Additionally, there is evidence that the CFTR plays an 
important role in the ability of phagocytic cells to acidify the phagosome.  This 
results in macrophages and monocytes in CF patients being less able to destroy 
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bacteria that they have internalized [25].  This is likely an additional reason why 
patients with CF are unable to effectively clear the bacteriawith which they have 
been colonized.  
Patients with CF are colonized with a wide variety of pathogens, and once 
colonized it is exceptionally difficult to clear these pathogens.  The pattern of 
bacterial colonization in patients with CF has shifted over time.  Traditionally, P. 
aeruginosa, methicillin-susceptible Staphlococcus aureus, and Haemophilus 
influenzae have been the primary pathogens that patients that CF are colonized 
with [26].  More recently, however, other bacteria are becoming increasingly 
common in patients with CF, most notably methicillin-resistant Staphlococcus 
aureus, although there has also been a great increase in patients colonized with 
Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and various 
mycobacteria [11, 26].   
By far, however, P. aeruginosa is the most significant pathogen in patients 
with CF [11].  The rate of colonization in patients with CF can exceed 70% in 
adults, and even in young children the rate of colonization can exceed 25% [27, 
28].  This pathogen produces thick alginate biofilms that aid its ability to survive 
in this setting [29].  By hiding in biofilms, the bacteria is able to avoid 
phagocytosis by macrophages and neutrophils, as well as avoid antibiotics.  
Biofilms also may prevent complement from being able to bind to the organism’s 
surface, preventing the bacteria from being targeted for destruction [30].  Indeed, 
conversion from a non-biofilm producing strain to a biofilm producing strain is 
considered one of the necessary steps for P. aeruginosa to permanently colonize 
the lungs of patients, as opposed to being present in the lungs intermittently [30].  
P. aeruginosa additionally produces elastases and proteases that allow it to 
cleave host defense proteins, such as defensins, allowing it to remain in the 
lungs of these patients [13].  P. aeruginosa is able to respond quickly to changes 
in the host environment, allowing it to out-compete other bacteria [13].  The 
biofilms that are formed also impair the ability of these patients to breathe, and 
result in a decline in lung function for these patients over time.  Evidence also 
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exists that P. aeruginosa is able to mutate more readily in patients with CF, 
allowing it to gain resistance to the antibiotics used to treat these patients [31].   
Hartl et. al. have shown that the lungs of patients with CF colonized with 
P. aeruginosa showed increased concentrations of IL4 and IL13, and decreased 
concentrations of IFNγ, consistent with a shift towards a Th2 polarization in the 
lungs of these patients [32].  This difference was even more pronounced when 
they assessed mRNA expression via qRT-PCR [32].  They also found that 
patients colonized with P. aeruginosa displayed higher levels of the inflammatory 
cytokine interleukin (IL)6 in their bronchoalveolar lavage fluid.  In their P. 
aeruginosa positive patients they additionally found a strong negative correlation 
between IL4 and IL13 concentrations and FEV1 % predicted [32].  This further 
suggests the negative repercussions associated with a shift to towards the Th2 
phenotype in the lungs of these patients, and shows a method by which this shift 
occurs.  Contrariwise, this may represent a reactionary response to a decline in 
lung function, with the increase in Th2 polarization being the response, rather 
than the cause of decreased lung function.  This shift may be attempting to 
minimize further damage in the lungs of patients.  
Patients with CF are treated with a wide variety of medications to manage 
their pulmonary symptoms.  Nebulized tobramycin is approved for use in patients 
who have been colonized with P. aeruginosa [14].  Treatment with Dornase alfa, 
a recombinant DNase, is common as well to help degrade the thickened 
secretions that are common in patients with CF [14].  Patients receive a variety of 
other antibiotics to control bacterial infections, and to attempt to decrease the 
incidence of acute bacterial flares.  Treatment with bronchodilators, as well as 
chest percussion is also commonly used and has been shown to improve lung 
function in these patients.  It is also common for patients to receive dietary 
enzymes to aid in digestion, and to take proton pump inhibitors to deal with other 
symptoms associated with their disease [33].  While the wide variety of 
treatments used in these patients greatly improves life span and patient quality of 
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life, it makes clinical studies difficult due to confounding the data analysis in our 
studies and the studies of others. 
C.  Macrophage Polarization 
Macrophages are important effector cells in the innate immune system 
[34].  Derived from circulating peripheral blood mononuclear cells (PBMCs), in 
their traditional roles, they reside in organs, and function both as a sentinel to 
invading bacteria, as well as one of the key phagocytic cells in the body.  This 
response is characterized by phagocytosis of pathogens, and production of 
reactive oxygen species (ROS) [35].  Additionally, they secrete cytokines that 
recruit other inflammatory cells to the site of an acute infection, primarily 
neutrophils [36].  This robust inflammatory response, while necessary to destroy 
the invading pathogen, is not without cost.  The production of pro-inflammatory 
cytokines, as well as ROS can lead to considerable tissue damage [37]. 
More recently, an additional phenotype for macrophage has been 
elucidated.  Alternatively activated macrophages (M2), as opposed to the 
classically activated macrophages (M1) described above, play a very different 
role in host defense to infections.  M2 macrophages are primarily involved in 
repairing the damage that is caused by a acute inflammatory injury.  Their key 
effector molecules are arginase, as well as polyamines, which are the precursors 
to the extracellular (ECM) proteins fibronectin and collagen [38].  The production 
of these fibrotic molecules is a necessary part of the repair process.  These 
molecules help damaged tissue regain integrity, and allow recovery from 
inflammatory damage.  Overproduction, however, can lead to scarring, fibrosis, 
and organ damage.  Indeed, in a variety of fibrotic lung diseases, it has been 
shown that the alternatively activated macrophage is the predominate phenotype 
in patients with these disorders [39].  Similar observations have been made for a 
number of autoimmune disorders as well, most notably multiple sclerosis and 
rheumatoid arthritis [38]. 
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M1 and M2 macrophages are derived from inactive resident 
macrophages, as well as circulating monocytes.  They are polarized to the 
classically or alternatively activated phenotype via signaling primarily from either 
Th-1 or Th-2 polarized T-cells, respectively [9, 35].  Cells are polarized to the 
classically activated phenotype via interferon-gamma (IFN-γ), in addition to 
signaling from the toll like receptors (TLRs) including TLR4 triggered by 
lipopolysaccharide (LPS).  Macrophages can be polarized to the alternatively 
activated phenotype via signaling from both IL4 and IL13 [3].  The two 
prototypical effector proteins produced in the two phenotypes, iNOS and 
arginase 1, appear to be reciprocally regulated, sharing the common substrate L-
arginine (Figure 1.1) [9, 10].  iNOS converts arginine to nitric oxide (NO) and 
citrulline.  NO is a key component in the oxidative burst, leading to destruction of 
intracellular bacteria.  It also, however, results in tissue damage, leading to 
inflammation at the site of infection.  Conversely, with alternative macrophage 
polarization, the enzyme arginase is expressed and converts arginine to both 
urea and ornithine.  Ornithine is then converted to polyamines, which can then be 
converted to precursors of matrix molecules including collagen.  These proteins 
form the building blocks for tissue repair that is necessary to recover from an 
inflammatory response to bacteria, and if the damage is severe enough, results 
in irreversible fibrotic changes [40-42].  It is important to note that, unlike T cells, 
macrophage polarization occurs on a spectrum, and is not a terminal 
differentiation.  A cell polarized to the classically activated phenotype can later be 
polarized to the alternatively activated phenotype, and vice versa [35]. 
The terminology used to describe macrophage polarization is a topic of 
ongoing discussion.  It is generally accepted that the classically activated 
phenotype is relatively homogenous in its polarization and function.  However, 
alternatively activated macrophages are considerably more variable in their 
description in terms of gene expression.  An overview of the different phenotypes 
of macrophages can be seen in Table 1.1.  Mantovani et. al. describe 3 different 
types of alternatively activated macrophages.  M2a are polarized by IL4 and 
IL13.  These cells display high expression of surface mannose receptor, and 
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express proteins including IL10, IL1ra, and the decoy IL1RII.  They describe 
these macrophages as being heavily involved in type 2 inflammation, allergy, and 
the killing and encapsulation of parasites.  They describe M2b macrophages as 
being activated by immune complexes and TLR or IL1R.  M2b macrophages 
express high levels of CD86, IL10, TNF, IL1 and IL6.  These macrophages are 
also known as type II macrophages, and are involved in immunoregulation and 
Th2 activation.  Finally, they describe an M2c phenotype.  These macrophages 
are activated by IL10, and express high levels of IL10, TGF-β, MR, and produce 
pro-fibrotic proteins involved in matrix deposition [3].  Others group one or more 
of these phenotypes together [1, 35].  In fact, rather than view macrophage 
polarization as a spectrum with M1 or M2 macrophages on either pole of the 
spectrum, some view there to be three primary poles of macrophage polarization, 
with classically activated macrophages, wound healing macrophages (essentially 
M2 macrophages), and regulatory macrophages representing the three poles, 
and various tissue macrophages that display markers of the three different 
phenotypes [35].  For the purposes of this dissertation, however, I will be treating 
macrophage polarization as a duality.  I will be describing macrophages as either 
M1 or M2, although the M2 macrophages that I will be focusing on most closely 
resemble the M2a phenotype that Mantovani et. al. described.  This does not, 
however, eliminate the possibility that AZM polarizes macrophages to a novel 
phenotype, as opposed to polarizing to the traditionally thought of alternatively 
activated phenotype.  AZM may be polarizing macrophages to a novel phenotype 
that avoids both the inflammatory component of an M1 macrophage and the pro-
fibrotic component of the M2 macrophage. 
In the lung of the patient with CF during an acute bacterial infection, or 
during an acute flare of a chronic infection, both resident and infiltrating 
macrophages are quickly polarized by the cytokines in the lung milieu to the M1 
phenotype.  Additionally, M1 macrophages produce cytokines, including IL8, that 
result in a strong neutrophilic response [11, 43].  The strong M1 polarization in 
the lungs during an acute infection results in phagocytosis and destruction of 
bacteria in the lung.  This results in the up-regulation of inflammatory markers, as 
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well as free radical levels in the lung [44].  There is also evidence that 
macrophages with deficient CFTR may indeed be playing a disproportionate role 
in this strong inflammatory shiftby producing higher amounts of proinflammatory 
cytokines including IL6 and TNFα as compared to macrophages with normal 
CFTR function [45].   
T cells play an important role in the orchestration of the immune response.  
CD4+ T cells can be classified as having a T helper (Th) type 1, or a type 2 
response.  A Th1 response is characterized by production of the cytokine IFNγ, 
and leads to activation of macrophages to efficiently kill phagocytosed 
organisms, and a robust pro-inflammatory response [46].  A Th2 response, on 
the other hand, is primarily characterized by IL4 production, and leads to 
activation of humoral immunity.  In addition, activation of the Th2 response leads 
to production of cytokines that polarize macrophages towards the alternatively 
activated phenotype in response to some pathogens [46].  In the lungs of 
patients with CF, the Th1 polarization is traditionally associated with improved 
outcomes.  However, over time, a net shift to a Th2 polarization is observed in 
these patients.  This shift is associated with a worsening in outcomes in patients 
with CF [47].  Indeed in other fibrotic lung diseases, most notably idiopathic 
pulmonary fibrosis, a vicious cycle persists in the lungs, wherein the Th2 
polarization shifts macrophages to the alternatively activated phenotype, leading 
to increased production of collagen in the lungs of these patients, and a decline 
in lung function [48].  Others have shown that targeting IL4 and IL13-responsive 
cells (including macrophages and fibroblasts) in fibrotic lung disease in animals 
can lead to decreased fibrosis [49].  While similar findings have not yet been 
observed in patients with CF, it is reasonable to surmise that the damage caused 
during acute flares of CF results in an inordinately strong shift to the M2 
phenotype, causing scarring and fibrosis in the lungs of these patients.  While T 
cells coordinate the adaptive and chronic phases of host defense, macrophages 
also coordinate aspects of chronic inflammation in the lungs and in other tissues 
[50, 51].  Instead of the inflammatory response maturing into a more T cell-
dominated process, in CF the response continues to be neutrophil-driven, 
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described by other investigators as more of a “sustained acute response” in 
contrast to a maturing, chronic inflammation [52].  While in normal circumstances 
this repair and remodeling is both necessary and beneficial in patients, in the 
face of the dysregulated inflammatory response in CF and the excessive damage 
that then results, it leads to pulmonary functional decline. 
This exaggerated immune response, while necessary to respond to the 
acute infection, is not without costs.  Considerable debris is accumulated in the 
lungs in the aftermath of an infection.  This debris consists of portions of bacteria, 
as well as dead and dying epithelial cells and macrophages [53].  Alternatively 
activated macrophages are able to efficiently internalize and destroy this cellular 
debris [35].  They also produce profibrotic proteins, providing the necessary 
building materials for tissue repair to occur [54].  This repair commonly results in 
scarring and fibrosis of the lungs, especially when the initial immune response is 
robust [55].  Unfortunately, this scarring can lead to decreases in the parameters 
of lung function, including FEV1 % predicted [11].  This decline additionally 
increases the probability of a future acute bacterial flare, and the cycle of a 
damaging inflammatory response followed by tissue repair and remodeling is 
responsible for much of the mortality associated with CF [15].  The remodeling 
occurs primarily in the peribronchiolar regions of the lungs, with considerable 
bronchiectasis and scarring occurring in the lungs of these patients over time.  
Damage to the alveoli of the lungs is much less common, and also less severe in 
patients with CF, although it does occur in some patients, especially those with 
severe disease [56]. 
D.  Azithromycin 
 AZM is a macrolide antibiotic that is commonly used for a variety of 
infections.  It functions as a bacteriostatic agent and has clinically effective 
activity against both gram positive and negative organisms [57].  It binds to the 
50s subunit of bacterial ribosomes and inhibits bacterial protein synthesis by 
blocking elongation of the peptide chain [58].  Interestingly, the drug is 
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extensively concentrated in immune cells:concentrations in alveolar 
macrophages have been reported to be 170 fold higher than in serum [58]. 
 AZM is one of the drugs of choice for a wide variety of infections.  The 
drug has been shown to be effective in a large percentage of community 
acquired pneumonia cases caused by the typical pathogens associated with this 
infection, including Streptococcus pneumoniae, and atypical organisms such as 
Chlamydia pneumoniae, Legionella sp., and Mycoplasma pneumoniae. [58].  Its 
spectrum of activity combined with the ease of administration results in it 
commonly being used for acute exacerbations of chronic bronchitis, otitis media 
infections, streptococcal pharyngitis, sinusitis, and both upper and lower 
respiratory tract infections [58].   
 Additionally, it has been shown that the macrolides exert anti-
inflammatory effects independent of their effects on microorganisms [59].  
Patients with advanced CF derive their benefits from the anti-inflammatory, rather 
than the anti-infective properties of the medication. Indeed, it appears to be a 
class effect of the macrolides, with clarithromycin displaying a less potent effect 
on inflammation, while roxithromycin (not approved for clinical use in the United 
States) is more potent [59]. Macrolides have also been shown to decrease 
inflammatory cytokine concentrations in the lungs, including IL6, IL8, and TNFα 
[37, 60].  It has been shown that while AZM does not destroy P. aeruginosa, it 
does exert indirect effects on the bacteria.  AZM decreases transcription of the 
quorum sensing genes lasR and rhlR, resulting in a decrease in the production of 
bacterial virulence factors [61].  Importantly, it has been shown that treatment 
with macrolides decreases neutrophil influx in the lungs of patients with CF [62].  
The importance of this effect, as well as the determination of a molecular 
mechanism by which this effect occurs is currently unknown.   
Key to the development of this project, our lab has demonstrated that AZM 
is able to shift macrophage polarization away from the classically activated 
phenotype, and towards the alternatively activated phenotype, even in the 
presence of M1 stimulating cytokines [63].  We showed that macrophages 
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treated with AZM, bacterial LPS, and IFNγ increased expression of macrophage 
surface markers that was consistent with macrophages treated with IL4/IL13 and 
LPS.  We also published that AZM treated macrophages exhibit increased 
arginase activity, as well as decreased expression of the iNOS protein.  Finally, 
we showed that the pattern of cytokine expression in macrophages treated with 
AZM is less inflammatory, and more anti-inflammatory than macrophages that 
did not receive AZM [63]. 
AZM has been shown in a variety of studies to be beneficial for patients 
with CF.  It has been shown to improve lung function, measured via the FEV1% 
predicted [16, 18].  Saimin et. al. have found this is a mild increase, on the order 
of 3-4% over the placebo group over the course of 3-6 months.  Subjects with CF 
were randomized to receive either AZM or a placebo.  Interestingly, this 
difference disappeared once the patients were taken off the medication [18].  
This group went on to separately analyze data from both patients colonized with 
P. aeruginosa, as well as patients who have not been colonized with the 
organism.  While differences in FEV1% predicted occur in both patients in both 
groups, the effect is much more pronounced in subjects who have been 
colonized with P. aeruginosa [17, 18].  Additionally, they found that CF patients 
treated with AZM are more likely to go longer without an acute lung exacerbation 
of their disease, a result that was consistent over 2 trials performed by this group 
[18, 19].  Additionally, AZM increases the time to a first exacerbation in both 
patients colonized with P. aeruginosa, as well as patients who have not been 
colonized with P. aeruginosa [17, 18].   
Equi et. al. utilized a cross-over design with both AZM and a placebo, and 
found that the treatment group had a slight but significant increase in FEV1 % 
predicted on the order of 10% [16].  They also found that differences in FEV1% 
predicted declined when patients were taken off of the medication.  Subjects who 
were receiving AZM were additionally less likely to be taking other oral antibiotics 
to control their symptoms, although they did not find significant differences in 
hospitalization rates between the two groups [16].   
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Finally, Wolter et. al., in addition to finding similar results as the other 
groups with regard to lung function, also found that AZM treated patients were 
significantly less likely to receive IV antibiotics.  They also investigated C-reactive 
protein levels, a marker of systemic inflammation in the blood of these patients.  
They found that patients treated with AZM showed decreased C-reactive protein 
levels in their blood at the end of 3 months of treatment with AZM, as compared 
to patients that received a placebo.  Finally they had patients complete quality of 
life questionnaires both before and after treatment.  Patients reported less 
dyspnea and fatigue, as well as general improvements in their quality of life [20]. 
As one might expect, long term treatment with AZM is not without 
repercussions in these patients.  In patients with CF treated with AZM, there 
were significant increases in the amount of bacteria resistant to macrolides in 
one of the trials outlined above [17].  Specifically, the rates of macrolide resistant 
S. aureus increased from 28% to 37% over 6 months, while the rates of 
macrolide resistant H. influenzae increased from 1% to 8% [17].  Additionally, the 
collateral damage inflicted by long-term AZM exposure to pathogen susceptibility 
to other antimicrobials is unknown. 
In summary, the studies investigating AZM have shown that patients 
receiving the drug have slight but significant improvements in lung function, most 
notably measured by FEV 1% predicted.  Additional improvements were 
observed for number and time to an acute exacerbation of the disease, and 
general patient quality of life.  Because of these investigations, the Cystic 
Fibrosis Foundation currently recommends chronic AZM therapy for patients over 
the age of 6 years who are colonized with P. aeruginosa, as a method to improve 
lung function [14].  A recent meta-analysis reviewed 8 different studies assessing 
the effect of AZM in CF.   Combining the data resulted in the drug inducing  an 
overall increase in FEV1% predicted [64].  This improvement was again more 
pronounced in patients who were colonized with P. aeruginosa [64].  They also 
showed that these patients were less likely to experience an acute exacerbation 
of the disease, as well as a decrease in hospitalizations [64].  While it considers 
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the potential benefit to be great, the CF Foundation considers the strength of the 
data to only be fair.  Thus it is currently classified as grade “B”, and not as a gold-
standard therapy [14].  Improvements in the medications that patients with CF 
take has lead to great improvements in the length of time that patients with CF 
live, although the average age still is in the mid 30’s [11].  The consensus is that 
AZM contributes to this success. 
Others have also investigated the positive effects of AZM in other 
pulmonary disorders.  Notably, Beigelman et. al. showed that in an experimental 
asthma model that mice treated with AZM displayed decreased influx of 
macrophages and neutrophils, as well as a decrease in the influx of eosinophils 
[65].  AZM treated mice also displayed fewer inflammatory cells around the 
airways in their lungs [65].  Others have shown that AZM decreases acute 
exacerbations and hospitalization in patients with COPD [66].  These findings 
suggest a role for AZM in a wide variety of inflammatory and fibrotic lung 
diseases, and further the importance of discovering the mechanism by which 
AZM improves symptoms. 
E.  Cell signaling and macrophage phenotype 
The NF-κB signaling pathway 
The NF-κB signaling cascade is an important pathway that leads to the 
up-regulation of many pro-inflammatory genes, and is a major transcription factor 
that controls inflammation.  A schematic of the NF-κB signaling pathway can be 
seen in figure 1.2.  Activation begins with stimulation from an external signal.  
When macrophages are exposed to Gram-negative bacteria, including P. 
aeruginosa, it is signaling through TLR4, which responds to binding to bacterial 
LPS.  The I kappa kinase (IKK) complex consists of three subunits, α,β, and γ.  
The complex is next phosphorylated via TLR4 bound My88.  Upon 
phosphorylation of this complex, the complex phosphorylates IκB.  In its 
unphosphorylated form, IκB is bound to the p50 and p65 subunits of NF-κB in the 
cytoplasm, and prevents these subunits from translocating to the nucleus.  Upon 
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phosphorylation, however, IκB is targeted for ubiquitination and destruction.  With 
the loss of its chaperone, NF-κB translocates to the nucleus, and upregulates the 
expression of a wide variety of pro-inflammatory cytokines and other cellular 
mediators [6-8].  The activation of the NF-κB cascade is one of the two steps 
necessary for macrophages to be polarized to the M1 phenotype. 
The interferon-γ STAT1 cascade 
M1 macrophages additionally require signaling from IFNγ which has been 
produced from Th1 polarized T cells (Figure 1.3).  IFNγ binding signals through 
the STAT1 signaling cascade.  Briefly, IFNγ binds to both the type 1 IFNγr, and 
the type 2 IFNγr.  These receptors are pre-associated with either Janus 
associated Kinase (JAK) 1 or 2.  Upon IFNγ binding, these receptors oligomerize.  
This allows JAK1 and JAK2 to phosphorylate both of the IFNγRs.  
Phosphorylation of the IFNγRs creates binding sites on the IFNγR for STAT1.  
Upon the binding of STAT1 to the cytoplasmic portion of the IFNγR, it is then 
phosphorylated by JAK2.  P-STAT1 then dimerizes, and is able to translocate to 
the nucleus, and binds to IFNγ associated sequences.  This induces the 
expression of proteins associated with inflammation and the M1 macrophage 
phenotype [4, 5].   
Crosstalk between the two signaling cascades  
For a macrophage to be polarized to the classically activated phenotype, 
signaling from both of these pathways is necessary [67].  Stimulating 
macrophages with either IFNγ or LPS is insufficient to achieve classical 
activation.  Likewise, if we stimulate cells with AZM alone, or with both IFNγ and 
AZM, we are unable to shift the polarization of the macrophages to the M2 
phenotype.  Both cytokine signaling, as well as signaling from LPS are necessary 
to achieve macrophage polarization [10].  It is reasonable to believe that these 
cells are wired to require signaling from both of these pathways to polarize a 
macrophage to an M1 phenotype in order to ensure that a strong inflammatory 
and destructive cell type is not needlessly activated.  However, there are 
16 
 
increasing indications that the two pathways directly interact with each other, 
rather than macrophage polarization being an additive effect of the pathways 
(Figure 1.4).   
Fong et. al. described a series of experiments suggesting a more direct 
interaction between the two pathways.  Utilizing Cre-recombinase technology, 
they created mice that were deficient in IKKβ in either their airway epithelial 
tissue, or in their myeloid cells (including macrophages).  They then infected the 
mice intranasally with group B streptococcus.  As they expected, mice with IKKβ 
selectively knocked out of their lung epithelial cells displayed a decrease in 
inflammation, and increased proliferation of group B strep.  More interestingly, 
however, was the data from the mice deficient in IKKβ in their myeloid cells.  
These mice actually had fewer bacteria in their lungs, indicating that they 
responded well to clear the infection.  They also displayed increased serum 
levels of pro-inflammatory cytokines, as well as decreased arginase 1 mRNA in 
their spleens.  The cells also showed increased iNOS protein expression [68].  
The authors suggested that IKKβ decreased M1 polarization.  It is, however, 
reasonable to assume that M2 polarization would also be increased.  They next 
found that IKKβ deficient cells displayed increased amounts of phosphorylated 
STAT1, suggesting that activated IKKβ was inhibiting the activation of the IFNγ 
signaling cascade, and that this was the mechanism by which they saw an 
increase in M1 macrophage polarization in the IKKβ KO cells [68].  They suggest 
that the crosstalk between the two pathways may exist as a mechanism by which 
the body can prevent an overly-zealous M1 response to an infection, and prevent 
any damage that may result from such a strong polarization.   
IL4rα chain and M2 macrophage signaling 
 Inactive macrophages are polarized to an M2 phenotype via signaling 
from interleukins 4 and 13 (IL4, IL13) produced by Th2 cells, mast cells, and 
basophils [69-73].  What is interesting about alternative macrophage polarization, 
however, is that both IL4 and IL13 share a common receptor chain for their cell 
signaling (Figure 1.5).  IL4 binds when the IL4rα chain and the common γc 
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receptor chain dimerize, forming the type I receptor.  The binding of IL13, on the 
other hand, causes the IL4rα chain and the IL13rα chain to dimerize, forming the 
type II receptor.  IL4 can, however, also bind to the type II receptor as well as the 
type I receptor [71].  Once either cytokine binds to either the type I or type II 
receptor, it recruits JAK 1 to the intracellular portion of the receptor, and induces 
phosphorylation.  This allows STAT6 to bind to the receptor and be 
phosphorylated.  Once phosphorylated, STAT6 dimerizes, translocates to the 
nucleus, and induces gene expression for genes that are upregulated in the M2 
phenotype [71].  In our work, we will take advantage of the commonality among 
IL4 and IL13 receptors, and employ an IL4rαKO mouse strain that lacks the 
ability to respond to either cytokine.  In using these animals, we will investigate 
the impact of an absence of the M2 subtype upon the immune response to P. 
aeruginosa infection. 
F.  Overview of the dissertation 
 With AZM, we have a commonly used medication in CF, with an unknown 
mechanism of action.  While we have previously shown that AZM is able to 
polarize macrophages to an alternatively activated phenotype, the mechanism by 
which this occurs is currently unknown.  It has been shown that one potential 
mechanism is via inhibition of NF-κB activation, although it is important to note 
that this inhibition is markedly less than by corticosteroids [74].  There is also 
evidence that there is cross-talk in the signaling pathways between the NF-κB 
signaling cascade and the IFNγ signaling cascade.  Specifically, it appears that 
IKK-β, a molecule in the NF-κB cascade that inhibits activation of NF-κB, is also 
able to inhibit phosphorylation and activation of STAT1.  STAT1 is activated by 
IFNγ, and once activated, it translocates to the nucleus and up-regulates the 
production of classically activated macrophage makers. We show below that one 
method by which AZM may polarize macrophages to the alternatively activated 
phenotype is via increasing activation of IKK-β, without a resulting increase in 
NFκB activation.   
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We also are interested in what the role of increased M2 activation in the 
lungs of patients with CF may mean in the long term for these patients.  The 
three major studies assessing AZM in CF have been conducted over a short time 
period (3-12 months) [16, 18, 20].  The long term effects of the medication are 
unknown.  On first consideration, changing the polarization of macrophages 
towards a pro-fibrotic phenotype is counterintuitive.  Indeed, there is data 
suggesting that in other fibrotic lung diseases a Th2 polarization leads to 
alternatively activated macrophages, and results in increased scarring and 
fibrosis [55].  Another possibility, however, is that by altering macrophage 
polarization away from the M1 phenotype and towards the M2 phenotype, AZM is 
able to blunt an overly zealous inflammatory response.  By doing so, there will be 
less damage to the lung parenchyma and peribronchiolar tissues, and a resultant 
decrease in scarring and fibrosis in the lungs of these patients.  This possibility is 
also consistent with data showing that AZM treatment results in a decrease in 
acute exacerbations of CF, as well as a decline in the amount of courses of 
intravenous antibiotics that patients taking AZM experience [18, 20].    
We hypothesize that AZM polarizes macrophages to an alternatively 
activated phenotype via IKKβ dependent mechanisms.  We also hypothesize that 
by increasing M2 activation and decreasing M1 activation, AZM will improve the 
response of mice and humans to pulmonary infections and CF.  This will be 
investigated through a variety of in vitro, in vivo, and human based studies.   
In this dissertation, I will utilize a combination of cell culture, in vivo 
experiments with mice, and human clinical research to test the mechanism and 
importance of AZM dependent macrophage polarization in inflammatory lung 
diseases.  I will describe how AZM polarized macrophages alter the production of 
fibrotic markers in a co-culture system of macrophages and fibroblasts.  
Alternatively activated macrophages produce the precursors to fibrotic proteins, 
and we hypothesized that macrophages polarized by AZM would increase the 
production of fibrotic proteins in the co-culture system [2].  At first thought, 
increasing the amount of a pro-fibrotic macrophage phenotype in a fibrotic lung 
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disease such as CF seems counterproductive.  Indeed, if a Th2 polarization in 
the lungs is associated with a decline in outcomes in patients with CF, it would be 
reasonable to suggest that a shift to an M2 phenotype would be associated with 
a decline in outcomes in these patients [32].  A greater understanding of the 
effector functions of AZM polarized macrophages will allow us to understand 
whether the drug is polarizing macrophages to a novel phenotype, which may 
function in a manner different than a traditional alternatively activated 
macrophage. 
Second, I will describe a potential mechanism by which AZM is able to 
alter the polarization of macrophages, towards an M2-like phenotype.  The 
manner by which macrolide antibiotics are able to polarize to an alternatively 
activated-like phenotype is currently unknown.  A greater understanding of this 
could provide future targets for medications that provide the immunomodulatory 
effects of macrolides, without the need to place patients on antibiotics 
chronically.  I will additionally describe the role of M2 macrophages in the context 
of acute infections with PA, and whether AZM is able to polarize macrophages to 
the alternatively activated phenotype in a manner independent of IL4 and IL13 
signaling, continuing the investigations into potential mechanisms by which AZM 
is able to alter macrophage polarization.  We have access in our laboratory to a 
mouse strain that is deficient in the IL4rα chain.  This receptor subchain is 
necessary for both IL4 and IL13 to properly signal [2].  Macrophages from mice 
deficient in the IL4rα chain display an impaired ability to be polarized to the 
alternatively activated phenotype.  We have used these mice to first characterize 
the host response to P. aeruginosa infection with a lack of alternative 
macrophage activation by the cytokines.  These results describe the importance 
of M2 macrophages in the response to intratracheal infection with P. aeruginosa.  
Then, by treating mice deficient in the IL4rα chain with AZM, as well as 
conducting ex vivo experiments on the cells collected from these mice, we were 
able to assess whether the ability of AZM to polarize macrophages is dependent 
on IL4 or IL13 signaling.   
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Finally, I will describe a pilot human study that was conducted in 
conjunction with our translational team of investigators.  We collected sputum 
samples from patients with CF, isolated mRNA, and performed quantitative real-
time PCR on a variety of M1 and M2 proteins, as well as inflammatory and 
fibrotic markers.  We then correlated these gene markers to the clinical 
parameters of the patients.  We additionally performed principal component 
analysis as a data reduction method to assess which gene markers are 
correlated with each other.  By doing this, we were able to place our subjects into 
subgroups that are high or low in the various components, and assess whether 
these patient groupings corresponded with certain clinical features.  This allowed 
us to determine if differences in gene expression were associated with clinical 
outcomes or disease severity in subjects with CF.  We hypothesized that 
increased markers of M2 activation would be associated with AZM use and 
declines in lung function in these subjects.  An increased understanding of 
macrophage associated gene expression in subjects with CF will lead to clinical 
validation of our molecular and animal data, to provide a basis for future research 
in therapeutic target discovery. 
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Figure 1.1.  Overview of arginine metabolism with macrophage polarization.  M1 
macrophages upregulate iNOS, leading to the conversion of arginine to citrulline 
and nitric oxide.  The produced nitric oxide is part of an oxidative burst in 
macrophages, leading to destruction of internalized bacteria and localized 
inflammation.  M2 macrophages upregulate arginase.  Arginase competes with 
iNOS for arginine, and catalyzes arginine to urea and ornithine.  Ornithine is a 
necessary component of polyamines, which are then converted into fibrotic 
molecules including collagen.  Collagen production and incorporation into the 
extracellular matrix is essential for tissue repair and fibrogenesis.  Adapted from 
[9, 10].   
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Table 1.1.  Function and markers of different macrophage phenotypes.  Listed 
are the macrophage phenotype, the stimulation necessary to polarize an inactive 
macrophage to that phenotype, the function of the cell, surface markers, 
functional markers, and the cytokines produced (adapted from [1-3]). 
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Figure 1.2.  Activation of the NF-κB signaling cascade.  LPS binds to TLR4, 
eventually leading to activation of the IKK complex.  Upon activation of the IKK 
complex, it phosphorylates IκB, leading to the destruction of IκB.  IκB had been 
bound to NF-κB, preventing it from translocating to the nucleus of the cell.  When 
NFκB translocates to the nucleus, it binds to DNA leading to the transcription of 
genes associated with inflammation.  Adapted from [6-8] 
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Figure 1.3.  Activation of the IFNγ-STAT1 cascade.  IFNγ binds to the IFNγr, 
leading to the recruitment of JAK1 and JAK2 to the receptor.  The binding of 
these two molecules allows STAT1 to bind to the receptor and become 
phosphorylated.  P-STAT1 dimerizes and translocates to the nucleus, leading to 
the transcription of genes associated with M1 macrophage polarization.  Adapted 
from [4, 5].   
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Figure 1.4.  Crosstalk between the NF-κB and IFNγ-STAT1 cascade.  Evidence 
exists that IKKβ prevents STAT1 from being phosphorylated.  It has been 
hypothesized that this exists in part to eventually dampen a potent inflammatory 
response.  We will address the effect the AZM has upon IKKβ activation, leading 
to the prevention of the IFNγ-STAT1 cascade. 
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Figure 1.5.  The IL4/IL13 signaling cascade.  IL4 binds to dimers of the IL4rα 
chain and the common cytokine gamma chain.  IL13 binds to dimers of the IL4rα 
chain and the IL13rα chain.  JAK1is then recruited to the intracellular portion of 
the receptor.  This leads to recruitment and phosphorylation of STAT6.  P-STAT6 
then dimerizes and translocates to the nucleus, leading to the transcription of 
genes associated with the M2 phenotype. 
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Chapter 2:  Azithromycin alters interactions between macrophages and 
other cell types 
A.  Introduction 
Chapter overview 
 To build upon previously generated data from our laboratory, we 
expanded our investigation of the impact of AZM exposure, this time in a series 
of in vitro experiments designed to test the impact the drug has upon 
macrophage function.  While our previous work has described the ability of AZM 
to affect changes in macrophage polarization to an M2-like phenotype we still 
have little knowledge as to the functional abilities of cells treated with the drug 
[63, 75].  Because of the role that M2 cells play in orchestrating tissue 
remodeling and fibrosis in damaged lungs [2], we set out to investigate the 
interplay between AZM polarized macrophages and fibroblasts.  This was done 
to determine more about the phenotype of AZM polarized macrophages, and the 
mechanisms by which macrophages interact with cells that produce fibrotic 
proteins.  We hypothesized that AZM polarized macrophages would interact with 
fibroblasts in a co-culture system resulting in increased fibrogenesis. 
 Macrophage polarization: a brief overview 
 Macrophages are polarized to either the M1 or the M2 phenotype primarily 
by cytokines produced from T cells [1-3].  Polarization to the M1 phenotype 
requires signaling from the Th1 derived cytokine IFNγ, as well as a bacterial 
signal such as LPS.  The M2 phenotype requires signaling from IL4 and IL13, 
which are produced primarily from Th2 polarized T cells [3].  It is important to 
note that this polarization is not terminal, unlike T cells.  If an M1 macrophage is 
exposed to IL4/13, it can be shifted to the M2 phenotype, and vice versa. 
 Historically, when describing macrophages, it has been the classically 
activated, or M1 phenotype that has been described.  M1 macrophages are 
phagocytic, and produce reactive oxygen species such as nitric oxide (NO).  This 
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allows these cells to rapidly and effectively internalize and destroy infectious 
pathogens [35].  Macrophages are polarized to the M1 phenotype primarily from 
Th1 T cell produced IFNγ [76, 77].  M1 macrophages additionally initiate 
inflammation by producing inflammatory cytokines including TNFα, IL12, IL1 and 
IL6 that draw other inflammatory cell types to the site of an acute infection [34, 
36].  Classically activated macrophages additionally upregulate adhesion 
molecules such as CCR7 that allow macrophages that have internalized bacteria 
to then relocate to the lymph nodes, allowing presentation to the rest of the 
immune system [3].  Both the influx of inflammatory cells, as well as the oxidative 
burst caused by M1 macrophages leads to tissue damage, which over time 
adversely effects lung function [37]. 
 The host response to these bacteria is, in normal circumstances, under 
tight control and regulation.  However, the damage and destruction caused by 
both pathogens and the immune system’s response to that damage then requires 
considerable repair [78].  This repair is in part orchestrated by M2 macrophages 
[2].  These macrophages are both anti-inflammatory and profibrotic.  The M2 
macrophage pattern of gene expression increases during the regulatory phase of 
an acute infection in part to produce anti-inflammatory cytokines to prevent 
excessive damage [79].  M2 macrophages additionally produce the precursors to 
fibrotic proteins such as polyamines, leading to repair, fibrosis, and scarring [38].  
These polyamines precursors are produced primarily from arginase dependent 
catabolism of arginine to ornithine [80].  M2 macrophages additionally upregulate 
expression of transforming growth factor beta (TGFβ).  During fibrotic lung 
diseases, increased TGFβ signaling results in chemotaxis of macrophages and 
fibroblasts to the site of damage, secretion of growth factors, fibroblast 
proliferation, and production of extracellular matrix molecules by fibroblasts [69, 
81]. 
Transforming growth factor beta 
 Transforming growth factor beta (TGFβ) exists in three different isoforms, 
TGFβ 1, 2, and 3.  Among these, TGFβ 1 is the best characterized [81-83].  It is 
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thought that all three isoforms exert similar effects  [83].  TGFβ is secreted in an 
inactive form from cells including macrophages, and is then attached to the 
extracellular matrix.  TGFβ activation plays a vital role in the generation of the 
fibrotic molecules of the extracellular matrix, including fibronectin and collagen 
[84].  It can then be cleaved to its active form by a variety of enzymes, including 
elastases and metalloproteases [82].  Cells secrete large amounts of inactive 
TGFβ, to allow the body to allow quick activation of the protein and facilitate cell 
proliferation and fibrogenesis [82].  The secretion of inactive TGFβ, followed by 
its eventual activation, allows the rapid marshalling of a large amount of activated 
TGFβ in the face of a strong inflammatory response [82, 83]. 
Macrophage polarization by azithromycin 
 Our group has previously shown that AZM is able to polarize 
macrophages to a phenotype resembling that of alternatively activated cells.  We 
have demonstrated this by assessing surface expression of markers of 
macrophage polarization, functional proteins produced by each type of cell, and 
the cytokine production profile [63].  What we do not know, however, is if AZM is 
polarizing macrophages to the M2 phenotype, or to a novel phenotype that 
contains unique characteristics.  This possibility would explain in part why AZM 
benefits patients with CF.  At first glance, one might assume that shifting 
macrophage gene expression to the pro-fibrotic M2 phenotype would be 
detrimental for these patients.  More cells with the pro-fibrotic M2 phenotype 
could conceivably lead to increased scarring and fibrosis in the lungs of these 
patients.  If this was the case, we would expect AZM treatment to worsen the 
functional decline for these patients.  Instead, as noted in Chapter 1, it has been 
shown that AZM modestly benefits patients with CF [16-18, 20]. 
We posit that by shifting the balance of macrophage polarization during an 
acute flare away from the pro-inflammatory M1 phenotype and towards the anti-
inflammatory, pro-fibrotic M2 phenotype which will inflict less damage.  A 
decrease in the damage associated with acute infection would then require less 
repair, and a resultant decrease in remodeling and fibrosis formation.  This is 
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especially true in the situation of CF, as the immune response in these patients is 
exaggerated [32, 45].  By decreasing the amount of pro-inflammatory M1 
macrophages in the lungs of these patients, AZM may be altering the “set point” 
for an acute flare of the disease.  That is, treatment with AZM may be preventing 
an overly zealous immune response from initially occurring, while allowing the 
immune system to still respond to the infection in a productive manner. 
Data from our lab and others support this notion.  In our mouse model of 
Pseudomonas infection, when AZM induces an M2 phenotype to predominate, 
neutrophil influx is blunted and peribronchiolar inflammation is lessened.  We 
additionally found greater macrophage influx into the lungs of these mice.  The 
cells that infiltrate into the lungs of these mice additionally produce fewer 
inflammatory cytokines and more anti-inflammatory cytokines [75].  Herbert et. al. 
have shown the importance of M2 macrophages in infections with Schistosoma 
mansoni.  They found that infected LysMcreIL4rα-/flox mice, which lack IL4 and 
IL13 signaling on their macrophages, displayed 100% mortality, as compared to 
wild-type controls, in which upwards of 75% survived the infection.  They 
determined that this increased mortality was due almost entirely to an overly 
zealous immune response, characterized by NOS2 overexpression and impaired 
egg expulsion [85].  Pesce et. al. found similar results with Schistosoma 
mansoni.  Intriguingly, however, they also found similar results with mice lacking 
arginase 1 expression in their macrophages.  They surmise that this is due to 
arginase 1 depleting arginine, leading to a blunting of the CD4+ T cell response.  
The addition of exogenous arginine similarly led to increased mortality, due 
primarily to the recovery of the CD4+ T cell response in these mice [86].  
Finally, AZM may be polarizing macrophages to a novel phenotype that is 
anti-inflammatory, while not playing a role in fibrogenesis.  In these experiments 
we set out to determine if the phenotype of AZM polarized macrophages leads to 
increased production of fibrotic proteins in a co-culture system with fibroblasts.  
An increase in fibrogenesis in this system would suggest that AZM-polarized 
macrophages and IL4/13-polarized macrophages function similarly.  A greater 
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understanding of the interplay between AZM-treated macrophages and 
fibroblasts may lead to a greater understanding of the benefits of AZM treatment.   
Production of fibrotic proteins and macrophages 
 Alternatively activated macrophages produce cytokines and other effector 
proteins that lead to increased production of fibrotic proteins, including TGFβ, 
fibronectin, and collagen in the lungs [3].  TGFβ signaling results in down-
regulation of the molecules that degrade the extracellular matrix, including the 
matrix metalloproteases [81].  High expression of TGFβ has also been 
associated with a decline in lung function in patients with CF [87].  Fibronectin 
and collagen production is also upregulated, both in the macrophages as well as 
the other cells present in the lung parenchyma.  This results from byproducts of 
arginase metabolism [80].  The enzyme arginase converts arginine to ornithine 
and urea.  Ornithine is a precursor to polyamines, which are, in turn, precursors 
to matrix proteins including collagen [46, 88].  There is also considerable 
evidence suggesting that M2 macrophages themselves produce fibronectin [89].  
This fibronectin, once produced by either macrophages or fibroblasts, is 
incorporated into the extracellular matrix, and provides strength and support to 
the remodeled tissue [89].  We can thus test for the presence of fibrotic proteins 
in vitro as we culture macrophages and fibroblasts together as a functional 
surrogate, and determine whether AZM treatment results in a macrophage that is 
pro-fibrotic.  We hypothesized that AZM polarized macrophages would increase 
the production of fibronectin in a co-culture with fibroblasts.  We aimed to 
determine the effect of AZM polarized macrophages on fibrogenesis by other cell 
types. 
B.  Detailed methods 
Co-culture of macrophages and fibroblasts 
The mouse cell lines NIH/3T3 and J774A.1 (ATCC, Manassas, VA) were 
used for all co-culture experiments.  The NIH/3T3 line (ATCC #CRL-1568) is a 
fibroblast cell line originally obtained from embryonic cultures of NIH Swiss mice 
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[90].  The J774 (J774A.1, ATCC #TIB-67) cell line is an immortalized 
macrophage cell line derived from BALB/cN adult mice [91].  Cells were grown in 
RPMI 1640 media (Invitrogen, Carlsbad, CA), supplemented with 5% fetal calf 
serum and 2x10-5M 2-mercaptoethanol at 37°C and 5% CO2.  On day 0 of the 
experiment, NIH/3T3 cells were added to 6 well plates at a density of 2.5 X 105 
cells/ml, and allowed to incubate overnight.  The media was removed the next 
morning and replaced with 5 milliliters of new medium along with 5 X 104 J774 
cells/1ml, and again allowed to incubate overnight.  The next morning, cells were 
stimulated by adding interferon-γ (R&D systems, Minneapolis, MN) (IFNγ) 
(100ng/mL) and 2.5 X 105 P. aeruginosa, of the strain PA39018, a non-biofilm 
producing strain obtained from ATCC (Manassas, VA).  To study the effects of 
the drug, designated wells additionally received 30μM AZM (Sigma Aldrich, St. 
Louis, MO) (AZM).  Some experiments additionally utilized a blocking antibody to 
TGFβ at a concentration of 0.5μg/ml (R&D Systems, Minneapolis, MN). Cells 
were incubated and harvested after 0, 6, 12, 24, 48, and 72 hours.  At these time 
points, cells were scraped and centrifuged, and 1mL of media was saved for 
TGFβ analysis.  Cells were washed, enumerated with trypan blue staining to 
assess viability, and aliquots were taken for the arginase activity assay and qRT-
PCR.  Supernatants and cell lysates were frozen at -80°C for later analysis, 
including arginase activity and fibronectin quantification.  Cell lysates were 
suspended in either 150μl of RIPA buffer with Roche Mini-tablet protease 
inhibitor cocktail, or in RNAlater (Applied Biosystems, Foster City, CA). 
Quantification of arginase activity 
 Arginase activity was assessed via the protocols first described by 
Corraliza et. al. [92].  This reaction assesses the concentration of urea in the 
culture supernatant.  Urea is a byproduct of the reaction converting arginine to 
ornithine, and directly correlates to the concentration of arginase present.  Briefly, 
12.5 μL of 10mM MnCl2 in 50mM Tris HCl was added to 12.5 μL of cell lysates.  
The arginase enzyme was activated by incubating the samples at 55°C for 10 
minutes.  A 0.5M arginine solution was then added, and the samples were 
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incubated at 37°C.  The reaction was terminated by the addition of 400 μL of an 
acid solution consisting of H2SO4, H3PO4, and water at a ratio of 1:3:7.  Alpha-
Isonitrosopropiophenone (9% w/v) dissolved in 100% ethanol was added, and 
the mixture was then heated at 95°C for 45 minutes.  All chemicals were 
purchased from Sigma Aldrich (St. Louis, MO).  Optical density was assessed 
utilizing an ELx808-I microplate reader and a 490 nM filter (Bio-Tek instruments, 
Winooski, VT).  Readings were compared to a standard curve of known urea 
concentrations, and then were then normalized both to protein concentration and 
to cell counts.  The values for arginase activity shown in this research are 
expressed in terms of units of arginase activity.  One unit of arginase activity is 
responsible for the catalysis of 1 μmole of L-arginine to ornithine and urea per 
minute at a pH of 9.5 at 37°C. 
Fibronectin protein quantification 
Cell culture supernatants were analyzed and the fibronectin 
concentrations quantified by indirect ELISA.  Samples were diluted in coating 
buffer and incubated at 4°C overnight for adherence to the ELISA plate.  Wells 
were blocked, then incubated with an antibody specific to MMP-9 (Abcam, 
Cambridge, MA), followed by an anti-rabbit HRP conjugated secondary antibody. 
Wells were analyzed by OD reading at 450nm, using OptEIA detection reagents 
(BD, ).  Readings were compared to a standard curve using MMP-9 or fibronectin 
recombinant protein. 
Surface marker expression 
 Cells were incubated with fluorescently-labeled monoclonal antibodies to 
both identify macrophages and detect surface receptors indicative of alternative 
activation. Antibodies specific for mouse mannose receptor (MR) (Serotec, 
Raleigh, NC), and CD11b (BD bioscience, San Jose, CA) were used. The cells 
were washed before and after antibody incubation with azide-containing buffer.  
Cells were analyzed by flow cytometry using a BD LSRII Flow Cytometer System 
(BD Biosciences, San Jose, CA) under the direction of a dedicated operator.  
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Fifty-thousand events per sample were routinely collected, and data was 
analyzed using FlowJo software package (Tree Star, Ashland, OR). 
qRT-PCR 
 RNA was isolated using RNeasy mini kits (QIAGEN, Valencia, CA).  
Isolated RNA was quantified using a Nanodrop 2000 (Thermo Fisher Scientific, 
Wilmington, DE).  Reverse transcription was performed on equal amounts of 
RNA utilizing Taqman Reverse Transcriptase Reagents (Applied Biosystems, 
Foster City, CA) according to manufacturer’s protocols.  Quantitative real-time 
PCR was initiated utilizing Taqman gene expression arrays for murine TGF-β1 
and GAPDH using an ABI Prism 7000 (Applied Biosystems, Foster City, CA). 
Preparation of P. aeruginosa impregnated agarose beads and mouse 
infection 
 To ensure a viable infection, P. aeruginosa of the biofilm producing strain 
M57-15 was impregnated in agarose beads.  Bead preparation was an 
adaptation of previously described methods [93, 94].  In the absence of agarose 
beads, mice are able to quickly clear infections with P. aeruginosa.  Impregnation 
in agarose beads allows for a more chronic, stable infection, and leads to greater 
cellular infiltration and weight loss in these animals [94].  In brief, P. aeruginosa 
was first grown to late log or early stationary phase in TSB.  The organism was 
then added to a 2% agarose solution in PBS.  This solution was then combined 
with warm mineral oil, and quickly cooled.  The beads were then washed twice in 
solutions of deoxycholic acid to remove the mineral oil, followed by 6 washes 
with PBS.  Beads were resuspended in PBS, and an aliquot was collected, 
homogenized, and plated on TSB agar plates to determine the number of viable 
bacteria in the beads.     
Tissue processing and cell phenotyping 
 Lungs were minced in RPMI and digested in 50U/ml DNase (Sigma 
Aldrich, St. Louis, MO) and 1mg/ml collagenase A (Sigma Aldrich, St. Louis, 
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MO).  After incubation for 1 hour, cells were pushed through a mesh screen.  
Red blood cells were lysed using a hypotonic salt solution.  Cells were washed 
twice, enumerated, and transferred to 5ml round bottom polystyrene tubes for 
flow cytometry analysis.  Aliquots of cells were collected and lysed in RIPA buffer 
to protect protein in the samples.  These cells were then frozen at -80° C for later 
analysis.  An additional aliquot was incubated at 37°C with 5% CO2 for 2 hours 
with 50ng/ml phorbol 12-myristate 13-acetate (PMA) and 1μg/ml ionomycin, 
followed by 2 hours with 10 μg/ml brefeldin A to stimulate production of 
intracellular cytokines for flow cytometry analysis. 
 Cells were stained for flow cytometry for markers of general cell 
phenotype, as well as markers of macrophage phenotype and both inflammatory 
and anti-inflammatory cytokines.  Three different flow cytometry panels were 
assessed for each type of mouse.  The first panel for the C57bl/6 mice consisted 
of CD11b-PECy5 (Serotec, Raleigh, NC), a marker found on macrophages, GR1-
PECy7, a marker of neutrophils, MR-PE, a marker of M2 macrophages (Serotec, 
Raleigh, NC), CD80-FITC, a marker of M1 macrophages, and biotinylated I-A[b] 
MHC II, a protein that is increased in expression with classical macrophage 
activation.  Panel 2 consisted of CD11b-APC, CD11c-PECy7 (BD Bioscience, 
San Jose, CA), a marker of resident macrophages and dendritic cells, CD4-
PECy5, a marker of CD4+ T-cells, GR1-FITC, and CD19-PE, a marker of B-cells.  
Panel 3 consisted of CD11b-PEcy5, CD11c-PECy7, TNFα-FITC, biotinylated 
TGFβ, and IL10-PE.  Secondary staining was performed when appropriate 
utilizing a streptavadin conjugated to APC.  All antibodies were purchased from 
BD bioscience (San Jose, CA), unless otherwise stated.  Cells were analyzed 
with utilizing a FACSCaliber Flow Cytometer (BD Biosciences, San Jose, CA) 
with a dedicated operator.  Greater than 50 thousand events per sample were 
routinely examined.  Flow cytometry analysis was performed utilizing FlowJo 
(Treestar, Ashland, OR). 
Statistical analysis 
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Results are reported as mean ± SD and compared using GraphPad Prism 
(GraphPad Software, La Jolla, CA).  A repeated measures ANOVA with Tukey’s 
multiple comparison test were utilized for time courses.  For some data, T-tests 
were used to compare means between groups.  Non-linear regression utilized 
the least squares method for fit.  Differences in survival were assessed utilizing a 
log-rank (Mantel-Cox) test.  Unless otherwise stated, significance was deemed to 
be a p value <0.05.   
C.  Results and discussion 
Azithromycin increases markers of the M2 phenotype in the presence of P. 
aeruginosa when macrophages are co-cultured with fibroblasts 
 We first assessed markers of M2 activation in the co-culture system, to 
ensure that AZM was able to achieve this polarization in the presence of both a 
second cell type, as well as in the presence of a live P. aeruginosa, as opposed 
to bacterial LPS [63].  We measured arginase activity in the lysates from co-
cultured cells over time stimulated with the live organism in the presence of IFNγ 
as described in the Methods section (Figure 2.1).  We found that arginase activity 
was significantly higher in the cells treated with AZM, as compared to the cells 
that did not receive AZM after 24, 48, and 72 hours in culture.  Arginase 
concentrations decreased as expected when the organism was introduced, as 
this shifts macrophages into a pro-inflammatory state.  AZM exposure appeared 
to cause stabilization in production, so that by 24 hours the concentration of 
arginase rebounded to a significantly higher level than the control wells.  We next 
assessed the impact of AZM upon the numbers of cells expressing both CD11b 
and MR.  Cells positive for CD11b represent the macrophage cell line, as 
fibroblasts are negative for this surface protein, and MR is a representative 
protein with a trend towards upregulated expression during alternative 
polarization (Figure 2.2).  In concordance with the increases observed in 
arginase activity, we found that cells treated with AZM displayed increased MR 
expression at 24, 48, and 72 hours.  Both the arginase and mannose receptor 
data suggest that AZM is also able to polarize macrophages toward an M2-like 
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phenotype in the presence of viable P.aeruginosa, and the fibroblast cell line.  
This confirmation allowed us to move forward with the co-culture experiments 
confident that AZM is affecting the changes that we have observed previously in 
J774 cultures. 
Azithromycin increases TGFβ activation 
 We first assessed the concentration of activated TGFβ in the lysates from 
our co-culture system (Figure. 2.3 A.).  The assay that we utilized non-specifically 
measures activation of all 3 isoforms.  Here we found that after 24 and 48 hours 
of culture with P. aeruginosa in the presence of IFNγ, there was a marked 
increase in the amount of active TGFβ found in the supernatants when AZM was 
present (p<0.05 and p<0.01, respectively).  We then assessed the ratio of 
activated TGFβ to total TGFβ in the system (Figure. 2.3 B).  We found that the 
ratio was higher in the cells that were treated with AZM as compared to cells that 
did not receive AZM at 24 hours (p<0.05).  Intriguingly, in the cells that received 
IFN and LPS there were essentially no differences in the active TGFβ to total 
TGFβ ratio across the various timepoints.  It was only in the cells treated with 
AZM that we observed a marked increase in TGFβ activation.  We finally 
assessed TGFβ-1 gene expression via quantitative real-time PCR (Figure. 2.3 C) 
over time after P. aeruginosa stimulation.  While we observed a marked up-
regulation in TGFβ gene expression in both the IFN and IFN+AZM groups after 6 
hours, there was then a down-regulation of TGFβ gene expression in both 
groups.  There was less of a decrease in TGFβ-1 gene expression in the cells 
that received AZM, as compared to the cells that did not receive AZM, although 
neither individual timepoint differences nor differences of the entire curve were 
statistically significant. 
 This data suggests that AZM exerts a considerable effect on TGFβ 
activation in our co-culture system.  We additionally observed trends towards 
increased TGFβ-1 gene expression in the co-culture system in cells treated with 
AZM.  While the exact mechanism by which TGFβ activation in our co-culture 
system is increased is yet unknown, we have hypothesized that AZM may be 
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increasing expression of enzymes that activate TGFβ.  The matrix 
metalloproteases (MMPs) are molecules that play an important role in 
extracellular matrix homeostasis by cleaving the proteins in the extracellular 
matrix facilitating matrix turnover.  As part of the facilitation of this turnover, 
MMP-9 additionally plays a role in the cleavage and activation of matrix bound 
TGFβ, leading to new fibrogenesis [95].  Indeed, work done by others in our 
laboratory has shown that AZM up-regulates expression of MMP 9, and therefore 
we have hypothesized that this up-regulation is responsible, at least in part, for 
increased TGFβ activation.  While others have shown that the production of 
inactive TGFβ is upregulated in M2 macrophages, we did not observe significant 
differences, only trends in gene expression of TGFβ-1.  Three possibilities 
present themselves.  First, we may not have had adequate power to detect 
significant differences.  Second, we only assessed production of TGFβ-1, and did 
not assess gene expression of any other TGFβ isoforms.  Had we assessed 
these other isoforms, we may have detected significant differences in gene 
expression with AZM treatment.  Finally, AZM appears to  not be increasing 
TGFβ gene expression in our macrophages.  This would represent a difference 
between macrophages polarized to the M2 phenotype via IL4/13 and 
macrophages polarized to the M2 phenotype via AZM.  In IL4/13 dependent M2 
macrophage polarization, TGFβ production is upregulated [38].   
Azithromycin results in increased fibronectin production in co-cultured  
macrophages and fibroblasts 
 We then assessed the concentration of the fibrotic protein fibronectin in 
the co-culture system (Figure 2.4).  Fibronectin is secreted by macrophages and 
fibroblasts, and we would expect expression to be increased with the addition of 
AZM [81].  This is in fact what we observed.  After culturing cells in the presence 
of IFNγ and P. aeruginosa, significantly higher fibronectin concentrations were 
measured in the cell lysates at 12 and 24 hours with the addition of AZM (p<0.01, 
0.05, respectively).  Separate controls utilizing only J774 and NIH/3T3 were 
additionally utilized to confirm that changes in fibronectin expression was due to 
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effects between the two cell types, instead of AZM directly causing fibrogenesis 
(Figure 2.4 B., C.).  This suggests that macrophages polarized to the M2 
phenotype via AZM lead to increased fibronectin production, both from the 
macrophages and the fibroblasts in the co-culture system.  We surmise that this 
occurs for two reasons.  First, we believe that AZM stimulated macrophages are 
increasing their production of inactive TGFβ.  This is confirmed by our qRT-PCR 
data showing that at our later timepoints there is more TGFβ-1 mRNA in 
conditions treated with AZM.  Others have found similar findings with different co-
culture systems [54].  Second, we believe that the AZM treated macrophages are 
additionally upregulating metalloproteases including MMP, leading to increased 
activation of the inactive TGFβ in the extracellular matrix.  The combination of 
increased TGFβ production and increased activation of the TGFβ that is 
produced is responsible for increased fibrogenesis by the fibroblasts in the co-
culture system. 
 The increase in fibronectin concentration that we found suggests that AZM 
polarized macrophages function in a manner similar to M2 macrophages.  We 
have previously shown that AZM polarized macrophages display surface markers 
and functional proteins consistent with the M2 phenotype [63].  Here we 
demonstrate that AZM polarized macrophages exert a similar effect on 
fibroblasts and fibrogenesis as has been reported by others [55, 96].  This further 
supports the notion that AZM polarized macrophages function in a similar 
manner to that of M2 cells, rather than a novel phenotype. 
Blockade of TGFβ activity eliminates azithromycin dependent fibronectin 
expression in co-cultured macrophages and fibroblasts. 
 We finally repeated these experiments additionally utilizing a blocking 
antibody to TGFβ.  Addition of the blocking antibody eliminated the differences in 
fibronectin concentrations in the cell lysates between conditions treated with AZM 
and those that did not receive AZM (Figure 2.5).  This further mechanistically 
narrows the mechanism by which AZM treatment of macrophages results in 
increased fibrogenesis.  It appears that increased activation of macrophage-
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derived TGFβ is responsible for the increases in fibroblast derived fibrogenesis in 
the co-culture system. 
Azithromycin results in increased survival in C57bl/6 mice infected with P. 
aeruginosa 
 We next assessed the role of AZM in C57bl/6 mice infected with P. 
aeruginosa.  We wanted to assess the importance of this AZM dependent 
macrophage polarization in the context of a complete immune response, to 
further the work done in our in vitro system.  We examined the effect of AZM on 
weight loss, survival, and bacterial colony counts in our C57bl/6 mice that were 
treated with AZM.  We first assessed weight loss between mice that did or did not 
receive AZM (figure Figure 2.6 A.).  Infected mice lost weight consistently over 
the first 3 days after infection, after which time weight was regained over the 
remainder of the study period.  Statistically significant weight loss was noted in 
both infected groups of mice as compared to a sham-infection control group on 
days 1 through 3.  No statistically significant difference was observed as a result 
of AZM treatment between groups of infected animals, although the mice treated 
with AZM displayed a non-significant trend of gaining weight back more quickly 
around day 7 post-infection.  We then assessed differences in survival for 
animals infected with P. aeruginosa incorporated into agarose beads that did or 
did not receive AZM (Figure 2.6 B.).  This data represents pooled data from 
multiple iterations of our infections.  We found that mice treated with AZM had a 
significantly higher rate of survival compared to mice that did not receive the drug 
(p=0.0195).  Only a small amount of our AZM treated animals died or had to be 
sacrificed early in accordance with our protocol.  In animals that did not receive 
AZM, however, we observed a death rate approaching 50%.  Finally, we 
assessed the number of bacteria present in the lungs of these animals (Figure 
2.6 C.).  Importantly, we found no differences in the number of bacteria in the 
lungs of the mice between the two groups.  The bacterial burden, in fact, did not 
differ at any timepoint examined during any experiment performed, suggesting 
that AZM does not exert an effect on bacterial clearance in this  infection model. 
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Azithromycin increases monocyte influx and decreases neutrophils influx 
 We then assessed the of the characteristics of cellular influx in both the 
alveolar space (lavages) and lung digest samples in mice infected with P. 
aeruginosa incorporated into agarose beads, to determine if AZM treatment had 
an effect.  In the lung digests, we found a trend towards an increase in the 
number of cells present in the lungs of animals treated with AZM at day 14 of the 
experiment (p=0.067) (figure 2.7 A.) [75].  Expression of the protein CD11b was 
evaluated as a marker of monocytes that were elicited into the lungs post-
infection.  The marker is highly expressed on infiltrating macrophages.  We found 
significantly more CD11b+ cells in the lung lavages on day 7 post-infection 
(p=0.006), indicating an increase in the number of infiltrating monocytes present 
in the lungs of these mice (figure 2.7 B.).  Finally, we found that AZM treatment 
resulted in decreases in the numbers of neutrophils present in the lungs of these 
animals, both in the lung digest at day 7 (p=0.002) (figure 2.7 A.) and a trend 
towards a decrease in the numbers of neutrophils present in the lung lavage 
samples.  The number of CD4+ T cells in the lung parenchyma increased 
similarly through day 7, but by day 14 there was a significantly higher number of 
CD4+ T cells in the mice treated with AZM (p<0.001).  Similarly, the number of 
CD4+ T cells that infiltrated the alveolar space was higher in mice treated with 
AZM on day 7 post-infection (p=0.004).  This data shows that AZM appears to be 
altering the types of cellular influx present in the lungs of these mice.   
Azithromycin shifts macrophage polarization in the lungs to the M2 
phenotype 
 Because CD11b+ cells displayed differences in migration characteristics 
with AZM exposure, we analyzed the activation characteristics of these cells. 
(Figure 2.8 A.) [75].  When examining the surface protein expression of cells that 
were CD11b+GR1- (monocytes), MR expression was consistently increased in 
the AZM treatment group on day 7 post-infection (p=0.003).  Conversely, 
expression of the classical activation marker CD80 was decreased in the cells in 
the lung digest in mice receiving AZM (p=0.002).  Other surface receptors 
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including CD23, CCR7, and MHC II were up-regulated post-infection on 
CD11b+Gr-1– cells in a similar manner between the treatment groups.  We 
additionally observed increased arginase expression in the mice that received 
AZM on day 7 of the experiment (p<0.001) (Figure 2.8 B.).  This data further 
confirms the findings that we have previously observed in vitro concerning the 
ability of AZM to polarize macrophages to an alternative-like phenotype.   
Azithromycin alters the influx of inflammatory cells to the lungs of C57bl/6 
mice 
Patients with chronic inflammatory lung conditions who are infected with P. 
aeruginosa are susceptible to the development of inflammation and fibrosis 
surrounding the small airways.  To determine the extent to which AZM affected 
the damage to the lung parenchyma, histology sections were prepared from 
lungs isolated at each timepoint.  Evaluation using H&E staining revealed 
inflammatory changes in both AZM-treated and -untreated groups at days 3 and 
7 post-infection.  Day 7 sections from AZM-treated animals were suggestive 
however of a decreased amount of interstitial inflammation surrounding diseased 
bronchioles (Fig. 2.9).  In addition, on day 7 post-infection a systematic 
examination of the sections showed that inflammatory cells surrounding 
bronchioles mainly consisted of monocytic cells in mice that received AZM, as 
opposed to the neutrophil-dominated infiltrates in the control group (Figure 2.9).  
This finding corresponds to the flow cytometry data presented, and in addition 
confirms that a majority of the CD11b+GR1+ cells induced by AZM treatment 
were macrophages. 
D.  Conclusions 
General conclusions 
 Here we present data showing that AZM increases arginase activity and 
MR expression on macrophages when co-cultured with fibroblasts and stimulated 
with live P. aeruginosa.  While we expected to observe these changes based on 
our previous data, this work proves that this polarization occurs in a similar 
43 
 
manner when using either LPS or live bacteria.  We further observed significant 
increases in fibronectin levels in the co-culture system in cells that were treated 
with AZM.  The increases in TGFβ activation we observed, as well as the trend 
towards increases in TGFβ-1 gene expression suggest that AZM polarized 
macrophages result in increased fibrogenesis by fibroblasts in the co-culture 
system.  As part of this work, we have also shown that AZM additionally 
upregulates proteins that activate TGFβ, including MMP-9.  We hypothesize that 
the increase in TGFβ that we observe is due at least in part to upregulation of 
MMP9 by macrophages.  We believe that this upregulation then results in 
increased activation of TGFβ, leading to increases in fibrogenesis from the 
fibroblasts in the co-culture system.  Other work in our laboratory has also 
assessed MMP9 expression in the co-culture system with the addition of the 
TGFβ blocking antibody.  As expected, the addition of the TGFβ blocking 
antibody exerted no effect on MMP9 expression, showing that the effects of 
TGFβ in the system are focused on fibrogenesis.  This data will be presented in a 
future graduate dissertation.  We cannot, however, eliminate the possibility that 
AZM may be altering other activators of TGFβ, including plasmin, cathepsin D, or 
calpain [83].   
 We further found that AZM exerted considerable effects on macrophage 
polarization and survival in our C57bl/6 mouse infection model.  We found that on 
day 7 of the infection there was a marked shift in macrophage polarization 
towards the M2 phenotype in mice treated with AZM, and that mice treated with 
AZM were significantly less likely to die from their P. aeruginosa pneumonia.  
This shows the significance of macrophage polarization in the response to 
pulmonary P. aeruginosa infections.  We hypothesize that this improvement is 
due to a blunting of the initial potent inflammatory response that occurs in the 
context of infection with P. aeruginosa.   
Limitations 
 The system that we utilized is, by its very nature limited.  Our co-culture 
system was designed to approximate the processes that occur in the lungs 
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during an acute infection.  Extrapolations are difficult to make to in vivo systems, 
as well as to project the clinical relevance of the findings to apply to human 
therapies.  With this limitation in mind, however, we still believe that there are 
considerable comparisons that can be made between the two systems. 
 The utilization of live bacteria in some of these experiments also 
complicates the data.  The number of bacteria present in our wells greatly 
increases over the course of the experiment.  At the later timepoints the number 
of bacteria overwhelms the cells in the culture, leading to widescale death of cells 
in the system.  This may be influencing the results that we see at our later 
timepoints.  Importantly however, the presence of AZM did not alter the growth of 
the bacteria or the rate of cell death between groups. 
 In our in vivo experiments, we additionally were unable to collect any data 
from mice who died or were sacrificed according to protocol.  The absence of 
these animals may be skewing the data that we collect.  That is, we are unable to 
determine the phenotype and extent of infiltrating cells into the lungs of the 
animals that have died.  This may result in us observing differences that were not 
there, or missing significant differences between the two treatment groups. 
 In chapters three and four we will further examine the importance of AZM 
dependent M2 polarization in vivo.  We will examine the importance of M2 
macrophage polarization with mice with P. aeruginosa pneumonia, as well as in 
humans with CF. 
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Figure 2.1.  Arginase activity in co-culture treated with 30 μM AZM and P. 
aeruginosa.  NIH/3T3 were cultured overnight in RPMI + 5% FCS at 37°C with 
5% CO2.  The next morning J774 cells were added, and the cells were 
incubated together overnight.  The next morning and IFNγ, P. aeruginosa (PA), 
and AZM were added.  Cells were harvested at 0, 6, 12, 24, and 48 hours, and 
cell lysates were utilized for the arginase activity.  Graph shows arginase 
activity, a measurement of arginase concentrations, in the lysates preparations.  
Data shows mean ±SD, with each sample run in triplicate.  Data were analyzed 
by two-way ANOVA with a Bonferroni’s post-test. ** indicates a p value of < 
0.01.  *** indicates a p value of < 0.001.  Data representative of three replicates. 
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Figure 2.2.  Alternatively activated macrophages in a co-culture system treated 
with AZM and P. aeruginosa.  NIH/3T3 were cultured overnight in RPMI +5 % 
FCS at 37°C with 5% CO2.  The next morning J774 cells were added, and the 
cells were incubated together overnight.  The next morning IFNγ, P. aeruginosa 
(PA), and AZM were added.  Cells were harvested at 0, 6, 12, 24, 48, and 72 
hours, and cell lysates were utilized for the arginase activity.  Macrophages were 
analyzed by flow cytometry for surface expression of mannose receptor. Data 
were analyzed by two-way ANOVA with a Bonferroni’s post-test. ** indicates a p 
value of < 0.01.  Data representative of two replicates. 
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Figure 2.3.  TGFβ expression in a co-culture system.  NIH/3T3 were cultured 
overnight in RPMI + 5 % FCS at 37°C with 5% CO2.  The next morning J774 cells 
were added, and the cells were incubated together overnight.  The next morning 
and IFNγ, LPS, and AZM were added.  Cells were harvested at 0, 6, 12, 24, and 
48 hours, and cell lysates were collected.  Panel (A) Activated TGF-β 
concentrations in the culture supernatant as measured by TGFβ1 Emax 
ImmunoAssay System. (B) Ratios of active over total TGF-β were normalized to 
time zero. (C) PCR analysis of TGF-β mRNA was normalized to GAPDH 
expression in each sample, and then normalized to expression of TGF-β at time 
zero. Data were significant to a p value < 0.05. All data were analyzed with two-
way ANOVA with Bonferroni’s post-test. * equals p value < 0.05, ** p value < 
0.01, *** p value < 0.001.  Data representative of three replicates. 
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Figure 2.4.  Fibronectin expression in the co-culture system.  (A) NIH/3T3 were 
cultured overnight in RPMI + 5% FCS at 37°C with 5% CO2.  The next morning 
J774 cells were added, and the cells were incubated together overnight.  The 
next morning and IFNγ, P. aeruginosa (PA), and AZM were added.  Cells were 
harvested at 0, 6, 12, 24, and 48 hours, and cell lysates were utilized for the 
arginase activity.  (B) Fibronectin concentrations with just J774 cells, (C) 
Fibronectin concentrations with just NIH/3T3 cells.  Fibronectin concentration in 
the cell lysate was determined by indirect ELISA.  Data represents mean ± SD.    
*** equals a p value <0.001 while * equals a p value < 0.05.  Results were 
normalized to μg protein in each sample.  Data representative of three 
replicates. 
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Figure 2.5.  Fibronectin expression in the co-culture system in the presence of a 
TGFβ blocking antibody.  NIH/3T3 were cultured overnight in RPMI + 5% FCS at 
37°C with 5% CO2.  The next morning J774 cells were added, and the cells were 
incubated together overnight.  The next morning and IFNγ, P. aeruginosa (PA), 
AZM, and a blocking antibody to activated TGFβ were added  at a concentration 
of 5μg/ml.  Cells were harvested at 0, 6, 12, 24, and 48 hours, and cell lysates 
were utilized for the arginase activity.  Fibronectin concentration in the cell lysate 
was determined by indirect ELISA.  Results were normalized to μg protein in 
each sample.  Data representative of three replicates. 
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Figure 2.6.  Weight loss, survival, and infection burden over time in C57bl/6 
mice.  Mice were infected with P. aeruginosa impregnated agarose beads, 
and received either 3.2 mg AZM daily or vehicle control beginning 4 days 
before infection.  One group of mice additionally received AZM, but only a 
sham infection.  4 mice were sacrificed at each timepoint  (A) percent weight 
loss from baseline.  (B) Percent survival from multiple pooled replicates of the 
experiment.  (C) Number of bacteria present in the lungs of these mice.  
Significant differences (p<0.05) are indicated (*), and are representative of 
the results for multiple experiments.   
Copyright © 2010, American Society for Microbiology. All Rights Reserved 
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Figure 2.7.  Immune cell infiltration into lungs of P. aeruginosa infected 
mice treated with AZM.  Mice were infected with agarose beads containing 
between 105 and 106  P. aeruginosa.  Immune cell subtypes were quantified 
by flow cytometry in the (A) lung digest or (B) lung lavage.  Panels 
represent total cells, CD11b+ cells (infiltrating macrophages) (non-
lymphocyte gate), CD11c+ cells (resident macrophages) (non-lymphocyte 
gate), neutrophils and infiltrating monocytes (CD11b-GR1+), and CD4+ T 
cells (lymphocyte gate).  Mean values ± SD are depicted.  Significant 
differences (p<0.05) are shown for differences between groups at the same 
time point (*), and between groups when all animals were taken into 
account across time points (†) 
 
Copyright © 2010, American Society for Microbiology. All Rights Reserved 
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Figure 2.8.  Characteristics of macrophage activation status in AZM treated 
C57bl/6 mice infected with P. aeruginosa.  (A) Surface staining via flow 
cytometry of markers of M2 activation (MR, CD23), or M1 activation (CD80, 
CCR7, and MHC II) on cells that were CD11b+.  (B) Fold increase from 
baseline in arginase activity.  Samples from each mouse group were pooled 
and run in triplicate.  Mean values ± SD are depicted, and samples were 
deemed statistically significant with a p<0.05 (*) 
Copyright © 2010, American Society for Microbiology. All Rights Reserved 
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Figure 2.9.  Lung sections from mice which are day 7 post P. aeruginosa.  H & E 
stains of lung sections that received (A) AZM or (B) vehicle control.  
Magnification increases from top to bottom, with bars representing 50, 25, and 
12.5 μm, respectively.  Pictures represent a predominately monocytic cellular 
infiltration into the lung parenchyma in AZM-treated animals (triangular pointers), 
while in control mice the inflammatory response is dominated by neutrophils 
(arrows).  Br=bronchiole, V=venule. 
Copyright © 2010, American Society for Microbiology. All Rights Reserved 
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Chapter 3:  Mechanistic investigations into the anti-inflammatory effects of 
azithromycin 
A.  Introduction 
Chapter overview  
We next investigated aspects of the mechanism by which AZM polarizes 
macrophages to the M2 phenotype, and the importance of this polarization in the 
host response to P. aeruginosa infection.  The mechanism by which AZM affects 
the shift in macrophage polarization to an M2-like phenotype is as yet unknown.  
It has previously been shown that AZM decreases the activation of NF-κB 
signaling [74, 97].  NF-κB has been shown to play an important part in both the 
innate and adaptive immune system, leading to inflammation and cell death [7, 
98].  Activation of NF-κB leads to the up-regulation of a wide variety of pro-
inflammatory molecules including the cytokines IL-6, IL1-β, and TNFα; and 
enzymes including iNOS and COX-2 [7].  Some have hypothesized that by 
inhibiting activation of NF-κB, AZM decreases the net inflammatory response to 
pathogens in CF [74, 97].  It has been shown that through this mechanism of NF-
κB inhibition, AZM decreases the production of pro-inflammatory cytokines [97].  
Cheung et. al. utilized a cell line with a stably expressed reporter gene and found 
that the IC50 for AZM in the system was approximately 56μM [74].  Cigana et. al. 
observed that AZM exerted similar effects with DNA binding to NF-κB in CFTR 
deficient cell lines.  They additionally found that AZM treated cells produce less 
TNFα [97].  While these hypotheses may help to explain the beneficial effects of 
AZM in patients with CF, it does not by itself explain a mechanism by which AZM 
is able to polarize macrophages away from the M1 phenotype, and towards the 
M2 phenotype.  We hypothesized that AZM achieves this via inhibition of STAT1 
through cross-talk from NF-κB signaling mediators. 
To extend our cell culture experiments, we assessed the ability of AZM to 
alter macrophage phenotype in mice.  Specifically, we were interested in 
assessing the ability of AZM to polarize macrophages to an alternatively 
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activated phenotype in vivo, and whether this polarization occurs independent of 
the traditional mechanisms necessary to achieve M2 polarization.  As shown in 
Chapter 2, AZM can polarize macrophages to an alternatively activated 
phenotype in C57Bl/6 mice infected with P. aeruginosa.  The drug alters the 
cellular influx into the lung parenchyma and alveolar space during acute infection 
to a more monocytic, and less neutrophilic profile, and controls the inflammatory 
response observed [75].  We were curious if we would see a similar effect in 
mice that lack the IL4rα chain, which are unable to polarize to an M2 phenotype 
via IL4 or IL13 signaling.  Several groups (including our own studies) have 
demonstrated the impact that AZM exerts upon cytokine expression [37, 63, 99, 
100].  However, due to data presented below in the first half of this chapter 
concerning AZM’s effect on IKKβ activation, we believe that cell signaling 
mechanisms are altered such that the effects of the drug are independent of the 
downstream effects of cytokines.  It would be reasonable to surmise that the 
ability of AZM to polarize macrophages is due to alterations in cytokine 
production, or to effects on T cells.  However, we have shown in vitro that AZM 
exerts direct effects on macrophages, rather than on the milieu of cytokines in 
the lungs [63].  In the second half of this chapter, we will address the hypothesis 
that azithromcyin polarizes macrophages to an M2 phenotype independent of 
IL4rα function. 
Cell signaling and macrophage polarization:  A brief overview 
 Macrophages are polarized to one of the two traditional phenotypes via 
signaling from three distinct pathways.  M1 activation requires signaling from 
both the IFNγ and TLR4 signaling cascades.  IFNγ dependent signaling results in 
phosphorylation and dimerization of STAT1.  These dimers then translocate to 
the nucleus of the cell, and induce inflammatory gene expression [4, 5].  In M1 
activation, this signaling pathway synergizes with the NF-κB pathway, leading to 
the up-regulation of pro-inflammatory molecules.  The NF-κB pathway begins 
with LPS binding to TLR4.  This binding leads to phosphorylation of the IKK 
complex, including phosphorylation of IKKβ.  Activation of IKKβ leads to the 
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phosphorylation, ubiquitination, and the destruction of IκB.  The destruction of 
IκB, which sequesters NF-κB, then allows NF-κB to translocate to the nucleus of 
the cell.  This then results in up-regulation of pro-inflammatory cytokines such as 
IL6, IL1β, and TNFα.  Additionally, pro-inflammatory molecules including iNOS 
and COX-2 are up-regulated [6-8]. 
 Alternative polarization utilizes a different signaling pathway for its 
activation.  M2 polarization begins with the binding of either IL4 or IL13 to their 
respective receptors.  Interestingly, both the IL4r and the IL13r utilize, in part, the 
same receptor subchain, the IL4rα chain.  Activation of either the IL4r or the IL13r 
results in phosphoryaltion and dimerization of STAT6.  Upon activation, STAT6 
then translocates to the nucleus of the cell and up-regulates genes associated 
with anti-inflammatory processes and the M2 phenotype [69-73].  Many groups 
report being able to polarize macrophages to the M2 phenotype only by 
stimulating with either IL4 or IL13 [1, 34].  In our lab, we additionally utilize 
stimulation from LPS to polarize macrophages to the M2 phenotype.  We use this 
method because we learned that AZM is unable to polarize macrophages to the 
M2 phenotype in inactive macrophages.  Signaling from both IFNγ and LPS is 
required to be able to achieve this polarization to the M2 phenotype with AZM.  
This characteristic of AZM provides basis of support for our hypothesis that the 
mechanism of the drug’s ability to polarize cells lies in its interference with these 
signaling cascades. 
IL4rα chain KO mice 
 We utilized the mouse strain Balb/c-Il4ratm1Sz/J (IL4rαKO) for these 
experiments.  These mice are on a Balb/c background, and lack the IL4rα chain 
on all cell types.  They have been shown to display a decreased Th2 response, 
and have a markedly impaired Th2 polarization in response to infections with a 
wide variety of pathogens [101-103].  Most of the work performed with these 
mice has examined their ability to respond to pathogens that induce a robust Th2 
response, most notably parasites.  The IL4rαKO mice are less able to clear 
infections with the parasite Brugia malayi, an organism in which a strong Th2 
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response is necessary for clearance [102].  Similar responses have been shown 
in experiments utilizing the parasite Nippostrongylus brasiliensis, suggesting that 
IL4 and the IL4rα chain play an important role in the ability of the body to 
generate a robust Th2 response [101].  The role of IL4rα signaling has not been 
studied in the response to infection with extracellular bacteria. 
B.  Methods 
Isolation and ex vivo stimulation of splenocytes from IL4rαKO mice 
 Mice were humanely sacrificed and spleens were collected in RPMI + 5% 
fetal calf serum (FCS) (Invitrogen, San Diego, CA).  Spleens were homogenized 
by pushing them through a mesh screen.  Following homogenization, red blood 
cells were lysed with a hypotonic lysis buffer consisting of 0.15M ammonium 
chloride, 10mM potassium bicarbonate, and 0.1mM EDTA (ACK).  Cells were 
then washed twice with PBS and enumerated.  Cells were allowed to adhere on 
T75 flasks overnight in RPMI + 5% FCS.  The next morning, the media was 
discarded, and adherent cells were washed with PBS and scraped to enrich the 
population to primarily consist of macrophages. 
 Cells were cultured in 24 well plates at a concentration of 4x105 cells per 
well in 2ml of RPMI + 5% FCS.  Cells were then treated with IFNγ (20ng/ml), IL4 
(10ng/ml), IL13 (10ng/ml), both IL4 and IL13, or both IFN and AZM (60μM) 
overnight at 37°C with 5% CO2.  The next morning 50ng/ml of LPS was added to 
each well.  Cells were then cultured for 6 hours.  Cells were scraped, washed 
with PBS, and lysed in RIPA buffer consisting of 50mM Tris-HCl, 150mM NaCl, 
1% (v/v) triton X-100, 1% (w/v) sodium deoxycholate, 0.1% sodium dodecyl 
sulfate, and 4mM EDTA (Sigma Aldrich, St. Louis, MO).  Protein concentrations 
were quantified utilizing the Pierce BCA reaction kit (Rockford, IL).   
Stimulation of a macrophage cell line with cytokines 
 The mouse macrophage cell line J774A.1 (ATCC, Manassas, VA) was 
utilized for our cell culture experiments.  Cells were plated in 6 well plates at a 
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concentration of 2.5x106 cells/5 ml of RPMI + 5% FCS.  Wells were treated with 
20ng/ml IFN, 10ng/ml each of IL4 and IL13, or both 20ng/ml IFN and 60μM AZM 
to receive a robust polarization to the M2 phenotype.  Some wells were 
additionally treated with the IKKβ inhibitor IKK-16 (Tocris Bioscience, St. Louis, 
MO).  IKK-16 is a kinase inhibitor that prevents the phosphorylation and 
activation of IKKβ [104].  IKK-16 has also been shown to decrease TNF-α 
dependent upregulation of adhesion molecules, and to decrease LPS dependent 
TNF-α release in mice, showing that it exerts a significant effect on IKKβ 
signaling [104].  Cells were then incubated overnight at 37°C with 5% CO2.  The 
next morning 50ng/ml LPS was added to all wells, and the cells were incubated 
for 24 hours.  Cells were scraped, washed with PBS, enumerated, and lysed in 
0.1% (v/v) triton X-100.  Protein concentrations were quantified utilizing the 
Pierce BCA reaction kit.  An aliquot of the media supernatant was collected and 
frozen at -80°C for additional analysis.   
Quantification of arginase activity 
 Arginase activity was assessed via the protocols first described by 
Corraliza et. al., and is reported here as a surrogate measurement to the amount 
of arginase present [92].  For detailed methods please refer to chapter two.  In 
brief, samples were incubated with arginine, the reaction was terminated, and a 
detection reagent was added to the samples.  One unit of arginase activity is 
responsible for the catalysis of 1 μmole of L-arginine to ornithine and urea at a 
pH of 9.5 at 37°C. 
Quantification of Nitrite Concentration 
 Nitrite concentrations in cell culture supernatants were additionally 
obtained for some experiments.  When produced from NOS2, nitric oxide (NO) is 
quickly degraded into nitrite and nitrate at roughly equivalent rates.  These NO 
breakdown products are then relatively stable in the supernatants.  Nitrite 
concentrations were obtained via the griess reaction [105].  In brief, a solution of 
1% sulfanilamide in 5% phosphoric acid was mixed with a solution of 0.1% N-(1-
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napthyl)-ethylenediamine dihydrochloride.  The resulting solution was then mixed 
with an equivalent volume of cell culture supernatant.  The samples were run in 
triplicate on a microplate reader at 490nM.  Absorbance was compared to a 
standard curve of known nitrite concentration. 
Preparation of P. aeruginosa impregnated agarose beads and mouse 
infection 
 To ensure a viable infection, P. aeruginosa of the biofilm producing strain 
M57-15 was impregnated in agarose beads.  Bead preparation was an 
adaptation of previously described methods [93, 94].  In the absence of agarose 
beads, mice are able to quickly clear infections with P. aeruginosa.  Impregnation 
in agarose beads allows for a more chronic, stable infection, and leads to greater 
cellular infiltration and weight loss in these animals [94].  In brief, P. aeruginosa 
was first grown to late log or early stationary phase in TSB.  The organism was 
then added to a 2% agarose solution in PBS.  This solution was then combined 
with warm mineral oil, and quickly cooled.  The beads were then washed twice in 
solutions of deoxycholic acid to remove the mineral oil, followed by 6 washes 
with PBS.  Beads were resuspended in PBS, and an aliquot was collected, 
homogenized, and plated on TSB agar plates to determine the number of viable 
bacteria in the beads.    Considerable variability exists with the beads between 
infections, resulting in variability between infections. 
Dosing and Infection of IL4rαKO mice 
 Azithromycin tablets (Pliva, Zagreb, Croatia) were triturated and 
suspended in 2% methylcellulose.  Six to eight week old mice were housed in the 
DLAR facility at the Biopharmacy Building at the University of Kentucky under 
pathogen free conditions.  The treatment group received 3.2mg (approximately 
160mg/kg) of AZM daily via oral gavage, while the control group received only 
methylcellulose.  This AZM dose is high in comparison to the doses of AZM that 
are used in humans, where doses in the range of 3-4 mg/kg/day are commonly 
utilized in these patients.  This was done in order to increase the likelihood that 
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macrophages would be polarized to the M2 phenotype in these mice.  
Preliminary experiments in vitro have shown that this dose will shift the response 
toward an M2-like dominant phenotype in the lungs of these mice [63].  Thus, at 
this dose we were confident that intracellular concentrations of the drug would be 
adequate.  Mice have metabolism rates that are many fold higher than found in 
humans, producing difficulties in interspecies scaling of drug dosing in such 
studies [106, 107].  AZM is primarily found intracellularly due to its partitioning 
characteristics, with extremely low serum concentrations [108], therefore 
equating serum concentrations in mice to those found in humans would mean 
little.  Because this weakens our ability to extrapolate these results to predict 
clinical relevance, the importance of our translational studies (Chapter 4) is 
heightened.  As an antibiotic, AZM functions by binding to the ribosome of 
bacteria, preventing bacterial synthesis.  It is conceivable that AZM exerts 
beneficial effects in subjects with CF by altering protein synthesis of molecules 
involved in the degradation of IKKβ, or other molecules.  
Mice were sedated and infected intratracheally with 100μl of PBS 
containing P. aeruginosa agarose beads.  The goal was to target the mice with 
an infection of 2x105 bacteria.  Because of variability inherent in our preparation 
methods, and because we do not know the actual inoculum of the bead 
preparation until the day after infection, in these  experiments mice received 
between 1.6x105 and 1.2x106 CFU of bacteria.  After infection, mice were 
transferred to a BSL 2 room.  Mice were weighed daily, and humanely sacrificed 
at various post-infection timepoints.  Lung lavages were performed and first 
washes were collected.  Subsequently, lungs were collected and the left lower 
lobe of the lung was fixed in formalin for later sectioning on a Shandon cryotome 
(Thermo Scientific, Waltham, MA).  The remainder of the lung tissue was placed 
in RPMI + 5% FCS for additional processing.  This study and all procedures were 
approved by IACUC. 
Adoptive Transfer 
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Adoptive transfer methodologies were utilized to develop genetic 
chimeras.  The number of cells and timing of transfer were chosen based upon 
preliminary experiments and data from others showing the ability of adoptively 
transferred monocytes to abrogate inflammation-mediated pathology [51].  Bone 
marrow-derived monocytes and T cells from spleens of mice were purified using 
antibody cocktails with magnetic bead technologies (StemCell Technologies).  
Mice were anesthetized, and 1x106 T cells and/or 1x106 monocytes were infected 
retro-orbitally 1 day prior to being infected with P. aeruginosa.   
Immunohistochemistry of mouse lung  
 After harvest, the left lower lobe of the mouse lung was placed in formalin 
for at least two hours, then transferred to a 20% sucrose solution for 
cryopreservation.  Samples were then embedded in Tissue-Tek O.C.T. 
compound (Sakura Finetek, Torrance, CA), and frozen at -80°C.  Embedded 
samples were then sectioned at 10μm on a Cryotome (Thermo Scientific, 
Waltham, MA), and stored at -20°C until staining. 
 The O.C.T. compound was washed off of the sections with PBS with 0.2% 
Triton X-100 (PB-X).  Slides were blocked utilizing using a blocking buffer 
consisting of 5% normal goat serum and 5% bovine serum albumin in PB-X 
overnight at 4°C.  Slides were incubated first with an antibody for arginase-1, 
followed by three washes with PB-X.  A FITC labeled goat anti-rabbit antibody 
was then added and incubated for 1 hour at room temperature.  The process was 
then repeated utilizing an antibody for NOS2, and a Texas red labeled secondary 
antibody.  
Tissue Processing and Cell Phenotyping 
 Lungs were collected and processed for flow cytometry in the same 
manner as in chapter 2.  Three different flow cytometry panels were assessed for 
each type of mouse.  The first panel for the IL4rαKO mice consisted of CD11b-
PECy5 (Serotec, Raleigh, NC), a marker found on macrophages, GR1-PECy7, a 
marker of neutrophils, MR-PE, a marker of M2 macrophages (Serotec, Raleigh, 
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NC), CD80-FITC, a marker of M1 macrophages, and biotinylated I-A[d] MHC II, a 
protein that is increased in expression with classical macrophage activation.  
Panel 2 consisted of CD11b-APC, CD11c-PECy7 (BD Bioscience, San Jose, 
CA), a marker of resident macrophages and dendritic cells, CD4-PECy5, a 
marker of CD4+ T-cells, GR1-FITC, and CD19-PE, a marker of B-cells.  Panel 3 
consisted of CD11b-PEcy5, CD11c-PECy7, TNFα-FITC, biotinylated TGFβ, and 
IL10-PE.  Secondary staining was performed when appropriate utilizing a 
streptavadin conjugated to APC.  All antibodies were purchased from BD 
bioscience (San Jose, CA), unless otherwise stated.  Cells were analyzed with 
utilizing a FACSCaliber Flow Cytometer (BD Biosciences, San Jose, CA) with a 
dedicated operator.  Greater than 50 thousand events per sample were routinely 
examined.  Flow cytometry analysis was performed utilizing FlowJo (Treestar, 
Ashland, OR). 
Statistical Analysis 
Statistical analysis was performed utilizing Graphpad Prism (GraphPad 
software, La Jolla, CA).  Comparisons between groups were made via one way 
ANOVA with Tukey’s multiple comparison test for ratio level data, and by Fisher’s 
Exact test for nominal data.  A repeated measures ANOVA with Tukey’s multiple 
comparison test were utilized for time courses.  For some data, T-tests were 
used to compare means between groups.  Non-linear regression utilized the least 
squares method for fit.  Differences in survival were assessed utilizing a log-rank 
(Mantel-Cox) test.  Unless otherwise stated, significance was deemed to be a p 
value <0.05.   
C.  Results and discussion 
1.  Alteration of macrophage polarization with azithromycin is IKKβ 
dependent 
Azithromycin decreases NF-κB activation, while increasing IKKβ activation 
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We first assessed select proteins in the NF-κB signaling cascade to 
determine the effect that the presence of AZM has upon their activation (Figure 
3.1).  We treated cells with IFN, AZM, and LPS, and collected cell lysates at 
various timepoints.  We found that treatment with AZM resulted in increased 
levels of the inactive isoform of NF-κB (p105), and decreased levels of the active 
isoform (p50) NF-κB present in the cells, particularly between 5 and 30 minutes 
after the addition of LPS.  Congruent with these results, IκB expression was 
increased by AZM.  LPS causes IκB activation to decrease, as IκB binds to NF-
κB, keeping it inactive and preventing it from entering the nucleus to promote 
inflammatory gene expression.  Treatment with the drug caused IκB to reappear 
earlier in the cell lysates (15 minutes after stimulation), whereas IκB was not 
detected in the control samples until the 60 minute mark.  However, we 
additionally discovered that AZM treatment resulted in increased levels of IKKβ 
present in the cells.  This was surprising, because increased activation of IKKβ 
should result in an increased NF-κB activation, which was not the case.  The 
bottom portion of Figure 3.1 shows the effect of increasing AZM concentration 
upon IKKβ activation at 10 minutes after the addition of LPS (the point in time at 
which there is the most difference in NF-κB activation affected by the drug).  
IKKβ is dramatically increased at this timepoint at the 5, 10, and 15μM 
concentrations of AZM as compared to the zero drug lane.  These results 
suggest that the inhibition of NF-κB activation by AZM occurs in the pathway 
downstream of IKKβ (discussed below).  This data provided us with evidence 
suggesting that AZM polarizes macrophages to the M2 phenotype in part via 
crosstalk between IKKβ and the STAT1 signaling [68]. 
Inhibition of IKKβ activation prevents azithromycin from polarizing 
macrophages to the M2 phenotype 
 We then set out to determine whether AZM exerts its effect in part via the 
activation of IKKβ.  Fong et. al. have previously shown that activation of IKKβ 
prevented polarization to the classically activated phenotype [68].  Using a 
genetically engineered mouse strain that caused tissue-specific over-expression 
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of IKKβ, this group showed that over-expression of the protein caused an 
inhibition of M1 macrophage activation along with a blunting of inflammation 
associated with Streptococcal pneumonia [68].  We treated cells with cytokines 
and AZM to polarize to either the M1 or M2 phenotype, as well as with 100 nM 
IKK-16, a competitive inhibitor of IKKβ (Figure 3.2).  The compound displays the 
high affinity for IKKβ, with an IC50 of 40nM.  At higher concentrations, it can also 
inhibit the activation of the entire IKK complex as well [104].  We found that 
treatment with IKK-16 had no effect on arginase activity in cells treated with 
IL4/13 plus LPS (the M2 control condition).  In cells incubated with AZM, 
however, treatment with IKK-16 decreased arginase activity to similar levels of 
cells that were not exposed to the drug.  This suggests that inhibition of IKKβ 
prevents AZM from polarizing macrophages to the alternatively activated 
phenotype, and strongly supports the conclusion that AZM shifts the macrophage 
polarization balance through its effects on IKKβ.   
 We then assessed gene expression for arginase I in cells that were 
treated with IKK-16.  Cells were stimulated similarly to in the previous 
experiment, except that a concentration of 50nM IKK-16 was utilized to allow the 
potential for AZM to overcome this inhibition.  We found that in the presence of 
the inhibitor, gene expression for ARG1 was significantly decreased in cells that 
were treated with AZM (Figure 3.3) (P<0.05).  Interestingly, there was a trend 
towards a decrease in ARG1 gene expression for wells treated with IL4/13 and 
IKK-16, when compared to just the IL4/13 group (p=0.115).  This data further 
suggests that AZM’s ability to induce expression of ARG1, an important gene in 
M2 activation, is dependent on its ability to activate IKKβ. 
 Finally, we assessed whether increasing inhibition of IKKβ prevented AZM 
increases in arginase production (Figure 3.4).  We treated cells either with IFNγ, 
60μM AZM and LPS, or IL4/13 and LPS.  Cells were additionally exposed to 
increasing concentrations of IKK-16, to further assess the effect of IKKβ inhibition 
on AZM-dependent M2 activation.  We found, as expected, that inhibition of IKKβ 
had little effect on IL4/13 dependent arginase production.  Up to the highest 
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concentration studied, 200nM, IKK-16 did not significantly lower arginase activity.  
Interestingly, however, we found that in AZM treated cells, inhibition of IKKβ by 
IKK-16 greatly inhibited arginase activity in a concentration-dependent manner.  
This further suggests that AZM alters macrophage polarization via IKKβ 
dependent mechanisms.   
Increasing azithromycin concentrations overwhelms IKKβ inhibition 
 We next examined the effect of AZM concentration in the presence of 
IKKβ inhibition on the shift of cells to the M2 phenotype (Figure 3.5).  As 
expected, we found that in cells that were not treated with IKK-16, AZM treatment 
resulted in a dose-dependent effect on arginase activity.  When we treated cells 
with 12.5nM IKK-16, we found that AZM was still able to increase arginase 
activity in the cells.  We did observe, however, that treatment with IKK-16 shifted 
the dose-response curve to the right, showing that the inhibition caused by IKKβ 
can be overcome by increasing concentrations of AZM.  Increases in arginase 
activity by AZM were completely ablated in the presence of with the 25nM IKK-
16.  Unfortunately, we were not able to treat cells with AZM concentrations higher 
than those we utilized due to toxicity to the J774 cells.  This data suggests that 
AZM achieves its effect on macrophage polarization, at least in part, via 
activation of IKKβ and further pinpoints the molecular target of the anti-
inflammatory effects of AZM.  Due to toxicity associated with very high 
concentrations of AZM, we were not able to reach the plateau at which AZM 
maximally increases arginase activity with these cells, and were thus unable to 
fully determine the EC50. 
 We then assessed changes in nitrite concentration with increasing 
concentrations of AZM (Figure 3.6).  Nitrite concentrations in cell supernatants 
serve as a counterpoint to arginase activity in cells.  Nitrite is a stable breakdown 
product of NO, and high levels of nitrite in cell supernatants suggest a net M1 
polarization.  We anticipated that AZM would be unable to decrease nitrite 
concentration in cells treated with IKK-16.  In the absence of IKKβ inhibition, 
treatment with AZM resulted in decreased supernatant nitrite concentrations.  
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Surprisingly, however, we found that we still observed decreases in nitrite 
concentrations as we increased AZM concentration with our cells that were 
treated with IKK-16.  While it was somewhat surprising that we did not observe 
an increase in nitrite concentrations with IKKβ inhibition, corresponding to a 
decrease in arginase activity that we observed, these findings can still be 
explained.  IKKβ, as previously stated, plays an important role in multiple 
signaling cascades.  Inhibiting IKKβ activation results in decreased NF-κB 
activation.  This results in decreased activation of the M1 phenotype, and 
explains why we did not see increases in nitrite concentration in our cells treated 
with IKK-16.  This underscores the complexity present in cell signaling.  It also 
suggests that the effects reported by other groups on cytokine production could 
also be independent of the drug’s impact on macrophage polarization.  Indeed, 
IKKβ appears to be exerting two roles in macrophages, both a pro-inflammatory 
role via activation of NF-κB activation, and an immunoregulatory role via STAT1 
inhibition.  This signaling protein may be affecting a balance function in order to 
control inflammation in this setting:  as classical macrophage activation occurs 
along with inflammation, the NF-κB pathway could then participate in the 
regulation of STAT1 signaling over time. 
 In summary, the changes in arginase activity that we observed by shifting 
AZM and IKK-16 concentrations suggests that AZM exerts its effects on 
macrophage polarization via IKKβ dependent mechanisms.  A greater 
understanding of these interactions and the cellular targets of AZM may lead to 
future drug targets that would allow clinicians to alter inflammation without the 
need to place patients on antibiotics for an extended amount of time, which leads 
to increases in antimicrobial resistance. 
2.  Azithromycin polarizes macrophages to the M2 phenotype independent 
of IL4rα function 
IL4rαKO mouse splenocytes can be polarized to the M2 phenotype with 
azithromycin 
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 We then set out to determine whether AZM’s ability to polarize 
macrophages to the M2 phenotype is dependent on IL4/IL13 signaling.  While we 
have been able to show that AZM dependent M2 polarization requires IKKβ, we 
were curious to determine if the drug signals through the IL4r and IL13r [2, 3].  
First, we conducted a series of ex vivo experiments for which we collected 
splenocytes from both Balb/C and IL4rαKO mice and exposed them to LPS, 
cytokines, and AZM in a similar manner as described above.  Figure 3.7 shows 
arginase activity normalized to viable cell count for cells stimulated with LPS for 6 
hours.  We found that cells from KO animals treated with IFNγ plus LPS plus 
AZM displayed increased arginase activity compared to all of the other conditions 
that we tested.  However, arginase concentrations were significantly lower than 
those produced in the WT cells.  This suggests that AZM may be functioning in 
part by priming macrophage polarization to the M2 phenotype, at which point 
cytokines produced by these cells then shift more macrophages to the M2 
phenotype.  As expected, IL4, IL13, or both cytokines together had little effect on 
arginase production in the KO cells.  The up-regulation in arginase activity that 
was induced via AZM treatment in cells that are otherwise unable to be polarized 
to the M2 phenotype suggests that AZM exerts its effect via IL4 and IL13 
independent mechanisms. 
IL4rαKO mice are more susceptible to infection with P. aeruginosa than 
their parent strain 
We were additionally interested to determine how mice with a deficient 
ability to generate alternatively activated macrophages were able to respond to 
infections with bacterial pathogens.  We utilized the IL4rαKO in part to answer 
this question.  In addition to the IL4rαKO mice, we utilized 2 other strains of mice 
to help to assess this question, the Balb/c and C57bl/6 strains.  The Balb/C and 
C57bl/6 strains have extremely different cytokine profiles during infections, and 
resultingly respond to these infections very differently.  C57bl/6 mice display high 
levels of IFNγ and low levels of IL4.  Their macrophages additionally express 
high levels of iNOS, and low levels of the enzyme arginase [46].  Balb/c mice, 
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however, have more of a Th2-dominant response.  They in general produce high 
levels of IL4, low levels of IFNγ, and express lower levels of the protein iNOS as 
well as high levels of the enzyme arginase 1 [46].  Interestingly, when mice are 
infected intratracheally with bacteria, the Th2 polarization present in the Balb/c 
strain of mice is traditionally associated with better outcomes to the infection [46], 
with the mice being more likely to survive.  In fact, lung damage and fibrosis are 
readily induced by infection with P. aeruginosa in C57Bl/6 mice, but BALB/c mice 
are immune to this pathology [109-111]. 
 Because of the differences in response of the inbred strains, we infected 
C57bl/6, Balb/c and IL4rαKO intranasally with P. aeruginosa at various 
inoculums, and assessed survival (Figure 3.8).  Intranasal inoculations were 
utilized primarily to ensure a potent acute infection.  As we expected, C57bl/6 
mice were susceptible to infection with P. aeruginosa, while Balb/c mice were 
resistant, as it took an extremely high inoculum of 1010 CFU to cause appreciable 
mortality.  Interestingly, however, while their parent strain is resistant to 
intranasal infection with P. aeruginosa, the IL4rαKO strain was much more 
susceptible to infection with P. aeruginosa.  Indeed, the survival curve for the 
IL4rαKO mice more closely resembles the C57bl/6 strain than the Balb/c strain, 
suggesting that alternative macrophage activation through IL4rα may be partly 
responsible for the innocuous inflammatory response observed in the Balb/c 
strain. 
 We next examined histology for the three different strains of mice, and 
found marked differences.  Balb/c mice showed diffuse cellular infiltrations 
throughout the lungs (Figure 3.9 A.).  The cellular infiltrates in C57bl/6 were 
primarily concentrated along the edges of small airways (Figure 3.9 B.).  The 
lungs of the IL4rαKO mice displayed cellular infiltrates that, while somewhat 
diffuse, were more concentrated along the airways than those of their parent 
strain (Figure 3.9 C.).  This finding could have clinical relevance, due to the fact 
that P. aeruginosa infection in patients with CF primarily causes a peribronchiolar 
inflammation and damage.  This again shows that the IL4rαKO mice more closely 
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resemble the P. aeruginosa susceptible C57bl/6 strain, and suggests that 
alternatively activated macrophages play an important role in the ability of mice 
to blunt the damaging inflammatory response associated with P. aeruginosa 
infection.  
 We additionally examined differences in surface protein expression and 
cytokine production in IL4rα KO mice.  Mice were sacrificed 6 days after infection 
with between 3.8 x 104-3 x 105 CFU of P. aeruginosa incorporated into agarose 
bead, and lung digest samples underwent surface staining as well as intracellular 
cytokine staining, and analyzed by flow cytometry.  We first assessed the 
expression of surface markers of macrophages (CD11b), T cells (CD4), and 
neutrophils (approximated by GR-1 expression) (Figure 3.10 A.) and compared 
the results to the WT strain.  While we did not observe significant differences, we 
found trends that IL4rαKO mice displayed fewer CD4+ T cells (p=0.203), and 
more GR1+ cells (p=0.110).  We then assessed expression of surface markers of 
macrophage polarization and compared the results between the two strains 
(Figure 3.10 B.).  Encouragingly, we found that IL4rαKO mice displayed 
significantly fewer cells expressing the M2 markers MR (p=0.047) and CD23 
(p=0.043), while observing no differences in surface expression of the M1 marker 
CCR7 between the strains.  Finally, we assessed intracellular expression of pro- 
and anti-inflammatory cytokines including TNFα, TGFβ and IL10 (Figure 3.10 C.).  
We found a trend towards a decrease in the number of cells producing TNFα 
(p=0.109).  We additionally found no differences in the numbers of cells 
expressing the anti-inflammatory cytokines TGFβ and IL10, although there was a 
trend towards a significant difference in the latter (p=0.063).  These phenotypic 
differences suggest the importance of control of macrophage activation via the 
IL4 and IL13 receptors, and the role of these macrophages in the response to P. 
aeruginosa infections. 
 To this point, we have described how the absence of IL4rα function results 
in impaired survival and increased inflammation in mice infected with P. 
aeruginosa.  This suggests that M2 macrophages play an important role in the 
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response to P. aeruginosa in the lungs of these mice.  We believe that the lack of 
M2 macrophage polarization results in an overly zealous inflammatory response 
that causes excessive damage, thereby increasing morbidity and mortality.   
IL4rαKO mice adoptively transferred with cells from Balb/c mice display 
IL4rα+ cells in their lungs 
 A confounding factor in using this genetically engineered strain of mouse 
is that not only are macrophages devoid of IL4rα—this defect is also present 
among T lymphocytes.  Therefore, to address this issue, we utilized an adoptive 
transfer approach to restore normal IL4rα expression in these cell types.  We set 
out to compare the response to P. aeruginosa pneumonia among IL4rαKO mice 
that received adoptive transfer of either normal T cells only, or both normal T 
cells and monocytes.  In order to validate the transfer of cells, we first confirmed 
that WT cells adoptively transferred into IL4rαKO mice would migrate to the lungs 
in response to infection.  On the day before infection, IL4rαKO mice were 
adoptively transferred with both monocytes and T cells, or with only T cells from 
Balb/c mice, as described above.  The IL4rαKO mice have deficient IL4rα KO 
function on all of their cells, including T cells.  Mice were then infected 
intratracheally with P. aeruginosa-incorporated agarose beads, and sacrificed at 
various time points.  Cells were collected and stained for CD11b, GR1, CD4, and 
IL4rα.  We first assessed the presence of the IL4rα chain on macrophages, 
defined as cells being CD11b+ as well as GR1-.  As expected, we found 
macrophages expressing the IL4rα chain in mice that received both 
macrophages and T cells, whereas IL4rα expression was absent in the group 
receiving normal T cells only (Figure 3.11).  Interestingly, we first began to see 
this difference at 7 days post infection.  This resembles our previous studies in 
C57bl/6 mice, showing that the influx of cells into the lungs of mice is most 
pronounced at 7 days post infection.  When we assessed the presence of the 
IL4rα chain on T cells that had been adoptively transferred, we found significant 
amounts of T cells that expressed the ILr4α chain in both of the groups.  This 
data shows that we are able to effectively adoptively transfer cells with normal 
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IL4rα chain function to mice lacking the IL4rα chain.  This allows us to assess the 
importance of IL4rα chain signaling specifically associated with macrophages in 
the context of pulmonary infections with P. aeruginosa. 
Impact of Adoptive Transfer on Weight Loss and Survival 
 We assessed survival and weight loss in our IL4rαKO mice that had been 
adoptively transferred with cells from Balb/c mice.  We pooled survival data from 
3 replicate experiments to determine whether there was a difference between the 
groups.  We first found that there was no difference in survival between animals 
that received both macrophages and T cells, as compared to animals that only 
received T cells (p=0.0939) (Figure 3.12 A.).  We also found no differences in 
weight loss between the two groups at any specific timepoint, or in total over time 
(p=0.3147) (Figure 3.12 B.).  It is important to note, however, that we observed 
few fatalities in these experiments.  This may be due to the initial inoculula that 
we utilized being too low for the mice.  Additionally, with the addition of normal T 
cells to these mice, these cells may allow for better control of the inflammatory 
response. 
Effect of adoptive transfer on cellular influx into lungs of IL4rα KO mice 
 We next examined the cellular infiltrates of infected IL4rαKO mice that 
underwent adoptive transfer of either WT macrophages and T cells or only T 
cells (Figure 3.13).  We observed a decrease in the numbers of infiltrating 
macrophages on day 7 post-infection (p=0.04) (CD11b+CD11c-GR1-) in mice 
that received both M and T cells, compared to mice that received only T cells.  
We did not, however, observe any differences in the amounts of the more 
alveolar subset of cells in the lungs, designated as CD11b-CD11c+GR1-.  
Importantly, mice that only received T cells and monocytes displayed 
dramatically greater neutrophil influx (as approximated by the number of GR1+ 
cells) in the lungs than mice that received T cells, peaking around day 7 post-
infection.  This suggests that M2 macrophages play an important role in 
decreasing the neutrophilic response in acute infections with P aeruginosa 
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pneumonia.  This is an important finding, as dysregulated inflammation 
characteristic of patients with CF is primarily neutrophil driven, as presented in 
detail in Chapter 1.  We also observed a decrease in CD4+ T cells in mice that 
received macrophages capable of M2 polarization.  Although adoptive transfer 
changed the influx of immune cells over time in the lungs, in general it did not 
bring the values to the levels observed in the WT strain. 
Ability of azithromycin to rescue mice infected with P. aeruginosa that lack 
IL4rα responses 
We demonstrated in Chapter 2 that AZM can blunt inflammation and 
improve lung damage and survival in C57Bl/6 mice infected with P. aeruginosa.  
Data presented in this chapter suggests that the converse is also true:  that the 
absence of alternative macrophage activation (i.e. absence of IL4rα signaling) 
worsens neutrophil-driven pulmonary inflammation associated with this infection.  
To apply these results to our mechanistic investigation of the drug, we next 
assessed the ability of AZM to induce alternative macrophage activation in 
IL4rαKO mice, and whether this will blunt the excessive inflammation associated 
with P. aeruginosa infection in this strain.  IL4rαKO mice were infected with 
agarose beads containing between 5.5 x 104 and 1.5 x 105 P. aeruginosa for 
these experiments.  Beginning 4 days before infection mice were dosed with 
3.2mg AZM per day, and mice sacrificed at various timepoints for analysis. 
 We first assessed the numbers of bacteria present in the lungs of KO mice 
that had been infected with P. aeruginosa beads.  In the past, we have observed 
that treatment with AZM exerted no effects on bacterial colony counts in Balb/c 
mice that had been infected with P.aeruginosa [75].  Here, we found similar 
results.  We found no differences in bacterial CFU at any of the three timepoints 
that we collected (Figure 3.14).  We then assessed the percentage of weight loss 
from day 0 in our KO animals (Figure 3.15).  Here we found no differences in 
weight loss between the KO animals that received AZM as animals that did not 
receive AZM (p=0.0649 by 2-way ANOVA).  These findings mimic those that we 
observed with our adoptive transfer.   
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Azithromycin shifts cells in the lung to the M2 phenotype in IL4rαKO mice 
 We next assessed the phenotype of cells in both the lung lavage and lung 
digests of the IL4rαKO mice infected with P. aeruginosa for markers of M1 and 
M2 activation via flow cytometry.  We found a non-significant trend towards 
increased expression of the M2 marker mannose receptor on cells in the lung 
lavages of mice treated with AZM (Figure 3.16 A.).  We additionally observed 
trends towards increased MR expression in the percentages of cells in the lung 
lavage of the mice, which became statistically significant at day 14 (p<0.05) 
(Figure 3.16 C.).  Intriguingly, we did not observe differences in mannose 
receptor expression in the lung digests, both when assessing the total number of 
cells positive for both CD11b and MR, as well as when we compared the 
percentages of cells in the digest that were CD11b+ that also expressed MR 
(Figure 3.16 B., D.).  It is possible that the large amount bacterial antigen in the 
lungs of these mice was able to overwhelm the ability of AZM to alter 
macrophage to the M2 phenotype.   
 We next assessed surface expression of CD80, a marker of M1 activation.  
Here we found few differences between the two groups, and in fact observed a 
slight increase in both the number and percent of cells expression CD11b that 
also expressed CD80 (Figure 3.17 A., C.).  Again, we observed no differences 
between the two groups in the lung digest (Figure 3.17 B., D.).  It is important to 
note, however, the very large percentages of cells, especially in the lung lavage, 
that were positive for CD80 across all of the time points.  This again suggests 
that in IL4rαKO animals there is strong inflammatory response to bacteria.  In a 
mouse with normal IL4rα function we would expect this inflammatory response to 
be dampened by M2 macrophages that were activated via traditional 
mechanisms.  In the IL4rαKO mice, however, there may be less of a shift away 
from an M1 macrophage polarization, even in the presence of AZM.  Again, this 
could be a matter that the large amount of bacterial signaling that is present in 
the lungs of these mice is overwhelming the ability of AZM to help achieve a shift 
to the M2 phenotype. 
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 We then plotted the ratio of cells that had CD80 surface expression to that 
of cells that had MR surface expression, the results of which can be seen in 
figure 3.18.  In the lung lavage we observed that the ratio of cells that expressed 
either CD80 or MR at day 0, 4, and 7 (Figure 3.18 A.).  Interestingly, however, at 
day 14 we observed an increase in the ratio of CD80 positive cells to MR+ cells.  
This increase was significantly higher in mice that did not receive AZM as 
compared to mice that received AZM.  By day 14, mice had essentially cleared 
the bacteria, and were in the process of recovering from the infection.  It is only 
after the infection had been cleared that we are able to observe significant 
differences in the CD80/MR ratio, suggesting that AZM is able to shift 
macrophage polarization in these mice towards the M2 phenotype.  We observed 
similar findings in the lung digest (Figure 3.18 B.), although rather than observing 
essentially no changes in the ratio across days 0, 4, and 7, we saw a trend 
towards a gradual, non-significant increase in the ratio of CD80/MR positive cells.  
Again, we observed that at day 14 a significantly higher CD80/MR ratio in mice 
that did not receive AZM when compared to mice that did receive AZM.   
Azithromycin alters influx of inflammatory cell types in IL4rαKO mice  
We then assessed the ability of AZM to alter cellular influx to the lungs of 
mice during infection with P. aeruginosa.  We have previously shown that in 
C57bl/6 mice treatment with AZM increases the influx of CD11b+ cells, and 
decreases the influx of neutrophils in the lungs [75].  Here we observed similar 
findings in our KO animals.  In the lung digests, we found a significant increase in 
the ratio of CD11b+ cells (representing infiltrating macrophages) to neutrophils 
(CD11b- GR1+) at day 7 in the lung digest (Figure 3.19 B.).  Unfortunately, the 
large variability in the lung lavage data on day 7 made it impossible to observe 
any differences in cell influx (Figure 3.19. A.).  The large difference at day 7 in 
the lung digest, however, suggests that AZM is altering the types of cells that 
influx into the lungs of mice during an acute infection with P. aeruginosa 
independent of IL4 and IL13 dependent mechanisms.    
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 We also examined lung histology from the mice at various timepoints, to 
visually assess the types of cells that infiltrate into the lungs (Figure 3.20).  On 
day 0, we found few cells in the lungs, and the cells that we did see were 
mononuclear, and appeared to be monocytes and macrophages.  On day 4 we 
observed many more cells in the lungs of the mice.  While in both the AZM and 
non-AZM treated animals we observed more neutrophils (as determined by the 
appearance of the nuclei of the cells), it appears that there were fewer 
neutrophils in the mice treated with AZM than in the animals that did not receive 
AZM.  On day 7, we observed similar trends, although the differences between 
the AZM treated animals and the animals that did not receive AZM was not very 
large.  By day 14 the infection is essentially resolved, and we observed many 
fewer cells in the lungs of the animals at this point in time.  We also did not 
observe major differences in the types of cells present in the lungs of the animals 
at this timepoint.   
Azithromycin treated IL4rαKO mice display shifts in arginase 1 and NOS2 
localization 
 We additionally assessed the localization of two of the prototypical 
proteins of macrophage polarization, NOS2 for M1 macrophages, and arginase 1 
for M2 macrophages.  While we did not observe large differences in total 
arginase activity in our IL4rαKO mice that we treated with AZM (Figure 3.21), we 
found profound differences in the relative location of arginase in the lungs of 
these animals when employing IHC.  On day 14 post-infection with 1.5 x 105 CFU 
of P. aeruginosa incorporated into agarose beads, we found that animals that 
had not received AZM displayed expression of both NOS2 and arginase 1 
(Figure 3.22).  Animals that did receive AZM, however, expressed markedly less 
NOS2 protein.  Interestingly, we found a marked up-regulation of arginase 1 
protein in the animals treated with AZM.  This increase was most pronounced in 
the areas around the small airways of these mice, as compared to the rest of 
their lungs.  This is the typical location of P. aeruginosa infection, and is 
additionally the area affected most severely in CF pathogenesis.  This suggests 
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that AZM is able to polarize macrophages away from the M1 phenotype (as 
determined via NOS2 protein expression).  It also appears that AZM treatment is 
increasing M2 polarization in the lungs of these animals, to a certain extent in the 
entire lung, but to a greater extent around the airways.  This suggests that AZM, 
in addition to the effects that it exerts on macrophage polarization, is affecting 
trafficking of macrophages in the lungs of these animals.  In fact, it appears that 
AZM is causing M2 macrophages to concentrate in the peribronchiolar areas 
around the airways. 
 It is unknown what the impact of this effect may be.  First, it is possible 
that these M2 macrophages would result in increased fibrosis and scarring in the 
airways around the lung.  Second, the marked decrease in NOS2 protein 
expression in mice treated with AZM suggests that there may likely be less total 
damage in the lungs of these animals to recover from.  In that case, it may be 
that even though we found markers consistent with M2 macrophages around the 
airways of these mice, airway damage may not necessitate repair and 
remodeling to a significant extent.  
D.  Conclusions 
General Conclusions 
 Here we have shown data suggesting that AZM polarizes macrophages to 
the M2 phenotype via IKKβ-dependent, and IL4rα-independent mechanisms.  
Others have shown that IKKβ prevents activation of STAT1 in myeloid cells [68].  
We showed that treating cells with an inhibitor of IKKβ activation prevents AZM 
from polarizing macrophages to the M2 phenotype.  We additionally showed that 
with certain degrees of IKKβ inhibition, increasing AZM concentration was able to 
overwhelm this inhibition.  This suggests that AZM is somehow causing the 
activation of IKKβ, and that this activation is at least in part responsible for 
polarization away from the M1 phenotype, and towards the M2 phenotype for 
these macrophages.  We additionally showed, utilizing cells stimulated ex vivo 
from IL4rαKO mice,that AZM is still able to shift macrophages to the M2 
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phenotype, even in the absence of signaling via the traditional methods 
necessary for M2 polarization.   
 This data suggests future targets for investigation into the exact molecular 
site where AZM is exerting anti-inflammatory effects.  Future work targeting these 
molecules may allow for the creation of novel therapeutics that include the 
beneficial immunomodulatory effects of AZM, without the anti-infective 
properties.  This would result in the avoidance of inducing antimicrobial 
resistance that results from long term treatment with an antibiotic.  Antibiotic 
resistance is a growing problem, and it has been shown that long-term macrolide 
treatment greatly increases resistance to those medications [17].  While we were 
not able to find an exact target and mechanism by which AZM alters macrophage 
phenotype, we were able to considerably narrow the field of targets.  Namely, by 
showing that inhibition of IKKβ prevents AZM based M2 polarization, it suggests 
that activation IKKβ plays an important role in this activation.  We hypothesize 
that this is due to inhibition of the STAT1 cascade similar to what Fong et. al. 
have previously shown [68].  The Fong article suggests an interaction between 
the two important cell signaling mechanisms in macrophages.  They surmise that 
this interaction exists to down-regulate the inflammatory response in cells.  We 
believe that AZM polarizes macrophages to the M2 phenotype via this 
mechanism. 
  Additionally, we were able to show that AZM dependent M2 activation is 
independent of IL4 and IL13 function, suggesting that it does not depend on the 
traditional mechanisms associated with M2 activation.  This eliminates one 
prospective mechanism for AZM dependent activation, and further supports our 
previous finding that  AZM shifts macrophage polarization to an M2 phenotype in 
the presence M1 stimulation conditions. 
We additionally showed that AZM is able to exert many of the effects in 
vivo that it was able to exert in vitro, even in mice lacking IL4rα signaling.  AZM 
increased the number and percentages of cells in the lung lavage expressing 
MR.  When mice had cleared the infection on Day 14 of the experiment, we 
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observed a shift towards expression of the M2 marker MR, and a shift away from 
the M1 marker CD80.  In the absence of an intrinsic M2 response to blunt the 
initial inflammatory response to pulmonary infection with P. aeruginosa, AZM was 
unable to affect a major phenotypic shift in macrophages in vivo.  As the infection 
begins to clear, however, and the infectious burden falls in the lungs, it appears 
that AZM is able to exert a more major effect on the macrophage phenotype in 
the lungs of these animals. 
Limitations 
It was initially difficult for us to make comparisons between the three initial 
mouse strains that we utilized (C57,bl6, Balb/c, and the IL4rαKO mice).  As 
previously stated, the IL4rαKO mice are on a Balb/c background.  The Balb/c 
strain is traditionally thought to be resistant to pulmonary infection with 
Pseudomonas, especially compared to the C57bl/6 strain which is susceptible to 
severe acute pulmonary damage induced by Pseudomonas infection [46, 47].  
This means that our KO mice are on a background for a strain that is resistant to 
pulmonary infections.  While this allows us to make some interesting 
observations (e.g. that a defect in IL4rα signaling shifts the phenotype from a 
pulmonary infection resistant strain to a pulmonary infection susceptible strain), it 
does make comparisons between groups difficult.  Namely, it is difficult to 
compare these mice to their parent strain, since a bacterial inoculum that would 
kill an IL4rαKO or C57bl/6 mouse is easily cleared by a Balb/c mouse.  With that 
in mind, however, we were still able to make interesting observations with the 
IK4raKO mice on the background that we have them. 
There is variation between the flow cytometry assessment of the types of 
cells present in the lungs of these mice, and the visual inspection of the cells via 
histology.  Namely, we observed our largest differences in the ratio of 
macrophages to neutrophils at day 7 via our flow cytometry analysis, and in our 
visual analysis of the lungs the largest difference appears to have been on day 4.  
It is important to note that while the lung lavage and lung digest samples 
represent cells from the entire lungs of the animals, the histology sections 
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represent only a thin slice of the lungs.  This means that the histology results 
may not be fully representative of the rest of the lungs of the animal.  Regardless 
of the specific day that we observed the largest difference in the macrophage to 
neutrophil ratio in the lungs of these mice, the consistent trend between the two 
groups is that AZM treated animals displayed a more monocytic, and less 
neutrophilic influx into their lungs in the context of a bacterial pneumonia. 
We additionally had considerable variation in our mouse experiments in 
regards to our infections of IL4rαKO animals.  The infection model that we use for 
our mice is extremely complex and results in considerable variation, both 
between individual mice that are infected, as well as between experiments.  The 
P. aeruginosa agarose beads are extremely difficult to make, and variability in 
bead production makes it difficult to target the same inter-experiment dose.  This 
results in difficulty comparing replicates of infections.  Additionally, there is 
difficulty in ensuring that all mice receive the same amounts of bacteria in their 
intratracheal inoculation.  This may explain some of the considerable variability 
that we observed with our flow cytometry and other data from our mice.  Instead 
of the intratracheal infection approach that our lab utilizes for the infections, 
others first tracheotomize the animals for the infection [112].  That approach, 
however, has considerable trauma associated with it, leading to alterations in the 
immune response.  We believe that these alterations make the infection 
approach that we utilize to be more appropriate, as we see fewer alterations in 
the immune response.  Due to the nature of our infection model, and the ease in 
which mice are able to clear pulmonary infections with P. aeruginosa, we are 
forced to utilize this model, with all of the benefits and difficulties entailed to it.  
Finally, we cannot eliminate the possibility that AZM is exerting effects on other 
cells, including neutrophils T cells, and epithelial cells.  These effects on other 
cells may be responsible in part for the beneficial effects seen with AZM. 
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Figure 3.1.  Western blots of proteins in the NF-κB cascade.  J774 cells were 
stimulated with IFN, LPS and 30 μM AZM for variable amounts of time at 37°C 
with 5% CO2.  Lysates were probed for proteins in the NF-κB cascade, including 
inactive NF-κB (p105), active NF-κB (p50), and IκB.  Cells were then stimulated 
for 10 minutes for IFN, LPS, and variable concentrations of AZM, and probed for 
IKKβ.  10 minutes were utilized for IKKβ experiments due to large differences in 
NF-κB activation observed in the samples.  
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Figure 3.2.  Arginase activity in the presence of an IKKβ inhibitor.  J774 cells 
were stimulated overnight with IFN, IL4/13, 30 μM AZM, and 100nM of the IKKβ 
inhibitor IKK-16 at 37°C with 5% CO2.  Cells were then stimulated with LPS for 24 
hours.  Cells were then lysed, and lysates were utilized for the arginase assay.  
Statistical analysis was performed with a one way ANOVA with Tukey’s multiple 
comparison test.  Arginase samples were run in triplicate, and data represents 
mean ± SD.  Data representative of 3 replicates.  Data deemed statistically 
significant with P<0.05 
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  Figure 3.3.  Arginase 1 gene expression in the presence of an IKKβ inhibitor.  
J774 cells were stimulated overnight with IFN, IL4/13, 30 μM AZM, and 50 nM of 
the IKKβ inhibitor IKK-16.  Cells were then stimulated with LPS for 24 hours at 
37°C with 5% CO2.  Cells were preserved in RNAlater, mRNA was isolated, and 
qRT-PCR was performed on each sample in triplicate.  Statistical analysis was 
performed via T-tests for related samples.  Data represents mean ± SD.  Data 
representative of 2 replicates. 
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Figure 3.4.  Arginase activity with increasing concentrations of an IKKβ inhibitor.  
J774 cells were stimulated overnight with IFN and 30 μM AZM or IL4/13.  Cells 
were also treated with increasing concentrations of IKK-16.  Cells were then 
stimulated with LPS for 24 hours at 37°C with 5% CO2.  Cells were lysed, and 
lysates were utilized for the arginase assay.  Results were normalized to 
conditions with no IKK-16.  * represent significant decreases from baseline 
assessed via ANOVA.  Arginase samples were run in triplicate, and data 
represents mean ± SD. 
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Figure 3.5.  Arginase activity with increasing concentrations of AZM.  J774 cells 
were stimulated overnight with IFN, IL4/13, IKK-16, and variable concentrations 
of AZM.  Cells were then stimulated with LPS for 24 hours at 37°C with 5% CO2.  
Arginase samples were run in triplicate, and data represents mean ± SD.  
Results were normalized to conditions with no AZM.  Non-linear regression of 
data was fit utilizing a log(agonist) vs. three parameter response in Graphpad 
Prism.  Data representative of three replicates. 
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Figure 3.6.  Nitrite concentration with increasing concentrations of AZM.  J774 
cells were stimulated overnight with IFN, IL4/13, IKK-16, and variable 
concentrations of AZM.  Cells were then stimulated with LPS for 24 hours at 
37°C with 5% CO2.  Samples were run in triplicate, and data represents mean ± 
SD.  Non-linear regression of data was fit utilizing a log(agonist) vs. three 
parameter response in Graphpad Prism.  Data representative of three 
replicates 
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Figure 3.7. Arginase activity in ex vivo stimulated mouse splenocytes.  
Splenocytes were collected and stimulated overnight with IFN, IFN+AZM, IL4, 
IL13, IL4/13, or no cytokines at 37°C with 5% CO2.  Cells were then treated for 6 
hours with LPS.  Lysates were collected, and the arginase assay was performed 
on the lysates.  Each sample was run in triplicate.  Statistical analysis was 
performed via one way ANOVA with Dunnett’s multiple comparison test.  
Samples were compared to the IFN+AZM+LPS group.  Differences were deemed 
significant with a p<0.05. 
 
87 
 
 
  Figure 3.8. Survival curves with increasing inocula of P. aeruginosa in C57bl/6, 
Balb/c, and IL4rαKO mice.  Mice were infected intranasally with between 105 and 
1010 P. aeruginosa, and monitored over time.   
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  Figure 3.9. Lung sections from mice infected with P.aeruginosa.  Lung sections 
were collected, and H & E staining was performed on the lung sections.  
Sections are from mice that were of the strain (A) Balb/c; (B) C57bl/6; (C) IL4rα 
KO.  Balb/c mice displayed diffuse cellular infiltrations throughout the lung 
section, while in C57bl/6 mice cells are concentrated along the small airways.  
Cellular infiltrates in the IL4rα KO mice more closely resemble the C57bl/6 mice 
than those of Balb/c.  Pictures representative from multiple pictures/mouse. 
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Figure 3.10. Phenotype of cells collected from either Balb/c or IL4rα mice.  
Lungs were collected, and lung digests were stained for flow cytometry.  Panel 
(A) cells positive for CD11b (macrophages), CD4 (T cells), or GR1 (neutrophils 
and inflammatory monocytes); (B) The subset of CD11b positive cells positive for 
MR, CCR7, CD23; (C) subset of CD11b positive cells intracellularly expressing 
TNFα, TGFβ and IL10.  Data represents mean number of cells expressing the 
surface markers ± SD, and are from 4 mice/group. 
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Figure 3.11. Adoptive transfer into IL4rα KO mice.  Bone marrow derived 
monocytes and T cells (M + T) from spleens, or just T cells (T) of Balb/c mice 
were isolated and adoptively transferred into IL4rα KO mice on day -4 before the 
experiment.  On day 0, mice were intratracheally infected with agarose beads 
containing 5 x 105 P. aeruginosa.  Surface receptor expression in the lung 
digest samples were assessed via flow cytometry.  Cell counts are depicted for 
the CD11b+GR1-IL4rα+ and the CD4+IL4rα+ subsets of cells.  Data represents 
mean ± SD for 4 mice/group.   
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Figure 3.12. Survival and weight loss with adoptively transferred mice.  IL4rαKO 
mice were adoptively transferred with either macrophages and T cells (M + T), or 
just T cells from Balb/c mice on day -4 of the experiment.  On day 0, mice were 
infected with agarose beads containing P. aeruginosa.  Data is pooled from 3 
replicates of the experiments.  Panel (A) represents percent survival between the 
two groups; (B) weight loss normalized to day 0.  Data represents mean ± SD.  
Experiment began with 16 mice/group 
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Figure 3.13. Phenotype of cells in lungs of adoptively transferred mice.  Cells 
from Balb/c mice were adoptively transferred to IL4rαKO mice on day -1, and 
infected with agarose beads containing P. aeruginosa.  Balb/c animals were 
utilized as a control.  Cell phenotypes were assessed via flow cytometry.  Panels 
represent post infection lung digest cell counts for CD11b+CD11c-GR1- 
(infiltrating macrophages), CD11b-CD11c+GR1- (resident macrophages), GR1+ 
(neutrophils), and CD4+ (T cells).  Data represents mean ± SD with 4 
mice/group. 
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Figure 3.14. Bacterial CFU in IL4rαKO mice treated with AZM.  Beginning four 
days before infection, mice received either 3.2 mg AZM daily, or vehicle control 
beginning 4 days before infection, and continuing throughout the infection.  Mice 
were then infected intratracheally with 5.5 x 104 bacteria, and monitored over 
time.  Lungs were collected, and a portion were homogenized and plated to 
determine the numbers of viable P. aeruginosa.  Data represents mean ± SD 
with 4 mice/group.   
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Figure 3.15. Weight loss in IL4rαKO mice treated with AZM.  Mice were 
treated with 3.2 mg AZM or vehicle control daily beginning 4 days before 
infection with agarose beads containing 1.5 x 105 P. aeruginosa.  Data 
shown is normalized to percent weight from day 0.  Data represents 
mean ± SD, and is representative of two experiments.   
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Figure 3.16. Counts and percentages of CD11b+MR+ cells in the lungs 
of IL4rαKO mice treated with AZM .  Mice were treated with AZM or 
vehicle control beginning 4 days before infection with agarose beads 
containing 1.5 x 105 P. aeruginosa.  Cell phenotypes were assessed via 
flow cytometry.  Panels (A) and (B) represent the number of cells 
positive for CD11b which also expressed MR in the (A) lung lavage; (B) 
lung digest.  Panels (C) and (D) represent the percentage of CD11b+ 
cells also expressing MR in the (C) lung lavage; (D) lung digest.  Data 
represents mean ± SD from 4 mice/group.  Statistical analysis was 
performed utilizing repeated measures ANOVA with Bonferroni’s post 
test.  Data is representative of two experiments. 
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Figure 3.17. Counts and percentages of CD11b+CD80+ cells in the lungs of 
IL4rαKO mice treated with AZM.  Mice were treated with 3.2 mg AZM or vehicle 
control beginning 4 days before infection with agarose beads containing 1.5 x 
105 P. aeruginosa.  Cell phenotypes were determined via flow cytometry.  
Panels (A) and (B) represent the number of cells positive for CD11b which also 
expressed CD80 in the (A) lung lavage; (B) lung digest.  Panels (C) and (D) 
represent the percentage of CD11b+ cells also expressing CD80 in the (C) lung 
lavage; (D) lung digest.  Data represents mean ± SD from 4 mice/group.   
Statistical analysis was performed utilizing repeated measures ANOVA with 
Bonferroni’s post test.  Data is representative of two experiments. 
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Figure 3.18. Ratio of CD80 to MR positive cells in lungs of IL4rαKO mice 
treated with AZM.  Mice were treated with 3.2 mg AZM or vehicle control daily 
beginning 4 days before infection with agarose beads containing 1.5 x 105 P. 
aeruginosa.  The number of CD11b+ cells expressing CD80 were divided by 
the number of CD11b+ cells expressing MR.  Number of cells positive for 
various surface markers were determined via flow cytometry.  Data represents 
mean ± SD from from 4 mice/group.  Statistical analysis was performed 
utilizing repeated measures ANOVA with Bonferroni’s post test.  Assessing 
differences in ratios was utilized to determine subtle differences in net 
macrophage polarization. 
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Figure 3.19. Ratio of CD11b+ cells to neutrophils in lungs of IL4rαKO mice.  
Mice were treated with 3.2 mg AZM or vehicle control daily beginning 4 days 
before infection with agarose beads containing 1.5 x 105 P. aeruginosa.  The 
number of CD11b+GR1- cells were divided by the number of CD11b-GR1+ 
cells.  Number of cells positive for various surface markers were determined via 
flow cytometry.  Data represents mean ± SD from from 4 mice/group.  Statistical 
analysis was performed utilizing repeated measures ANOVA with Bonferroni’s 
post test. 
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Figure 3.20. Lung sections of IL4rαKO mice treated with AZM.  Mice were 
treated with 3.2 mg AZM daily beginning 4 days before infection with agarose 
beads containing P. aeruginosa.  Lung sections were stained with H & E.  
Columns represent mice that did or did not receive AZM, while rows show the 
various days in which sections were collected.   
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Figure 3.21. Arginase activity in IL4rαKO mice treated with AZM.  Mice were 
treated with either 3.2 mg AZM or a vehicle control daily beginning 4 days 
before infection with agarose beads containing 1.5 x 105 P. aeruginosa.  Lung 
digests were collected, lysed in RIPA buffer, and analyzed with the arginase 
assay.  Data represents mean ± SD with four mice/group, and is representative 
of two experiments. 
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Figure 3.22.  Arginase 1 and iNOS localization in IL4rαKO mice treated with 
AZM.  Lung sections from mice 14 days post infection with agarose beads 
containing 1.5 x 105 P. aeruginosa were stained with primary antibodies to both 
arginase 1 and iNOS, with either FITC or texas red secondary staining.  Panels 
represent arginase 1 localization, iNOS localization, and merged data, from left 
to right.  Data representative of multiple pictures from one mouse/group.  Other 
timepoints displayed similar results (data not shown). 
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Chapter 4.  Correlation of macrophage-associated gene expression to 
clinical characteristics in patients with cystic fibrosis 
A.  Introduction 
Chapter overview 
To conclude this work we characterized the impact of chronic AZM 
therapy on macrophage gene expression and markers of inflammation in the 
lungs of patients with CF, as well as the relationship between macrophage 
polarization and lung function in these patients.  While it has previously been 
shown that AZM improves markers of clinical function in patients with CF, we 
were interested in determining whether AZM  alters macrophage phenotype in 
patients with stable CF, to extend our earlier findings both in vitro and utilizing 
our mouse infection model [16, 18, 20].  The data presented to this point was 
generated in cells and animals with functional CFTR protein, a difference that 
could potentially lead to difficulty in extrapolating that data to humans.  To 
assess the impact of AZM therapy on macrophage phenotype in patients with 
CF, we collected sputum samples from patients at both the pediatric and adult 
Cystic Fibrosis clinics at the Kentucky Clinic, isolated mRNA from the cells, and 
correlated the gene expression to the patient’s clinical status.  We were primarily 
interested in assessing gene expression in patients who were stable in their 
disease.  This was to assess the effect of AZM on macrophage polarization 
while minimizing confounding factors associated with acute infection and flare of 
the disease, and the changes in gene expression and cellular influx that results.  
We hypothesized that M2 macrophage polarization would be correlated to 
declines in lung function in patients with CF and that AZM therapy would 
additionally polarize macrophages to the M2 phenotype. 
Cystic Fibrosis:  a brief overview 
Defects in the CFTR lead to impaired chloride reabsorption.  This results 
in thick, dehydrated secretions in the lungs of patients with CF [11].  These 
thickened secretions provide an excellent breeding ground for a wide variety of 
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bacteria, most notably P. aeruginosa [11].  It is exceptionally difficult for patients 
with CF to clear the bacteria, and over time they are considered to be chronically 
colonized with the organism.  The course of the disease is characterized by 
repeated flares of inflammation caused by acute infections, followed by repair 
and recovery.  The cycle then repeats, causing a vicious circle of exacerbation, 
followed by a decline in lung function over time, which then makes it more likely 
that the patient will have a bacterial flare in the future [113].  These changes in 
lung function can be tracked in a variety of ways, most notably by assessing the 
forced expiratory volume in one second (FEV1), specifically the percent of the 
predicted value for the patient.  FEV1 represents the volume of air that a patient 
can expel from their lungs in 1 second after fully inhaling.  This value can then be 
compared to the expected volumes of a patient with similar age, height, and 
other physical parameters [114].  FEV1% predicted is commonly used as one of 
the key parameters in assessing disease progression in patients with CF.  While 
the lungs are the organ in which CF symptoms are the most life-threatening, it 
also effects many other organ systems in patients, including the pancreas, the 
digestive tracts, and the reproductive tracts [22, 23].  As one would expect from a 
disease that affects multiple systems, patients with CF commonly receive large 
numbers of medications to treat the associated symptoms.  This results in a 
significant number of potential confounding factors in any clinical study, and 
makes comparisons difficult.  For the purposes of this dissertation, we will be 
focusing on medications that deal with the pulmonary symptoms of CF, as well 
as any immunomodulatory agents that they may be taking.  Previous data from 
our laboratory has shown that subjects with CF displayed an inverse correlation 
between parameters of lung function and markers of M2 activation [115].  We 
found that the negative relationship in MR surface expression was more 
pronounced in subjects who were not colonized with P. aeruginosa, as compared 
to subjects who were colonized with P. aeruginosa.  We also found that arginase 
activity was inversely correlated with lung function in subjects colonized with P. 
aeruginosa, while there was no relationship in subjects who were not colonized 
with the organism.  We also found that these changes were associated with 
104 
 
changes in the Th1/Th2 balance in the lungs of these subjects [115].  While 
others had previously described the role of the Th1/Th2 polarization in CF, we 
were the first to assess macrophage polarization in these patients.  This research 
continues our previous work to assess gene markers associated with 
inflammation, macrophage phenotype, and fibrosis.  We hypothesized that 
inflammatory genes would be associated with improvements in lung function in 
these patients, and that AZM treatment would be associated with a shift in gene 
expression towards the M2 phenotype in these patients. 
 
B.  Detailed methods 
Clinical design 
 Subjects were recruited from both the pediatric and adult cystic fibrosis 
clinics at the Kentucky Clinic at the University of Kentucky Chandler Medical 
Center, during routine clinic visits.  For inclusion, patients diagnosed with CF 
were to be between the ages of 2-50 years, and not be in an acute exacerbation 
of their disease.  This determination was made by the treating pulmonologist.  
Patients were ineligible to participate in the study if they were experiencing an 
acute exacerbation of their disease at the time of initial sample collection (e.g. a 
clinically relevant decline in FEV1% predicted since their previous appointment, 
or if their disease required hospitalization to treat their symptoms).  Additional 
exclusion criteria included any active infectious process, malnutrition, HIV 
infection, cancer, or women who were pregnant or breastfeeding.  Subjects 18 
and older were consented, while the parents of subjects under the age of 18 
signed parental consent forms, and the subjects signed assent forms.  All 
patients or their legal guardians additionally signed HIPAA waivers to allow us to 
perform chart reviews at a later date.   
Sample collection 
 Sputum samples were collected from patients at both the pediatric and 
adult cystic fibrosis clinics at the Kentucky Clinic.  The University of Kentucky 
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Institutional review board allowed us to collect samples during normal follow up 
clinic visits.  Patients were asked to provide a spontaneous sputum sample 
during the course of a routine clinic visit.  Samples were collected within 30 
minutes of lung function tests being performed.  Samples were immediately 
placed on ice and transported to the laboratory, at which time 5 ml of PBS was 
added, followed by the addition of 5 ml of digestion buffer (0.1% DL-Dithiothreitol 
[Promega, Madison, WI] + 50 units/ml Deoxyribonuclease I [Sigma Aldrich, St. 
Louis, MO]).  Samples were then incubated for 30 minutes at 37°C, with shaking 
every 5 minutes to aid in the digestion.  After incubation, samples were 
centrifuged for 7 minutes at 1200 RPM.  The incubation process was repeated 
once if the sample was deemed to still be overly viscous.  Cells were 
enumerated, and aliquots were collected for cytospin and Diff-Quick staining.  
Cells were placed in RNAlater (Ambion, Austin, TX), and frozen at -80°C for 
subsequent analysis.  Spontaneously provided sputum samples are composed of 
macrophages, neutrophils, and epithelial cells.  Epithelial cell contamination is 
one of the weaknesses associated with the collection of sputum samples. 
RNA isolation 
 Digested sputum samples were thawed and RNAlater was removed.  
Cells were lysed utilizing Qiashredders and RNeasy mini-kits (Qiagen, Valencia, 
CA), and samples were processed according to the provided protocols.  Samples 
were initially lysed in 600ul of buffer RLT, containing guanidinium thiocyanate, 
and finally suspended in 30ul of nanopure water.  RNA was quantified using a 
Nanodrop 2000 (Thermo Scientific, Wilmington, DE).  RNA samples were frozen 
at -80°C for future analysis. 
Generation of cDNA 
 Reverse Transcription was performed utilizing materials from Applied 
Biosystems (Foster City, CA).  A set amount of isolated mRNA was incubated 
with a reverse transcriptase cocktail consisting of 5.5 mM magnesium chloride, 
500μM deoxy NTP, 2.5μM random hexamers, 0.4U/μL Rnase inhibitor, 1.25U/μL 
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MultiScribe Reverse Transcriptase, and TAQMAN RT buffer.  Incubation 
conditions were 10 minutes at 25°C, 30 minutes at 48°C, and finally 5 minutes at 
95°C.  cDNA was frozen at -80°C until ready for quantitative real-time PCR. 
Quantitative real-time PCR (qRT-PCR)  
 qRT-PCR was performed on the samples for a variety of gene markers of 
M1 and M2 polarization, as well as inflammation and fibrosis.  TAQMAN gene 
probes (Applied Biosystems, Foster City, CA) were used for analysis.  A 
complete list of genes probed for is given in table 4.1.  These genes were chosen 
to allow us to examine the net macrophage polarization, as well as the total 
inflammatory and fibrotic profile of the cells in the sputum samples.  Samples 
were run in triplicate for each gene.  The final volume for each sample was 20μL, 
consisting of TAQMAN universal PCR MasterMix (Applied Biosystems, Foster 
City, CA) and TAQMAN gene probes in concentrations suggested by the 
manufacturers.  Samples were run utilizing an ABI 7900 HT fast real time PCR 
system (Applied Biosystems, Foster City, CA), and the amplification phase of the 
reaction was run for 50 cycles.  The complete cycling parameters can be seen in 
table 4.2.  Gene expression was calculated as 2^-(average Ct gene of interest-
average Ct GAPDH).   
Statistical analyses 
 Principal component analysis (PCA) was performed as a method of data 
reduction utilizing the statistical software package SPSS (IBM, Chicago, IL).  
PCA allows the creation of new variables comprised of combinations of the 
previously collected data.  These new variables are weighted based off of the 
correlations between the various genes.  The output is designed such that the 
first newly generated variable (or “component”) explains the highest amount of 
the total variance between the initial genes; the second component explains the 
next highest amount of total variance, and so forth.  Generated components were 
deemed to explain a significant amount of the total variance if they had an 
eigenvalue greater than 1.  Additional statistical analysis was performed utilizing 
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Graphpad Prism (GraphPad software, La Jolla, CA).  Comparisons between 
groups was made via one way ANOVA with Tukey’s multiple comparison test for 
ratio level data, and by Fisher’s exact test for nominal data. 
C.  Results and discussion 
Subject demographics 
 Thirty patients were recruited for the study, with a total of 66 samples 
collected from September 2009 to December 2010.  We collected 30 original 
samples, 18 first follow-up samples, 12 second follow-up samples, 4 third follow-
up samples, and 1 fourth follow-up sample.  Subject demographics are shown in 
Table 4.3.  Of particular note is the large percentage of patients that are taking 
AZM.  While not yet considered as standard of care, AZM’s use is wide-spread in 
patients with CF who are chronically colonized with Pseudomonas, a practice 
that is anticipated to become standard of care in the near future [14].  Additionally 
we observed that a large number of our subjects were receiving other antibiotics 
to control their disease progression.  This is commonly done by utilizing two 
antibiotics in an alternating month schedule, to attempt to prevent acute 
exacerbations of their disease.  Treatment with other antibiotics may conceivably 
be altering macrophage polarization and therefore confounding our results.  
Interestingly, among our subject population was a higher percentage of 
individuals who were colonized with S. aureus than patients who were colonized 
with P. aeruginosa.  This is most likely due to the large amount of patients that 
we have in the study who are under the age of 18.  While P. aeruginosa 
eventually becomes the most significant pathogens in patients with CF, younger 
patients are more likely to be colonized with S. aureus [11].  And, S. aureus is 
considered an emerging pathogen in this patient population, as the incidence of 
colonization and infection grows [116]. 
Correlations between macrophage, inflammatory, and fibrotic gene 
markers   
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We first assessed whether there were linear correlations between gene 
markers of macrophage phenotype, and markers of inflammation and fibrosis.  
While the relationship between macrophage polarization and expression of 
various inflammatory and fibrotic markers has been established in many disease 
states, there is no evidence examining gene expression from cells isolated from 
the lungs of subjects with CF.  We first assessed the correlations between all of 
our gene expression values, to attempt to find significant relationships.  We first 
assessed the correlation between TLR4, a marker of M1 activation, and the 
inflammatory marker IL1α and the pro-fibrotic marker TGFβ.  We found a linear 
correlation between TLR4 and IL1α gene expression (Figure 4.1 A.) (R2=0.3901, 
p<0.0001).  This confirms the relationship that others have shown between 
markers of M1 activation and inflammatory cytokine production.  We observed 
similar findings between TLR4 and TGFβ (Figure 4.1 B.) (R2=0.5037, p<0.0001). 
While at first glance it may seem counterintuitive to find a linear relationship 
between a marker of M1 macrophage activation and an anti-inflammatory, pro-
fibrotic marker, it is important to note that when subjects are not in an acute 
exacerbation of their disease, there is homeostasis that occurs in the lungs of 
these subjects in a balance of both pro- and anti-inflammatory markers.  We also 
found a linear relationship between gene expression of the pro-inflammatory 
cytokine TNFα and the fibrotic protein fibronectin (Figure 4.1 C.) (R2=0.2575, 
p<0.0001).  Much of the reason for damage that occurs in the lungs of patients 
with CF is due to an overly zealous initial inflammatory response.  One of the 
potential methods by which AZM improves lung function in these subjects is by 
shifting macrophage polarization from the M1 to the M2 phenotype, and 
decreasing the amount of damage done by the initial inflammatory response to 
an infection. 
We next examined the relationship between markers of M2 activation and 
genes associated with fibrosis.  We were interested in determining if markers of 
alternative macrophage polarization correlated with fibrotic markers in our subject 
population, including subjects taking AZM.  We found a linear relationship 
between CCL-18, and fibronectin gene expression (Figure 4.1 D.) (R2=0.3341, 
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p<0.0001).  We found an extremely strong linear relationship between MR and 
fibronectin gene expression (Figure 4.1 E.) (R2=0.8981, p<0.0001).  CCL-18 is 
upregulated in M2 macrophages, resulting in chemotaxis of T-cells and activated 
monocytes and dendritic cells [117].  While not surprising, it is encouraging to 
see that this relationship still holds strong in the lungs of subjects with CF.  As we 
have seen previously, this relationship seemingly suggests that an M2 
macrophage polarization may exert a deleterious effect on the lungs of subjects 
with CF, and seems to imply that AZM is not beneficial in these subjects.  Again, 
however, the other possibility is that AZM is blunting the initial inflammatory 
response to infections in the lungs of subjects with CF, resulting in less damage 
to be repaired in the lungs of these subjects.  Finally, we found a linear 
relationship between gene expression of MR and IL10 (Figure 4.1 F.) 
(R2=0.2411, p<0.0001).  While not surprising, it is encouraging to observe that 
gene expression of the anti-inflammatory cytokine IL10 was correlated with gene 
expression of markers of M2 macrophage activation.  We did not observe any 
other significant relationships for the expression of these genes.  This again 
shows that the M2 macrophages that we observe in subjects with CF are 
phenotypically similar to M2 macrophages that have been observed by others. 
Impact of azithromycin treatment and age on gene expression, clinical 
parameters 
 We next assessed the impact of clinical parameters, including treatment 
with AZM, upon gene expression associated with macrophage polarization.  We 
did this by utilizing data not only from initial visits, but from all subject samples 
collected.  By doing so we were able to increase the power of our analysis.  
Additionally, it was necessary to do this in order to increase the number of 
samples from subjects not on AZM.  We first examined differences in lung 
function between subject groups stratified by various parameters.  Figure 4.2 A. 
shows FEV1% predicted for subjects stratified on the basis of AZM therapy at the 
time of sample collection.  We found that FEV1% predicted in patients taking 
AZM was statistically significantly lower than that of patients who were not 
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receiving AZM.  This is almost certainly due to the fact that as patients advance 
in their disease progression, they are more likely to be placed upon long-term 
AZM therapy.  Similarly, adult patients displayed significantly decreased FEV1% 
predicted when compared to pediatric patients (Figure 4.2 B.).  Again, this 
difference is likely due to routine decline in lung functions that occur as patients 
age.  Finally, figure 4.2 C. depicts the impact of stratification by AZM therapy in 
both age groups individually.  Here we can see that most of the differences in 
FEV1 % predicted observed in the previous two graphs lie within the pediatric 
subgroup.  There were essentially no differences between adult patients 
receiving or not receiving AZM.  However, the low number of samples from adult 
patients who were not receiving AZM makes comparisons difficult, as the chance 
of a type II error is high.   
We next assessed NOS2 and ARG1 gene expression in our patient 
populations.  NOS2 is widely considered to be one of the prototypical markers of 
classical macrophage activation [1, 3].  ARG1 is similarly considered to be a 
marker of M2 activation in mice, there is, however, evidence that it may be a less 
significant marker of M2 activation in humans [118].  Figure 4.3 A. shows 
differences in NOS2 gene expression between subjects who either did or did not 
receive AZM.  We found a significantly lower expression of NOS2 in subjects 
treated with AZM.  We observed the opposite trends for ARG1 gene expression, 
as it was increased in subjects receiving AZM (Figure 4.3 B.).  While we did not 
observe statistically significant differences between the two groups for ARG1 
gene expression, this may be due to having insufficient power to detect the 
differences between the two groups.  Due to the time consuming nature of 
subject recruitment, as well as the expense associated with processing subject 
samples, we limited ourselves to 30 subjects for this study. 
When we separated the samples not only by AZM status, but additionally 
stratifying subjects by age, additional interesting observations were made.  In 
figure 4.3 C. we can see that the difference in NOS2 gene expression is most 
pronounced in our pediatric subjects, with almost all of our pediatric subjects 
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receiving AZM having little to no gene expression of NOS2.  When we examined 
ARG1 gene expression, however, we found that this difference is most 
pronounced in our adult subject population, and less pronounced in our pediatric 
population.  While we did notice trends in ARG1 gene expression in our adult 
subjects who were either on or off AZM, we did not observe significant 
differences.  These two findings suggest that AZM is able to polarize 
macrophages to an alternatively activated phenotype in the sputum samples that 
we collected.  It is important to note that there is a great deal of variability in gene 
expression between our various samples, which may explain the difficulty that we 
had to obtain statistical differences between the groups.   
We then compared expression of other inflammatory, fibrotic, and M2 
genes between subject groups stratified on the basis and AZM treatment.  We 
found a trend towards a decrease in gene expression for the pro-inflammatory 
cytokine IL1α (Figure 4.4 A.) (p=0.1241), suggesting that AZM may be 
decreasing pro-inflammatory cytokine expression among our subject population.  
We also found a non-significant decrease in fibronectin gene expression (Figure 
4.4 B.) (p=0.2947).  When we assessed other gene markers for M2 activation, we 
found no differences in CCL18 gene expression (Figure 4.4 C.), and a slight 
decrease in MR gene expression (Figure 4.4 D.) (p=0.0835).  The slight 
decrease in IL1α gene expression in subjects who were receiving AZM further 
describes ways that AZM appears to benefit these subjects.  More difficult to 
explain, however, is that we observed no differences in gene expression for 
CCL18, and even a slight decrease in MR gene expression in subjects treated 
with AZM.  It is possible that this is due more to the types of subjects who are 
likely to be receiving AZM, e.g. subjects with more severe declines in lung 
function are more likely to have impaired expression of the genes that we 
assessed.  The small degree of differences that we observed, well above 
statistical significance, however, makes it difficult to truly assess any differences 
among these samples.  
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Finally we assessed gene expression related to the clinical parameters 
used to measure lung function and disease progression, FEV1 and FVC (forced 
vital capacity) % predicted.  While we did not observe significant correlations 
among any of the gene expression values and FEV1% predicted, we did find 
significant linear correlations between FVC % predicted and the inflammatory 
cytokines IL1α and TNFα (Figure 4.5 A. and figure 4.5 B.).  This suggests that 
declines in lung function are associated with a decrease in gene expression for 
these pro-inflammatory M1 related cytokines.  This can potentially be explained 
by the shift that occurs over time in the lungs of CF subjects from a Th1 dominant 
polarization to more of a Th2 polarization.  It may also be due to a decline in the 
number of cells in the lungs of subjects who have been long colonized with 
bacteria, with a resulting decrease in the mRNA that we were able to collect from 
the subjects.  It may also be due to changes in the profiles of cells that are 
present in the lungs of the subjects as lung function declines.  Interestingly, we 
also found a linear correlation between FVC % predicted and gene expression of 
the anti-inflammatory cytokine IL10 (Figure 4.5 C.).  This gene is most likely 
upregulated in order to ensure that the inflammatory response does not become 
dysregulated.  Similarly to the inflammatory cytokines, it may also be a response 
that as lung function declines in subjects with CF the cells are less robust than 
they are in subjects with better lung function.  
Principal component analysis and gene grouping 
 To this point, we have been able to make observations in how the 
expression of certain genes of interest varies among our subjects, and how gene 
expression indicative of macrophage phenotype polarization relates to markers of 
inflammation, fibrosis, and clinical indices.  However, these previous analyses do 
not present a robust profile that can correlate a certain macrophage gene 
expression profile to the clinical parameters (including AZM therapy) of our 
subject population.  In order to determine whether such a description can be 
purported, we utilized principle component analysis (PCA) to simultaneously 
examine the expression variability of all genes measured. 
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An initial round of PCA was performed using the gene data from the initial 
clinic visit for each subject only.  This is because PCA requires independence 
among all data measurements.  All 15 genes of interest were included in the first 
round of analysis.  This first round of PCA created 5 components.  The weighting 
of genes in each component for this analysis shown in Table 4.4.  Component 1 
accounted for 32% of the total variance of the gene samples, while component 2 
accounted for an additional 18% of the total variance.  Components 3, 4, and 5 
explained an additional 12%, 10%, and 7% of the total variance for these genes, 
respectively.  We found 4 genes with a high weighting in component 1 and a low 
weighting in component 2. Conversely, we determined that an additional 4 genes 
were weighted high in component 2, and a low in component 1.  These groupings 
explain genes with expression that vary in a similar manner, showing that these 
genes are associated with each other. 
This is especially interesting when one considers the function of the genes 
that were grouped together in the process of creating the first 2 components.  
The genes MMP9, NOS2, TGFB, and TLR4 had high weighting in component 1 
and low weighting in component 2.  NOS2 and TLR4 both are traditionally 
associated with the M1 phenotype [3].  CCL18, fibronectin, IL12b, and MR were 
highly weighted in component 2, and had a low weighting in component 1.  
CCL18, fibronectin, and MR are traditionally associated with the M2 phenotype 
[3].  That the gene weightings generally grouped in a manner consistent with 
either an M1 or M2 activation confirms the validity of utilizing PCA.  Component 1 
did contain some M2 associated genes, contrariwise component 2 contained 
some genes traditionally associated with inflammation.  It is important to note, 
however, that the inflammatory profile in the lungs of these patients is dynamic.  
Anti-inflammatory genes may be up-regulated in the aftermath of an inflammatory 
flare, and vice versa.  Interestingly, arginase 1 was not strongly associated with 
any of the components.  This is consistent with findings from others suggesting 
that while arginase 1 is an important marker of macrophage polarization in mice, 
it may be a less important marker in humans [118].  We did, however, find other 
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markers that are traditionally associated with the M2 phenotype were highly 
weighted into component 2. 
 We next performed an additional round of PCA utilizing only the genes 
that were highly weighted in either component 1 or component 2.  The previous 
round of PCA produced gene weighting that varied similarly among subject 
samples.  The second round was performed to allow us to focus just on the most 
significant genes that we assessed.  The gene weightings from the second round 
of PCA are presented in figure 4.5.  Utilizing the restricted gene set, 2 
components were generated.  These two components were responsible for 39% 
and 34% of the total variance among the 8 genes in the restricted gene set, 
respectively.  The weightings from these two components were utilized to 
generate individual values for each sample.  These two generated components 
were utilized for the next series of analysis. 
Subject clinical data stratified via PCA components 
 We plotted the values for components 1 and 2 for each initial subject visit, 
as shown in figure 4.6.  One of the basic assumptions of PCA is that each 
component is orthogonal to every other component; that is, there should be no 
correlations between individual components.  This allows us to graph the two 
components, and determine if individual subjects group together.  We found that 
the subject samples sorted into three distinct groups.  There was first a group of 
subjects that had low values for both component 1 and component 2.  It is 
reasonable to assume that macrophages in these patients were not polarized to 
either the M1 or M2 phenotype.  Next, there was a group of subjects that had a 
higher value in component 1 than component 2.  These patients are considered 
to have had a macrophage profile that was polarized more toward that of an M1 
phenotype.  Finally, there was a group of subjects that had a higher value in 
component 2 than component 1.  The macrophage populations of these 
individuals can be considered to have a net M2 polarization.   
115 
 
We first assessed AZM status in each of the three groups to see if this 
differed according to macrophage gene expression status.  Figure 4.7 A. shows 
the percentage of patients in each of the three groups that were taking AZM.  
According to these results, AZM therapy did not influence the gene expression 
profile as stratified by PCA (p=0.6465, Fisher’s Exact Test).  It is important to 
note, however, that the percentage of patients taking AZM was extremely high in 
all three groups.  As patient lung function declines, clinicians at the University of 
Kentucky CF clinics are extremely likely to place the patients on the drug.  Due to 
this, it made it difficult to assess the impact of AZM therapy in this analysis.   
Figure 4.7 B. shows the average age of subjects in the three groups.  We 
found that patients with a high PC2 value (M2-biased) were significantly older 
than patients who were high in PC1 (M1-biased).  This is consistent with data in 
the literature showing that a Th2 polarization increasingly persists in the lungs of 
patients with CF as they age [32].  This Th2 polarization likely would correlate 
with an increase in polarization of macrophages to the M2 phenotype, and 
suggests a possible explanation for why we observed that patients who had 
higher gene expression of M2 markers were significantly older than patients with 
high gene expression of M1 markers. 
We next compared lung function of subjects in the three groups. Figure 
4.8 A. shows that there were no differences in the mean FEV1% predicted 
between the three groups.    Figure 4.8 B. shows the FVC % predicted.  Here 
again we did not observe a difference in this parameter between the three 
groups.  We had initially anticipated that there would be differences between the 
component 1 high and the component 2 high groups.  This data suggests that 
macrophage phenotype does not correlate to baseline lung disease severity in 
these patients, as analyzed by this variable reduction process. 
We then compared additional antibiotic use among the three groups.  
Patients with CF are routinely placed on other antibiotics as a means to either 
treat acute exacerbations or limit their incidence.  Figure 4.9 shows non-AZM 
antibiotic use between the three groups.  We first assessed the percentages of 
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patients receiving oral and IV antibiotics other than AZM for their disease (Figure 
4.9 A.).  We found that patients that had high values for component 2 were less 
likely to be taking other antibiotics than patients with low values for both 
components (Fisher’s Exact Test, p=0.0932).  We observed a similar trend in 
patients with high values in component 1 (p=0.0809), but the results were not 
significant, due in part to the relatively small number of patients in the group.  We 
next assessed the percentages of subjects receiving inhaled tobramycin therapy 
(Figure 4.9 B.).  Inhaled tobramycin is commonly used to control pulmonary 
infections in patients with CF, most notably for patients colonized with P. 
aeruginosa [14].  We observed similar trends in inhaled tobramycin usage as we 
did in the non-AZM antibiotic usage in these subjects.  Namely, patients with high 
values for component 2 appeared to be less likely to receive inhaled tobramycin 
than patients with either high values in component 1 or with low values for both 
components.  There are a few possible explanations for this.  First, patients with 
either polarization to the M1 or M2 phenotype may be innately more stable in 
their disease, and be less likely to require other antibiotics than patients whose 
macrophages are inactive.  Second, treatment with other antibiotics may be 
helping to keep bacteria at a state where a robust macrophage response of 
either phenotype may not be necessary.  Unfortunately, due to the nature of the 
data that we collected for this study, it is impossible to determine which of these 
two possibilities is the case for our patients with CF.  
Lastly, we assessed the bacterial colonization status among our PCA-
stratified subject groups.  Figure 4.10 presents the percentages of subjects that 
were colonized with either P. aeruginosa or S. aureus.  Due primarily to the 
difficulty that CF patients experience in clearing infectious pathogens from their 
lungs once they have been infected, subjects were deemed to be colonized with 
one of the two bacteria if the last recorded sputum cultures in their charts showed 
a positive culture.  We did not find statistically significant differences in bacterial 
colonization between the three groups.  One of the initial assumptions of PCA 
(sample independence) prevented us from utilizing all 66 of our samples, 
restricting us to just the initial visits for the 30 subjects.  The smaller number of 
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samples likely prevented us from being able to find significant differences 
between the three groups.  The trends that we observed, however, were very 
intriguing.  Most interestingly, subjects with high values in component 2 were 
more likely to be colonized with P. aeruginosa, but less likely to be colonized with 
S. aureus. The reason for these differences in bacterial colonization status is 
unclear.   When considering our population, subjects with high values for 
component 2 were significantly older than patients with high values for 
component 1.  P. aeruginosa becomes the most significant pathogen in patients 
with CF as they age, with studies suggesting colonization rates in excess of 80% 
in adult patients [11].  Contrariwise, younger subjects are more likely to be 
colonized with S. aureus [11].  There is also evidence that the microbial infection 
patterns are changing across the United States in subjects with CF.  One of 
these shifts is a greatly increased rate of colonization (upwards of 20%) with S. 
aureus, especially MRSA [116, 119].  Additionally, evidence exists that the rates 
of P. aeruginosa colonization have been declining in patients with CF, on the 
order of 5-6% in most patient age ranges over the time span from 1995-2005 
[116].  These differences in bacterial colonization rates in patients over time may 
suggest a possible explanation for the differences seen in the three groups.  
Another possibility, however, is that the pathogens themselves are playing a role 
in macrophage polarization, or that different macrophage polarizations may be 
more beneficial in subjects colonized with one of these two pathogens. 
D.  Conclusions 
General Conclusions  
In these experiments we present data suggesting a possible mechanism 
by which AZM benefits patients with CF.  By utilizing PCA, we were able to 
observe 2 distinct gene groupings consistent with an M1 or an M2 macrophage 
polarization.  By utilizing these two distinct components, we were able to place 
our subjects into three different groups, and assess clinical parameters for these 
subjects.  Disappointingly, we were not able to determine whether AZM treatment 
correlated with one or more groups.  We believe that this is primarily due to the 
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high prevalence of subjects receiving AZM in our study.  Future consideration of 
the duration of treatment with AZM for subjects may enhance this analysis.  It 
was also intriguing that we did not observe differences in FEV1 % predicted 
between the three groups.  While we focus on the role of AZM in these subjects, 
there are also a wide variety of other treatments that these subjects are taking to 
improve their lung function, both pharmacologic and non-pharmacologic, and the 
effects of these other treatments may be overwhelming our ability to tease out 
the effects of AZM.  While AZM therapy did not influence the stratification of 
subjects here based upon macrophage-related gene expression, it has been 
shown by others in the past to improve parameters in patients with CF [16, 18, 
20].  We were, however, able to show gene groupings that are consistent with 
either an M1 or an M2 macrophage polarization.  This suggests that differences 
in macrophage polarization do exist in these subjects.   
It was also interesting to observe the gene groupings in our two principal 
components.  Our first component consisted of MMP9, NOS2, TGFB, and TLR4.  
NOS2 and TLR4 have traditionally been very strongly associated with the M1 
phenotype.  MMP9, a metalloprotease, is associated with cleavage of the fibrotic 
proteins, and can be considered in terms of its role as a marker of remodeling 
and ECM turnover.  While it has been linked to the M1 phenotype in the past, this 
data further links MMP9 with other M1 associated genes.  PCA groups genes 
with similar variances, and finding MMP9 associated with genes strongly 
associated with the M1 phenotype strongly suggests that MMP9 gene expression 
is upregulated as part of the gene expression profile of M1 macrophages.  In our 
second principal component, we found strong weightings for the genes CCL18, 
fibronectin, IL12b, and MR.  CCL18 and MR have traditionally been strongly 
associated with the M2 phenotype.  Finding fibronectin expression to be 
associated with other M2 associated genes was additionally not particularly 
surprising.  This upregulation in fibronectin expression associated with M2 
macrophages could additionally explain why the Th2 phenotype is associated 
with declining function in subjects with CF as they age. 
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Most intriguing are the differences that we observed in bacterial 
colonization status for subjects in the three groups, as well as the differences that 
we observed in age between the three groups.  Subjects with high values for M2 
gene markers were significantly older than subjects with high values for M1 gene 
markers, suggesting a shift towards the M2 phenotype as subjects age.  While 
consistent with observations from others showing a Th2 polarization over time in 
patients with CF, it was interesting to see that this observation holds true for 
macrophages as well.  Additionally, the differences we observed in bacterial 
colonization status may illustrate the shifting patterns of bacterial colonization 
that is occurring in patients with CF.  Differences in bacterial colonization may 
also be driving differences that we observe in macrophage polarization.   
 At first glance, much of this data seems to suggest that treatment with 
AZM may be deleterious in many patients.  Namely, we showed that in our 
subject population, pro-inflammatory cytokine gene expression was increased 
with higher values for lung function.  Treatment with AZM results in decreased 
inflammatory markers as well as an upregulation in a cell type that produces 
fibrotic proteins.  This would seem to suggest that AZM may potentially result in 
harm in patients with CF.  However, we also observed that AZM resulted in 
decreases in NOS2 gene expression.  The M2 shift, therefore, results in a 
decrease of genes necessary for the oxidative burst to destroy bacteria.  This 
oxidative burst, however, leads to damage in the airway, both during an acute 
flare of the disease, and during the resting state of the disorder.  In light of the 
beneficial effects that patients with CF have long reported with AZM, another 
possibility presents itself.  By shifting macrophage polarization away from the 
inflammatory M1 phenotype, and towards the pro-fibrotic M2 phenotype, this may 
be resulting in less oxidative damage occurring in the lungs of these patients.  
The decrease in damage may then result in less need for repair from the M2 
phenotype, and a resultant decrease in scarring and fibrosis. 
Limitations 
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 There are several limitations associated with the data generated here.  
First, not all patients with CF are able to provide sputum samples.  Sputum 
production becomes more likely as subjects age.  Very young patients, as well as 
patients with mild disease are less likely to be sputum producers.  Thus, while 
our age range for subjects in our study was technically between the ages of 2-50, 
the youngest subject that we recruited in the study was in fact 8 years old.  This 
also results in our data being skewed towards older, less healthy subjects.  This 
is also in part likely one of the reasons why a large amount of our subjects were 
on AZM.   
Additionally, there is considerable variability in the quality of sputum 
samples that subjects provide.  While sputum samples consist predominately of 
monocytes, macrophages, and neutrophils, low-quality samples can also have 
considerable epithelial cell contamination.  Some studies exist that suggest that 
the percentage of epithelial cells in collected sputum samples in patients may 
range from 20%-50% [120, 121].  Additionally, for gene analysis, having mRNA 
from a more representative sampling of cells in the lungs might allow us a better 
picture of the inflammatory and fibrotic state of these subjects. 
 The ideal method for acquiring cell from the lungs of patients is by 
bronchoalveolar lavage fluid (BALF).  BALF samples are considerably more pure, 
with a much higher percentage of monocytes and macrophages than sputum 
samples, and essentially no epithelial cells [122].  This procedure, however, is 
extremely invasive, requiring specialized training, as well as heavy anesthesia.  
Additionally, there are risks associated, including fever, pneumonitis, bleeding, 
and bronchospasm [123].  This results in BAL primarily being perfomed for 
patients who have been admitted to the hospital for an acute exacerbation of 
their disease.  Since we were interested in the status of patients who were at a 
baseline state of pulmonary function, we were unable to collect samples in this 
manner.  Ultimately, we felt that the disadvantages of collecting only sputum 
samples from these patients were outweighed by the advantages of being able to 
easily collect cells in a minimally invasive manner during a routine clinic visit.   
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We were additionally surprised to observe that such a large amount of our 
subjects were taking AZM.  From our previous work, we had anticipated that we 
would have fewer subjects that were taking the drug.  In our previous studies we 
found that only 65% of the subjects were taking AZM [115].  Here, almost 80% of 
our subjects were being treated with AZM.  The high rate of AZM usage in our 
subjects made it difficult to determine the significance of the impact that the drug 
may exert on macrophage gene expression.  We hope in the future to be able to 
have subjects stop taking AZM, and compare gene expression in the subjects 
when they are on AZM to when they are not receiving the agent. 
We were unable to record the duration that subjects were taking AZM due 
to the nature of our chart reviews.  It would have been interesting to assess how 
duration of AZM treatment in our subjects grouped with our principal component 
analysis, to determine whether duration of AZM treatment was associated with 
gene expression in our subjects.  Additionally, we were unable to take subjects 
off of AZM for the purposes of our study.  We plan to do this in the future.   
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Table 4.1.  List of genes utilized for qRT-PCR.  Data also includes 
classification of the role of the gene, the abbreviation utilized throughout this 
chapter, and the product number.  
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Table 4.2.  Cycling parameters utilized for qRT-PCR 
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Table 4.3.  Demographics of subjects enrolled in the study.   
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Figure 4.1.  Gene expression correlations in sputum samples from subjects with 
CF.  Sputum samples from CF patients were collected, and mRNA was isolated.  
Gene expression was assessed via qRT-PCR, and values for the genes of 
interest were normalized to expression of the housekeeping gene GAPDH.  
Panels represent (A) Correlation between TLR4 and IL1α; (B) TLR4 and TGFβ; 
(C) TNFα and fibronectin; (D) CCL-18 and fibronectin; (E) MR and fibronectin; 
and (F) MR and IL10.  Gene samples were run in triplicate, and average value 
for each gene was plotted.  R square and p values are listed below each graph.  
Linear regularity was assessed with Graphpad Prism.   
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Figure 4.2.  FEV1% predicted compared for both subject AZM status and 
subject age.  FEV1 % predicted was compared to (A) AZM usage; (B) subject 
age; (C) both age and AZM usage.  FEV1% predicted was collected from chart 
review.  Statistical analysis was performed via either an unpaired t-test, or a 
one-way ANOVA with Tukey’s multiple comparison test, where appropriate. 
Differences were deemed to be statistically significant with a p value <0.05 
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Figure 4.3.  Expression of prototypical M1 and M2 genes in subjects receiving 
AZM.  Sputum samples from subjects with CF were collected, and mRNA 
isolated.  Gene expression was assessed via qRT-PCR, and normalized to the 
housekeeping gene GAPDH.  Panels (A) and (B) are stratified to AZM usage, 
and are compared to either (A) the M1 gene marker NOS2; or (B) the M2 gene 
marker ARG1. Panels (C) and (D) are stratified with both AZM usage and 
subject age, and are compared to (C) NOS2; or (D) ARG1.  Statistical analysis 
was performed via either an unpaired t-test, or a one way ANOVA with Tukey’s 
multiple comparison, where appropriate.  Differences were deemed statistically 
significant with a p value <0.05. 
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Figure 4.4.  Gene expression of M1 and M2 associated genes in subjects 
with CF.  Sputum samples from subjects with CF were collected, and mRNA 
was isolated.  Gene expression was assessed via qRT-PCR, and gene 
expression was normalized to the housekeeping gene GAPDH.  Panels are 
stratified in terms of AZM usage, and consist of (A) the M1 gene marker IL1-α; 
(B) the fibrotic gene marker fibronectin; (C) the M2 gene marker CCL18; (D) 
the M2 gene marker MR.  Statistical analysis was performed via an unpaired 
t-test.  Statistically significant differences were not observed between any 
groups. 
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Figure 4.5.  Correlation between FVC% predicted and M1 and M2 associated 
genes.  Sputum samples were collected from subjects with CF, and mRNA 
was isolated.  Gene expression was assessed via qRT-PCR and normalized to 
the housekeeping gene GAPDH.  FVC % predicted (determined via chart 
review) was compared to (A) IL1α; (B) TNFα; (C) IL10.  Gene samples were 
run in triplicate, and average value for each gene was plotted.  R square and p 
values are listed below each graph.  Linear regularity was assessed with 
Graphpad Prism.   
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Table 4.4.  Component matrix for the first round of PCA.  Data was assessed 
via principal component analysis.  Component 1 and component 2 explained 
31.8% and 18.7% of the total variance in gene expression.  An eigenvalue >1 
was required for inclusion of the components that were generated. 
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Table 4.5.  Component matrix for the second round of PCA.  Genes with a 
high weighting in either component 1 or component 2 were included in the 
second round of PCA.  Data was assessed via principal component analysis.  
Component 1 and component 2 explained 38.8% and 33.6% of the total 
variance in gene expression.  An eigenvalue >1 was required for inclusion of 
the components that were generated. 
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Figure 4.6.  Plotting of principal components 1 and 2.  Components 1 and 2 
were graphed, and subjects were divided into one of three groups:one group 
with low values in both components 1 and 2, one group with greater values in 
component 1 than component 2, and one group with greater values in 
component 2 than component 1. 
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Figure 4.7.  Subject demographics with PCA subgroups.  Panel (A) describes 
the percentage of subjects who were receiving AZM; Panel (B) describes subject 
age.  Statistical analysis of percentage of subjects receiving AZM was performed 
with Fisher’s exact test for each possible comparison.  Subject age was analyzed 
with a one way ANOVA with Tukey’s multiple comparison test.  Panel (B) 
represents mean ± SD for all samples. 
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Figure 4.8.  Parameters of lung function in PCA subgroups.  Panel (A) 
describes FEV1% predicted in the three subgroups; (B) FVC% predicted in the 
three subgroups with PCA.  Parameters of lung function were determined from 
chart review.  Data represents mean ± SD of all samples.  Samples were 
analyzed with a one way ANOVA with Tukey’s multiple comparison test. 
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Figure 4.9.  Other antibiotic usage in PCA subgroups.  Panel (A) represents 
non-AZM oral and IV antibiotic usage in subjects receiving AZM.  Antibiotic 
usage was determined from chart review.  Statistical analysis of percentages 
were performed with Fisher’s exact test for each possible comparison.  
Samples were deemed statistically significant with a p < 0.1. 
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Figure 4.10.  Bacterial colonization rates in PCA subgroups.  Panel (A) 
represents the percentages of subjects colonized with P. aeruginosa; Panel 
(B) represents the percentages of subjects colonized with S. Aureus.  
Colonization rates were determined via chart review.  Statistical analysis of 
percentages were performed with Fisher’s exact test for each possible 
comparison.  Samples were deemed statistically significant with a p <0.05. 
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Chapter 5:  Discussion  
A.  Results Overview 
 The goal of this work was to further identify the mechanism and 
importance of AZM dependent macrophage polarization.  This was accomplished 
through a combination of cell culture, animal work, and clinical research.  We 
utilized a series co-culture experiment to assess the importance of AZM 
dependent macrophage polarization on fibrogenesis in fibroblasts.  We 
additionally examined the importance of AZM polarized macrophages in the 
context of P. aeruginosa pneumonia in the lungs of various mouse strains.  We 
finally assessed gene expression in subjects with CF, and correlated gene 
expression to clinical parameters. 
Further description of the phenotype of azithromycin polarized 
macrophages 
 We first assessed the ability of AZM to polarize macrophages to the M2 
phenotype in the presence of both another cell type (fibroblasts), as well as in the 
presence of viable bacteria.  This was done to confirm the results that we had 
previously seen in vitro [63].  While previous studies in our laboratory were 
descriptive in examining the effects of the drug on macrophages, here we extend 
the work to examine the function of macrophages treated with AZM, through both 
co-culture experiments to study the interaction with fibroblasts, and through our 
in vivo infection model.  We confirmed through both the arginase assay and 
expression of the surface molecule MR that the macrophages in both our co-
culture system and in infected mice are polarized by the drug to an M2-like 
phenotype. 
 We next examined expression and activation of the pro-fibrotic molecule 
TGFβ.  Here we found that AZM increased both levels of active TGFβ, as well as 
the ratio of active to total TGFβ, and the amount of TGFβ1 mRNA.  Work from 
others in our laboratory suggests that these increases in TGFβ activation are due 
at least in part to increases in molecules that cleave TGFβ from its inactive to 
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active form, including MMP9.  Consistent with our findings for TGFβ, we found 
increases in fibronectin in the co-culture system, showing that AZM polarized 
macrophages act in a matter consistent with what we would expect from M2 
macrophages.  This suggests that function of AZM-induced macrophages is 
similar to that of cells polarized by IL4 and IL13. 
Importance of M2 macrophages in response to P. aeruginosa pneumonia 
 We examined the role of M2 macrophages in P. aeruginosa pneumonia 
both in C57bl/6 mice as well as in IL4rαKO mice.  In our C57bl/6 mice we found 
that AZM treatment resulted in greater numbers of cells expressing M2 markers, 
and fewer cells expressing M1 markers, as well as increased arginase activity.  
We further found that AZM shifts the influx of cells in the lungs of these animals 
away from a neutrophilic response, and towards a more monocytic cellular 
response.  Importantly, C57bl/6 mice treated with AZM had significantly lower 
mortality from the infection, as compared to mice that did not receive AZM, while 
observing essentially no differences in the numbers of bacteria present in their 
lungs.  We hypothesize that the shift away from the M1 phenotype and towards 
the M2 phenotype is responsible, at least in part, for these improvements.  In 
essence, it is the overly zealous inflammatory response, rather than the bacteria, 
which results in the mortality associated with P. aeruginosa pneumonia in this 
model. 
 We observed similar, albeit less marked findings in our IL4rαKO mice, as 
well as IL4rαKO mice with cells adoptively transferred with Balb/c T cells and 
macrophages.  While we did not observe differences in survival between these 
two groups, we did still see increases in monocytes in the lungs of animals that 
received macrophage from Balb/c mice, as well as decreases in neutrophils 
present in the lungs of these animals.  When we treated IL4rαKO mice with AZM, 
we found that AZM was still able to polarize macrophages to the M2 phenotype 
in these mice.  Most interestingly, we found increased localization of arginase 1 
around small airways in the lungs of IL4rαKO mice treated with AZM, and 
decreased expression of iNOS.  The clinical relevance of this shift in specific 
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location of arginase expression is potentially large.  The peribronchiolar regions 
are impacted the most by the repeated inflammation and repair cycle in patients 
with CF, whereas the integrity of the alveoli are typically spared in this 
pathophysiology.  This in itself could be largely responsible for the beneficial 
effects of AZM.  Interestingly, other studies from our laboratory utilizing the 
Pseudomonas infection model have shown that the number of 
monocytes/macrophages infiltrating the airways is increased, corresponding with 
a decrease in neutrophil influx here [75].  The IHC data showing the location of 
heightened arginase expression supports these results.  These findings show 
that AZM is able to polarize macrophages to the M2 phenotype independent of 
IL4 and IL13 function. 
Mechanistic investigations into azithromycin-dependent M2 polarization 
 We further assessed the mechanism by which AZM polarizes 
macrophages to the M2 phenotype in vitro.  We first found that AZM was able to 
increase arginase activity, a marker of M2 activation in IL4rαKO splenocytes 
stimulated ex vivo.  We also found that AZM decreased activation of NF-κB while 
increasing levels of IKKβ present in the system.  These findings suggest that one 
potential mechanism by which AZM polarizes macrophage to the M2 phenotype 
is IKKβ dependent, presumably via activation of IKKβ.  This was further 
confirmed when we treated cells with the IKKβ inhibitor IKK-16.  IKK-16 was able 
to decrease arginase activity with AZM treated cells, while exerting no effects on 
arginase activity in cells treated with IL4/13.  While not confirming an exact 
mechanism for AZM dependent M2 polarization, it does further isolate molecular 
targets for future examinations.  From this work, it does appear that signaling 
through intracellular cascades is altered, and therefore responsible for the 
changes in gene expression in macrophages exposed to AZM.  To extend this, it 
was important for us to examine the role that IL4 and IL13 play.  A possible 
explanation of the changes could be that autocrine IL4/IL13 secretion was being 
altered by the drug, thereby affecting the change in phenotype.  This does not 
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appear to be the case however, because we show that AZM will polarize cells 
independently of IL4/IL13 signaling.   
Phenotypic determinations in patients with CF 
 We collected 66 sputum samples from 30 subjects with CF and isolated 
mRNA.  We performed qRT-PCR on these samples for a variety of genes for 
macrophage phenotype, inflammatory status, and fibrosis.  We additionally 
performed chart review on these subjects allowing us to review their clinical 
status, as well as determine other parameters of their health.  We first assessed 
correlations between various genes.  Here we found that gene markers of M1 
and M2 polarization correlated with inflammatory and fibrotic gene markers, 
respectively.  We next compared various clinical parameters of the subjects.  
Here we found that the FEV1% predicted was significantly lower in subjects 
receiving AZM.  We additionally found that older subjects had significantly lower 
FEV1% predicted than those who were younger.  These two findings are 
consistent with the place of AZM in treatment of CF, and the decline that occurs 
in these subjects as they age.   
Gene expression and AZM 
We then correlated various gene markers of these subjects to their AZM 
treatment status.  We found shifts in gene expression consistent with a shift to 
the M2 phenotype in the sputum samples of these subjects, as well as 
correlations between inflammatory cytokines and lung function.  This confirmed 
the protein data that we have previously observed [115], showing that AZM 
increases markers of M2 polarization, and that in subjects with CF markers of the 
M1 phenotype are associated with better outcomes.  This shows the potential 
importance of macrophage polarization in subjects with CF. 
Principal component analysis 
 We finally utilized principal component analysis as a method of data 
reduction.  We found two groupings, with one representing genes associated with 
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the M1 phenotype and one representing genes associated with the M2 
phenotype.  We then charted these two components, and found that our samples 
sorted into three different groups.  Gene expression in one group showed 
markers of neither phenotype.  Another group displayed increased expression of 
M1 activation, while a third displayed increased expression of M2 activation.   
 Clinical status in these subjects was then assessed.  Our findings were 
consistent with those of others with the net Th2 shift that occurs in patients as 
they age [32].  The cytokines produced as part of this shift result in an alteration 
in macrophage polarization, as exemplified by the increased age observed in the 
group with high expression of M2 markers.  We additionally observed differences 
in bacterial colonization between our groups, with subjects with high expression 
of M1 associated genes more likely to be colonized with S. aureus, and less 
likely to be colonized with P. aeruginosa than subjects with high expression of 
M2 markers.  This again reflects the observations of others, with the shifts we 
observed in bacterial colonization status being similar to those observed by 
others in the past [119].  It is unknown whether these changes are related to the 
difference in macrophage polarization, or are related to the difference in subject 
age between the two groups. 
B.  Significance 
IKKβ and macrophage polarization 
 We attempted to further isolate molecular targets by which AZM polarizes 
macrophages to the M2 phenotype.  Based on the work by Fong et. al., we 
assessed IKKβ as a target for AZM.  Their work utilized mice that were 
conditional knock-outs of IKKβ in either epithelial or myeloid cells.  In mice with 
the IKKβ deficiency in epithelial cells, they found decreased inflammation as they 
expected.  Surprisingly, however, in their mice with deficient IKKβ in myeloid 
cells, however, they found increased resistance to pulmonary infections with 
Group b Streptococci.  They went on to find that macrophages with deficient 
142 
 
IKKβ signaling displayed increased markers of M1 activation, primarily measured 
by cytokine expression [68]. 
  They then examined why eliminating IKKβ signaling in myeloid cells 
would lead to increased M1 signaling.  They found that STAT1 phosphorylation 
was increased in cells with deficient IKKβ signaling, suggesting that IKKβ 
prevents the activation of STAT1.  They hypothesize that this interaction is 
necessary in macrophages to allow for resolution of the immune response over 
time [68].   
 To attempt to determine if one of the ways that AZM polarizes 
macrophages to the M2 phenotype is via activation of IKKβ, we utilized a small 
molecule inhibitor of IKKβ to assess if IKKβ activation played a role.  We found 
that inhibition of IKKβ activation with IKK-16 eliminated AZM dependent arginase 
activity, while exerting essentially no effect on IL4/13 dependent arginase activity.  
We did, however, find that extremely high concentrations of AZM were able to 
overcome this inhibition.  This further confirms molecular targets by which AZM 
polarizes macrophages to the M2 phenotype.  Due to technical limitations, we 
were unable to confirm that AZM in fact prevents phosphorylation of STAT1, 
confirming that this is the mechanism by which AZM polarizes macrophages to 
the M2 phenotype.  In essence we were unable to detect p-STAT1 in our cells, 
including in positive controls (IFN +LPS stimulated cells).  Future work in our 
laboratory will focus on alternative experiments to confirm that STAT1 activation 
is decreased with AZM treatment. 
Breaking the cycle of inflammation and fibrosis 
 Disease progression in CF is characterized by repeated cycles of 
infection, inflammation, repair, and fibrosis [15].  We believe that the beneficial 
effects of AZM in these patients are due in part to decreasing the extent of the 
immune response to an acute flare of the disease.  Figure 5.1 shows our 
proposed model for the beneficial effects of AZM.  In the normal course of CF, 
there is a large inflammatory response consisting, among other cells, of M1 
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macrophages and neutrophils [44].  This overly zealous immune response, in the 
process of clearing the bacterial flare, results in the production of reactive oxygen 
species which leads to tissue damage in the lungs of these patients.  After the 
initial inflammatory response, alternatively activated macrophages are up-
regulated to help initiate the repair process.  These cells are responsible for 
cleaning up the damage that occurred during the acute bacterial flare.  They do 
this in part by internalizing the debris that was produced as part of the infection.  
M2 macrophages additionally up-regulate molecules leading to fibrosis, including 
fibronectin and collagen [38].  This process is necessary, allowing the lungs to 
repair.  Excessive scarring, however, leads to a decline in airway function.  This 
decline, then, increases the likelihood of a future flare occurring.  This cycle of 
inflammation and fibrosis leads to a decline in lung function for the patient over 
time, and is responsible for much of the morbidity and mortality associated with 
CF. 
 Others have utilized similar models and observed similar findings with 
AZM.  Tsai et. al. have utilized a P. aeruginosa infection model with a strain of 
mice with deficient CFTR function [100].  Unlike our findings, they observed that 
AZM treated mice displayed fewer bacteria in their lungs.  They did, however 
observe a similar increase in survival and decrease in neutrophils influx as we 
observed with our mice.  They also observed similar alterations in inflammatory 
cytokine production with their mice.  While this group did not examine differences 
in macrophage activation status, in conjunction with our data it supports the 
hypothesis that the benefits of AZM are due in part to alterations in macrophage 
polarization. 
With AZM, what we believe is occurring is that the initial inflammatory flare 
of the disease is being blunted.  By shifting some of the macrophage polarization 
away from the M1 phenotype and towards the M2 phenotype during the initiation 
of inflammation, the immune response, while still strong enough to clear the 
infection, does not cause the same degree of damage as the dysregulated 
response would.  There is then less repair and recovery necessary for the lungs 
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of these patients to recover from.  This model helps to explain the seeming 
contradiction that exists with AZM treatment in CF.  By decreasing the degree of 
an initial inflammatory flare, AZM improves lung function in patients with CF, 
even though it increases the amount of pro-fibrotic macrophages in the lungs. 
Importance of alternatively activated macrophages in the response to 
extracellular bacteria 
 Characterizations into the importance of alternatively activated 
macrophages have primarily focused on intracellular bacteria and parasites.  
Kasmi et. al. assessed the importance of alternatively activated macrophages in 
host response to the intracellular pathogens Mycobacterium tuberculosis and  
Toxoplasma Gondii [124].  They found that these pathogens actually up-regulate 
the M2 marker arginase.  This decreases intracellular arginine levels, and 
prevents the generation of a robust M1 dependent oxidative burst.  They 
additionally utilized an Arg 1 knockout mouse, and found that these mice 
survived infection with intracellular bacteria more readily than wild type mice.  
They concluded that M1 macrophages play an important role in the destruction of 
intracellular bacteria, while M2 macrophages allow these bacteria to evade 
destruction. 
 Others have investigated the role of M2 produced arginase 1 with 
parasites including S. mansoni.  Study of the inflammatory response to S. 
mansoni infection showed that mice with macrophages that lack arginase 1 
succumb to Th2-driven pathology associated with the pathogen, related a lack of 
inhibition of the CD4+ T cell response.  They concluded that arginase played an 
important role in the suppression of T cell dependent inflammation [85, 86]. 
 Considerably less is known about the role of M2 macrophages with 
extracellular bacteria.  This is primarily due to M2 macrophages not being 
present during the acute phase of these responses.  We have shown that the 
inducement of the M2 phenotype during the acute phase of an infection improves 
survival in C57bl/6 mice with P. aeruginosa pneumonia.  We have observed 
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similar trends with IL4rαKO mice adoptively transferred with functional 
macrophages.  We hypothesize that this improvement is due in part to a blunting 
of the robust immune response that occurs in the context of an extracellular 
infection.   
Future directions 
 While we were unable to determine an exact molecular mechanism by 
which AZM polarizes macrophages to the M2 phenotype, our investigations has 
greatly narrowed the number of targets that exist.  The continuation of this 
research will further define these molecular targets.  These investigations may 
allow the development of future therapeutic agents combining the beneficial 
immunomodulatory effects of AZM without the need for long term antibiotic 
usage. 
 Modulation of macrophage polarization may provide a new avenue for 
treatment of various infections.  In many infections, it is the strong inflammatory 
response to infectious pathogens, rather than the pathogen itself, which is 
responsible for much of the damage and pathology that follows.  AZM and other 
future AZM-like immunomodulatory drugs may be able to blunt the immune 
response, while still allowing for adequate clearance of the bacteria.   
 This work additionally provides the foundation for mechanistic 
investigations into specific molecular targets of M2 macrophages which lead to 
this immunomodulation.  With AZM, we have an agent that is able to shift 
macrophage polarization to the M2 phenotype.  AZM is able to modulate the 
immune system with few systemic complications, especially compared to other 
immunomodulators (e.g. corticosteroids, methotrexate, and cyclosporine), which 
profoundly suppress the immune system.  This polarization is clinically relevant, 
however, as AZM functions as a relatively blunt instrument to affect these 
changes.  It is conceivable that alterations in individual M2 effector proteins may 
be able to improve outcomes in a more selective manner.  It is unknown which 
proteins expressed in M2 macrophages play important roles in the response to 
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extracellular pathogens.  The determination of which specific proteins play an 
important role in the blunting of the inflammatory response to extracellular 
pathogens may allow for more specific modulation of the immune system.  Novel 
therapeutics that allow for a shift in the balance of macrophage polarization may 
allow for improved outcomes in the context of infection.   
C.  Conclusions 
 This research provides additional insights into the role of M1 and M2 
macrophages during acute infections and in CF.  Our research has shown that 
shifting macrophage polarization away from the M1 phenotype and towards the 
M2 phenotype increases survival in mice during acute infections.  This shift still 
allows for sufficient inflammation to clear the infection.  We believe that it is the 
inflammatory response that causes much of the mortality, which is especially 
applicable in chronic inflammatory conditions like CF and COPD. 
We conclude that shifts in macrophage phenotype towards an M2 
polarization result in improved outcomes in P. aeruginosa pneumonia, and may 
be responsible for improvements associated with AZM treatment in patients with 
CF.  We have previously shown that AZM shifts macrophage polarization away 
from the M2 phenotype in the presence of cytokines that would otherwise result 
in M1 polarization, and here we have expanded our knowledge of the functional 
role that AZM-exposed macrophages exhibit.   
 We additionally investigated potential molecular targets by which AZM 
polarizes macrophages to the M2 phenotype.  We believe that AZM increases 
IKKβ activation, and, in a manner similar to what Fong et. al. described, 
preventing activation of STAT1 [68].  Further research is necessary to confirm 
the exact mechanism by which AZM effects these changes.  Future research 
may lead to novel therapeutics that target specific aspects of alternative 
macrophage activation, as an immunomodulatory modality that is clinically 
effective in patients with chronic inflammatory lung diseases, while at the same 
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time are less toxic and immunosuppressive than therapies that are currently 
available. 
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Figure 5.1.  Proposed model for beneficial effects of AZM in patients with CF.  
Disease progression in CF is characterized by a cycle consisting of bacterial 
flares and a strong inflammatory response to the bacteria.  This strong 
response leads to tissue damage, and eventually tissue repair.  When 
excessive damage has occurred due to the immune response, scarring and 
fibrosis occurs, leading to future bacterial flares.  We propose that AZM 
decreases the degree of the initial inflammatory response, resulting in less 
extensive damage. 
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